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1.0 SYNTHESIS 
According to the World Health Organization (WHO), cancer is a leading cause of death 
worldwide and has accounted for 7.6 million deaths (13% of all deaths) in 2008. The number 
of effective drugs available has been reduced by chemo resistant malignant tumors. Similarly, 
bacterial infections are one of the world’s most pressing public health problem. The major 
challenge in anti-bacterial treatment is due to the development of bacteria strains that are 
resistant to antibiotics. Each year more than 11 million people die from major infections such 
as MDR tuberculosis. In 2013, 9 million people fell ill with TB and 1.5 million died from the 
disease (WHO). Therefore there is a need for novel therapeutic alternatives such as the 
discovery of new anti-cancer and anti-bacterial agents. Benzofurans have attracted much 
attention due to their broad spectrum of pharmacological activities such as anti-cancer and 
anti-bacterial activities and one classical example is usnic acid. Most of the published 
synthesis of the benzofuran moiety involved the formation of annellated furan ring by 
intramolecular cyclisation of benzene, and these procedures involved a multi-step, rigorous 
reaction conditions and expensive catalyst. This research investigated the novel synthesis of 
benzofurans through the application of biocatalysis, where the reactions involved the use of 
the oxidative enzyme laccase to generate carbon-carbon bonds, carbon-oxygen and carbon-
nitrogen bonds between aromatic compounds. The substrates used were o-diols from 
catechols 1, p-quinone 2 from naphthoquinones and naphthohydroquinone 3, which, when 
activated by the enzyme action, could be reacted with 1,3-diketones 4, 5 or coumarins 6 
(Figure 1). The aim of synthesising different classes of compounds was to vary the functional 
groups and to increase the number of rings, so as to possibly increase the biological activities.  
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Figure 1: Substrates of laccase (1, 2,3) and co-reactants (4,5,6) 
We exploited the application of a commercial laccase, Suberase® from Novozymes as the 
catalyst in these transformations. This oxidoreductase was successfully utilised in the 
synthesis of 5,6-dihydroxylated benzo[b]furans 7, synthesis of C-C coupled substituted 
dicarbonyls to catechols 8, benzofuro [3,2-c]chromen-6-one derivatives 9, C-C coupled 
naphthoquinone 10 and C-C bis-coupled naphthoquinone derivatives 11 and 12 (Figure 2). 
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Figure 2: The classes of synthesised compounds synthesised in this study 
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As an example, the synthesis of benzofurans takes place by the in situ oxidation of catechol 
13 facilitated by laccase to afford the ortho-quinone 14. This allows for a Michael addition of 
the 1,3-dicarbonyl 15 with 14. This is then followed by an oxa-Michael addition which allows 
for cyclisation as shown in Scheme 1 below to afford the benzofurans 7.  
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Scheme 1: Synthesis of the 5, 6-dihydroxylated benzo[b]furans  
Depending on the nature of the starting materials, a second reduction can only take place for 
un-substituted dicarbonyls at position 2. Interestingly, the substituted diketones formed a 
monocoupled product 8. Such a mechanism has been reported when using traditional 
synthetic methods in the classical cross coupling mechanism using palladium (Pd), or Nickel 
(Ni) or iron (Fe). However, the 1,4-naphthoquinones unexpectedly gave a C-C bis coupled 
product 10 and 11 when reacted with 1,3-diketones in the presence of laccase. This suggests 
that the reaction has undergone two Michael addition reactions without cyclisation. This 
mechanism is also observed for the first time through the application of laccase.  
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 The method was broadly applicable but unsuccessful regarding fluorinated and acid 
catechols, which  did not react with neither 1,3-dicarbonyls nor coumarins. Anthraquinones 
were also not susceptible to this reaction.  
A selection of the benzofurans were derivatized with a well-known anti-TB drugs; isoniazid 
and thiosemicarbizide. The motif is that drugs that modulate several targets have a potential 
to improve balance of efficacy in addition to safety when compared to single target agents. A 
total of 69 compounds were generated in this study, of which 19 were known and 50 were 
novel. 
 
2.0 BIOLOGICAL EVALUATION 
Biological evaluation, both anti-cancer and anti-bacterial, of selected synthesised compounds 
was performed. Anticancer screening was against a number of cancer cell-lines, which 
included renal (TK10), melanoma (UACC62), breast (MCF7) and cervical (HeLa) cancer cell 
lines
..
 The GI50, TGI and LC50 data for many of these compounds were reported for the first 
time. Anticancer screening showed that the cytostatic effects of the 5,6-dihydroxylated 
benzo[b]furans were most effective against the melanoma (UACC62) cancer cell line with 
several compounds exhibiting potent growth inhibitory activities (GI50 = 0.77–9.76 µM), of 
which two compounds had better activity than the well-known anticancer agent etoposide 
(GI50 = 0.89 µM). One compound exhibited potent activity of (GI50 = 9.73 µM) against the 
renal (TK10) cancer cell line and two exhibited potent activity (GI50 = 8.79 and 9.30 µM) 
against the breast (MCF7) cancer cell line (Figure 2). The three numbers at the bottom in the 
figure above represent the GI50 of renal (TK10), melanoma (UACC62) and breast (MCF7) 
cancer respectively.  Comparison of the structures relative to the biological activity showed 
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that the methoxy catechol was the most biologically active derivative, and the biological 
activity increased proportionally to the size of the 1,3-diketone. 
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Figure 2: Structures of most biological active compounds on cancer cell-lines 
 
Antibacterial evaluation involved screening selected compounds againstMycobacterium 
smegmatis MC2155, Staphylococcus aureus 32710 (MSSA), Bacillus subtilis 168 
and Escherichia coli DH10B. Mycobacterium smegmatis MC2155 was used as a pre-
screening model organism prior to screening compounds against Mycobacterium tuberculosis 
(M.tb). Only one compound, which belongs to the naphthoquinones (compound 22, Figure 3), 
showed potency against M. smegmatis (6.25 µg/mL).  This indicated that many benzofurans 
are not active against Gram negative and Gram positive bacteria, but have some application 
towards acid fast bacteria such as Mycobacteria. 
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Figure 3: Structure of the active 1,4-naphthoquinone derivative 
Compound 22 was then screened against three drug susceptible M.tb strains (two with 
different mutations in the rpoB gene and one a drug susceptible strain called BE), and was 
active against all three strains at 10 µg/mL.  
This study has demonstrated the applicability of oxidative biocatalysis to access novel furan 
compounds with activity towards cancer cell lines and acid fast bacteria. 
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1.0  BACKGROUND 
 
An overwhelming evidence has shown association between certain bacteria and cancer.1a The 
number of drugs available for treating malignant tumours and bacterial infections has been 
reduced by the development of chemoresistant and antibiotic resistance. Polyhydroxylated 
compounds have attracted much attention due to their broad spectrum of pharmacological 
activities such as anti-cancer and anti-bacterial activities and one classical example is usnic acid 
as previously mentioned. The structural motif of a great number of these compounds contain 
fused aromatic rings, quinones and hydroxyl moieties. These moieties have the ability to undergo 
redox cycling, this process is when compounds catalytically cycle and generate ROS such as 
hydrogen peroxide and superoxide which damages the cell. ROS also inhibit active efflux which 
is responsible for moving antibiotics out of the cell. The scope of this overview is broad 
therefore a wide range of reports is presented. Synthesis and mode of action of selected 
antibiotics, search for new drug candidates, cell circle in cancer cells, cancer in Africa and cancer 
treatment will be discussed.  
 
According to the World Health Organization (WHO) bacterial infection is one of the world’s 
most pressing public health problems.1b Bacteria are a diverse group of organism that are 
classified as Gram negative, Gram positive and acid fast bacteria according to the crystal violet 
staining technique used for preliminary identification based on cell wall composition.2 Gram 
positive bacteria retain the dye stain and appear violet, Gram negative bacteria loose the stain 
and appear red, while acid-fast bacteria do not stain (Figure 1).2 The acid fast bacteria have a 
similar cell wall structure to the Gram negative bacteria, but in addition to the peptidoglycan it 
also has mycolic acids.2  
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Figure 1: Structure of a gram positive and gram negative bacteria3 
 
Almost every type of bacterium is becoming less responsive to antibiotic treatment, resulting in 
antibiotic resistance.1 Antibiotic resistance is the ability of microorganism to survive the 
exposure to one or more antibiotics. These antibiotic-resistant bacteria can quickly spread to 
family members, schoolmates, and co-workers thus threatening the community with a new strain 
of infectious disease that is difficult to cure and more expensive to treat.4 Therefore there is a 
need for new potent antibiotic agents that are affordable. Figure 2 depicts drug susceptible, non-
resistant bacteria as well as drug resistant bacteria. 
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Figure 2: Drug susceptible, non-resistant and drug resistant bacteria4 
 
Astonishingly, there has been a decline in the approvals of new antibiotics in an era where drug 
resistant and extreme drug resistant bacteria are posing a great threat to human health.5-7 This is 
due to the common failure of new antibiotic drug candidates in the pipeline of pharmaceutical 
companies. The molecular framework of the first-line antibiotics contain fused aromatic rings, 
quinones and hydroxyl moieties. This framework has the ability to undergo redox cycling, this 
process is when compounds catalytically cycle and generate reactive oxygen species (ROS) such 
as hydrogen peroxide and superoxide which damages the cell. ROS also inhibit active efflux 
which is responsible for moving antibiotics out of the cell. 
Historically antibiotics such as penicillin G 1, tetracycline 2, erythromycin 3 and cephalosporin 
C 4 gave rise to a large fraction of the approved antibiotics (Figure 3) and the process of semi-
synthesis continues to be the predominant avenue to successful new ones 8 
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Figure 3: The first antibiotics to be discovered 
 
Penicillins were the first antibiotics to be discovered in 1928, by Sir Alexander Fleming, a 
professor of bacteriology.9 He noticed zones of inhibition where a contaminating mould was 
growing in a petri-dish culture of the Gram positive bacterium Staphylococcus aureus. He later 
named the mould Penicillium rubrum.9 The inhibition of bacterial growth was found to be 
caused by a compound that was named penicillin, one of a family of compounds characterized by 
a fused beta lactam, a carboxylic acid and one or more amino acid side chains. In 1930 Cecil 
George Piane, a pathologist at the royal infirmary in Sheffield, discovered that penicillin can be 
used in the treatment of a gonococcal eye infection in infants (a cause of ophthalmia 
neonatorum).10-12 In 1936 the Australian scientist Howard Florey and a team of researchers from 
the University of Oxford proved the in vivo bactericidal action of the drug. 13 John Bumstead and 
Ovan Hess saved a dying patient’s life using penicillin in 1942. Merck and company also used 
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penicillin to treat the burn victims from the Coconut Grove fire in Boston in 1942, and was found 
to be crucial in combating Staphylococcus bacteria which infect skin grafts.14 The narrow 
spectrum of activity however led to derivitization to antibiotics such as ampicillin 5, 
flucloxacillin 6, dicloxacillin 7 and methicillin 8 as shown in Figure 4.  
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Figure 4: Semisynthetic analogues of penicillin15 
 
All the derivatives shown in the Figure 4 above are very effective against both Gram positive and 
Gram negative with the exception of methicillin-resistant Staphylococcus aureus (MRSA) strain 
which has subsequently emerged.15 In 1945 tetracyclines 2 were discovered by Benjamin Minge. 
They are produced by the Streptomyces genus of actinobacteria.16 Tetracyclines are characterized 
by their exceptional chemotherapeutic efficacy against a wide range of both Gram positive and 
Gram negative bacteria.16 The main indications for the use of tetracyclines are infections due to 
Escherichia coli and Haemophilus influenza, infections of the bile duct, bacterial respiratory 
disorders including bronchitis prophylaxis, mixed infections arising from the mouth, pharynx, or 
intestinal tract, brucellosis, tularaemia, plague and other pasteurelloses, leptospirosis, 
lymphogranuloma inguinale, cholera, and rickettsiosis.17 Because of the development of strains 
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of microorganisms resistant to the tetracyclines, these antibiotics have lost some of their 
usefulness. They are no longer the drugs of first choice for treatment of staphylococcal, 
streptococcal, or pneumococcal infections.  
 
In 1952 a broad spectrum antibiotic called erythromycin 3 was discovered by Mc Guire and co-
workers.18 It was isolated from the actinomycete Saccharopolyspora erythrae. Erythromycin, 
commonly administered as the ester prodrug erythromycin ethylsuccinate (EES). It is a 
macrocyclic 14 membered lactone ring, with 10 asymmetric centres and 2 sugar moieties (L-
cladinose and D-desosamine).19 It is on the WHO’s list of essential medicine as the most 
important medication needed in a basic health system.19 It inhibits the growth of Staphylococcus 
aureus, Haemophilus influenzae. A second major group of beta-lactams is the cephalosporins 4 
that were discovered in 1956. These are broad type of antibiotics from Cephalosporium 
acremonium, a sewer fungus.19 They differ from penicillin by the presence of a 6 instead of a 5 
membered ring as well as the different substituent groups. They are used for treatment of 
Salmonella typhi, the bacterium that causes typhoid fever. It is most effective against Gram 
positive bacteria; however its derivatives are effective on Gram negative bacteria as well. 
 
1.1 BIOSYNTHESIS, SYNTHESIS AND MODE OF ACTION OF 
SELECTED ANTIBIOTICS 
Understanding the mode of action of anti-bacterial drugs not only guides the design and 
synthesis of novel antibiotics, it also helps to implement measures to prevent the development of 
resistance.20 In this section we will discuss the mode of action of the first four discovered 
antibiotics. 
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1.1.1 PENICILLIN (1928) 
Bio-Synthesis 
Initially we will look at the biosynthesis of penicillin G (benzyl penicillin) as an example. This 
involves what 3 sequential biosynthetic steps. The first step involves the condensation of three 
amino acids; L-α-aminoadipic acid 9, L-cysteine 10, and L-valine 11 to form a  tripeptide named 
δ-(l-α-aminoadipyl)-L-cysteine-D-valine (ACV) 12 as shown in Scheme 1.21, 22, 23  
HO
O
NH2
OH
O
+
OHO
H2N
SH
+
H2N
OH
O
HO
O
NH2
H
N
O N
H
O OH
O
HO
O
NH2
H
N
O O N
S
OHO
H
N
O O N
S
OH
O
amimo adipic acid                 L-cysteine                     D-valine
           9                                         10                                  11
ACV- Tripeptide
           12
Isopenicillin
          13
Penicillin G
      14
 
Scheme 1: Bio-synthesis of penicillin G.21 
Prior to tripeptide condensation, the amino acid L-valine undergoes epimerization to become D-
valine.24, 25  The enzyme responsible for this first step is called δ-(L-α-aminoadipyl)-L-cysteine-D-
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valine synthetase (ACVS), a nonribosomal peptide synthetase (NRPS). The second step is the 
oxidative conversion of linear ACV into the bicyclic intermediate isopenicillin N 13 by 
isopenicillin N synthase (IPNS), which is encoded by the gene pcbC.21, 22 Isopenicillin N is a 
very weak antibiotic.21 The final step is a transamination by isopenicillin N N-acyltransferase 
(encoded by the gene penDE), in which the α-aminoadipyl side-chain of isopenicillin N is 
removed and exchanged for a phenylacetyl side-chain to form penicillin G 14. 21 
Mode of Action 
β-lactam antibiotics act as bactericides, wherein they disrupt the synthesis of the peptidoglycan 
layer of the bacterial cell walls.26  This is achieved by binding of the β-lactam ring to the enzyme 
called DD-transpeptidase, an enzyme responsible for catalysing the peptidoglycan cross-
linkages. This then causes an imbalance between cell wall production and degradation, which 
eventually leads to cell death through osmolysis.   
 
1.1.2 TETRACYCLINES (1945) 
Synthesis 
Tetracycline has four linearly annulated six-membered rings with five asymmetric centres at C4, 
C4a, C5a, C6 and C12 as shown in Figure 5 below.27  
OH O
OH
O
NH2
OH O
NMe2OH
BCD
15
OH
156
12
 
Figure 5: Structure of tetracycline 
They can be prepared from cultures of several species of Streptomyces.27 The first synthesis to be 
reported was by Woodward and a group from Pfizer.27 A number of alternative synthetic 
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approaches were later developed by Shemyakin, Stork and more recently Meyers.28,29 However, 
we have elected to discuss the improved synthetic pathway developed by Stork as shown in 
Scheme 2 below.29 The most formidable challenge posed by tetracycline structure is the densely 
functionalized fused ring structure. The first step is the synthesis of the enantiomerically-pure 
ester 17 as shown in Scheme 2. This is prepared through fermentation of benzoic acid 16 and 
1,2-dihydrodiol with Alcaligenes eutrophus B9. This is followed by epoxidation, rearrangement 
and silylation. Acylation of the epoxide with 18 resulted in ketone 19.  
CO2H
O OCH3
O
OSBT
+ N
O
N
OBnTBSO
O
O
TBSO
TBSO
N
O
BnO
N
16                                   17                                            18                                           19
1. LiOTf
2. TFA
N
O
OBnO
N
TBSO OH
20                                                                       21
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N
O
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OO OBn
N
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N
O
OBnO
N
TBSO OH
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NBSH, PhCH3
1. HCl, MeOH
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3.TBSOTf. 2.6-lutidine
+
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-78 0C 0 0C
2. HF, MeCN
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OH O
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22                                       23
 
Scheme 2: Stork’s synthetic pathway of tetracyclines28 
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The ketone undergoes a C-C bond formation after selective desilylation with TFA in the 
presence of LiOTf. Construction of AB ring system was accomplished through the treatment of a 
ketone with lithium triflate at 60 °C and subsequent TBS deprotection to give tricycle 20. Double 
bond migration and reduction were carried out with triphenylphosphine, diethyl azodicarboxylate 
and o-nitrobenzylsulfonylhydrazine in 74% yield, giving allylsilyl ether 21. This is then followed 
by deprotection of TBS group with IBX and protection of tertiary alcohol with TBSOTf to afford 
α,β-unsaturated enone 22. The final step is the Michel-Diekmann reaction of 22 with 23 to form 
15.29 
 
Mode of action 
Tetracyclines act as bacteriostatics for both Gram positive and Gram negative bacteria, with the 
exceptions such as Pseudomonas aeruginosa. The B and C diketone system of the C11 and C12 
is the active centre, C4 and C5a are crucial for the antimicrobial activity (Figure 5).30,31 This 
pharmacophore is composed of the linear fused tetracycle, naturally occurring (α) stereochemical 
configuration at the 4a, 12a (A-B ring junction) and 4 (dimethyl amino group) positions and the 
presence of the keto-enol system at positions 11, 12 and 12a in the proximity of the D ring. 
 
OH O
OH
O
NH2
OH O
NMe2OH
BCD
15
OH
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34567
8
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Figure 6: Molecular frame-work of a tetracyclines 
 
Chapter  1                                                                            Bacteria and Cancer; An Overview 
 
 
12 | P a g e  
 
Tetracyclines are strong chelating agents and their antibacterial activity is influenced by the 
chelation of metal ions.32 The chelation site is comprised of the β-diketone system (11 and 12 
positions), the enol (1 and 2 positions) and the carboxamide (position 2) groups of the A system. 
They bind to the 30S ribosome of the bacteria and thereby preventing attachment of amino acyl 
tRNA to the RNA ribosome complex.30,31 
 
1.1.3 CEPHALOSPORINS (1956)  
Synthesis 
First generation cephalosporins are active predominantly against Gram positive bacteria and 
successive generations are also active against Gram negative bacteria. For this class of 
compound we will discuss the biosynthesis of cephalosporin C as an example. The first step in 
the biosynthesis is the deacetoxyacephalosporin A biosynthesis. This comprises the reaction of 
the aminoadipate 24, L-cysteine 25 and L-valine 26 in the presence of N-(5-amino-L-
carboxypentanoyl)-L-cysteinyl-D-valine synthase. This enzyme contains 4-phosphopantatethiene 
which may be involved in the reaction.33  
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Scheme 3: Bio-synthesis of cephalosporin C33 
The resulting product is the deacetoxycephelasporin C 26 is oxidised to deacetylcephalosporin C 
27 by deacetylcephalosporin C hydroxylase. Deacetylcephasporin C acetyltransferase catalyses 
the final step in the biosynthesis of cephalosporin C 29. 
 
Mode of action 
Cephalosporins act like penicillin in the inhibition of formation of peptidoglycan cross-links in 
the bacterial cell wall, but are less susceptible to β-lactamases.34 Biological activity is also 
achieved by binding the β-lactam ring of the cephalosporin to the enzyme called DD-
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transpeptidase, which is responsible for catalysing the formation of cross-links. This mechanism 
irreversibly inhibits cross-linkage of the peptidoglycan by mimicking the DD site. 
 
1.1.4 ERYTHROMYCIN (1952)  
 
Synthesis 
The 10 stereogenic centres and a number of substituents make erythromycin challenging to 
synthesize. However, Robert Woodward was the first person to successfully synthesize the 
antibiotic, using hydrolysis and stereospecific aldolization (Scheme 4).35 The key steps in the 
reaction sequence are such that compound 30 and 31 are coupled together to form compound 32 
(scheme 4). Compound 32 undergoes hydrolysis to form aldehyde 33, followed by proline-
catalysed stereoselective intramolecular aldol reaction to form enone 34. This is then followed by 
induced elimination of the mesylate to form compound 35. After this comes a Grieco 
dehydration to give compound 37.  Through a series of reduction and oxidations compound 37 
was reacted with compound 36 to form a dithiadecalin 38.  The final step involves hydration to 
give the desired erythromycin product 41. 
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Scheme 4: The Woodward synthesis of Erythromycin35 
Mode of action 
The erythromycins act as bacteriostatics.36 They bind to 50S subunit of the bacterial 70S rRNA 
complex. This then inhibits protein synthesis, a processes critical for cell life and replication. It 
interferes with aminoacyl translocation preventing the transfer of the tRNA bound at the A site 
of the rRNA complex.36 Without this translocation, the A site remains occupied thus the addition 
of tRNA and thereby inhibits transfer of its attached amino acid to polypeptide. The cell then 
stops the production of functional proteins, which ultimately results in cell death.  
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1.2 A SEARCH FOR NEW DRUG CANDIDATES 
The government and non-governmental organizations globally, have started to invest in 
antibiotic drug research and development. For this project we attempted the search for new drug 
entities that could be used for the treatment of tuberculosis. This is an infectious disease caused 
by an acid fast bacterium called   Mycobacterim tuberculosis.  We selected this disease as a 
target as South Africa has the third highest number of TB infections globally.1b  
 
The first-line anti-TB drugs that can be used for drug susceptible TB strain are; isoniazid (INH) 
42, pyrazinamide (PYR) 43, ethambutol (ETH) 44, stremptomycin (STR) 45 and rifampicin 
(RIF) 46 (Figure 7).37 
N
N
H
O
NH2
O
O
OH N N
N
NH
OOHO
O
O
O
N
H
H
N
CH2OH
O
O
O
O
HO
HO
NH
OH
HO
O
OH
NH
OH
NH2HO
HN
HN
H2N
NH
N
N
H2N
O
        Isoniazid 42                              Pyrazinamide 43                                 Ethambutol 44
Streptomycin  45                                                                       Rifampicin 46
HO
CH2OH
OHOH
OH
 
Figure 7:    First-line TB drugs.37 
 
Soon after the first anti-tuberculosis agents were introduced to humans the emergence of drug-
resistant isolates of M.tb was already observed.38-40 Since the early 1990s, there has been a great 
concern within public health institutions over the emergence of multiple drug resistant 
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tuberculosis (MDR-TB). This is caused by M.tb strains resistant to at least two first-line anti-TB 
drugs, isoniazid (INH) 42 and rifampicin (RIF) 46. MDR-TB develops during treatment of drug 
sensitive TB when the course of antibiotics regimen is interrupted and the levels of drug in the 
body are insufficient to completely eliminate the bacteria.41 In vitro studies showed that 
spontaneous mutations in M.tb can be associated with drug resistance, while selective (antibiotic) 
pressure can lead to enhanced accumulation of these drug resistant mutants.42,43 The efficient 
selection of drug resistance in the presence of a single antibiotic led investigators to recommend 
combination therapy, using more than one antibiotic to reduce the emergence of drug resistance 
during treatment.44-46 TB control has indeed been effective where combination treatment is 
properly managed.47 
 
In this study we adopted the use of the Mycobacterium smegmatis as the model for compounds to 
be further evaluated for anti-TB activity. This was primarily because it takes 3 months to grow 
M. tuberculosis, whereas it takes only about 4 days to grow M. smegatis. These two types of 
bacterial species belong to the same family and have many physiological similarities.  The M. 
smegmatis model involves pre-screening a library of compounds against M. smegmatis and 
selecting the reduced number of compounds that proved positive to screen against M. 
tuberculosis (M.tb). 
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1.2.1 ANOTHER CLASS OF COMPOUNDS 
1.2.1.1 FLUOROQUINOLONES 
The fluoroquinolones are a promising class of drugs for the treatment of TB.48 When they are 
used for treatment they are well distributed throughout the body, which explains their efficacy 
against intracellular mycobacteria. Fluoroquinolones are registered as second-line anti-TB 
drugs.48-51 Two examples are moxifloxacin 47 and gatifloxacin 48 and these are candidates for 
shortening TB treatment (Figure 8) as they have exhibited the lowest minimum inhibitory 
concentrations (MICs).52--58 They have also exhibited the greatest bactericidal activity as 
expressed in the rate of fall in Colony Forming Units (CFU).55,59-61 CFU is the estimate of the 
number of viable bacterial cells in the sample. The lesser the CFU the more active is the drug as 
this means that the bacteria’s ability to multiply via binary fission has been hindered. 
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Figure 8: Fluoroquinolone derivatives 
 
Bifunctional fluoroquinolone–hydroxyquinolines were also evaluated for antimycobacterial 
activity.62 The compounds that exhibited the best activity are the 7-piperidinyl-1-(2-fluoro-4-
nitrophenyl)quinolone  49 and 7-piperidinyl -(3,5-dimethylpiperazinyl)quinolone 50 derivatives, 
which exhibited 97% and 98% bacterial inhibition, respectively (Figure 9).  
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Figure 9: Fluoroquinolone derivatives 
 
Among the synthesized compounds 51 (Figure 10) was found to be the most active compound in 
vitro with a MIC of 0.0383 µM and was more potent than the first-line anti-tubercular drug 
isoniazid (MIC = 0.1822 µM).63 
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 Figure 10: Diclofenac 51 and fluoroquinolone derivatives 
This compound was suited for further modification to obtain a more efficacious and potent anti-
tuberculosis drug. Various diclofenac acid hydrazones and amides have also been synthesized 
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and evaluated for in vitro and in vivo anti-mycobacterial activities against M.tb.63 Preliminary 
results indicated that most of the compounds demonstrated better in vitro antimycobacterial 
activity (MIC = 0.0383–7.53 µM) than diclofenac 51 (MIC = 21.10 µM) and ciprofloxacin 52 
(MIC = 9.41 µM). 
 
Mechanism of Action of Fluoroquinolones 
Moxifloxacin 47 is a broad-spectrum antibacterial agent with activity against both Gram-positive 
and Gram-negative bacteria.63 It inhibits bacterial DNA gyrase, an enzyme that is essential for 
the maintenance of DNA supercoils, that are required for chromosomal replications.63  
 
1.2.1.2 RIFAMYCIN DERIVATIVES 
Rifampin is considered to be the cornerstone in the current treatment of TB.65 Rifamycin 
derivatives, such as rifapentine 53, rifabutin 54 and rifalazil 55 in Figure 12, have been 
synthesized from rifampicin to improve antimycobacterial activity and prolong their half-life. 
Rifapentine was approved by the FDA in 1998 for the treatment of TB. Rifapentine appears to be 
safe and well-tolerated at once-weekly dosing and is currently being evaluated in Phase III 
efficacy trials for treatment of latent tuberculosis.62 
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Figure 11: Structures of Rifamycin derivatives. 
 
Rifalazil (RLZ) 55 is a new semisynthetic rifamycin derivative with a long pharmacokinetic half-
life. It is highly active against a range of bacteria strains including M.tb, Mycobacterium avium, 
Chlamydia trachomatis, Chlamydia pneumoniae, and Helicobacter pylori.66 RLZ is more active 
than RIF or rifabutin 53 against M. tuberculosis in mice both in vitro and in vivo.67 
 
1.2.1.3 OXAZOLIDINONES 
Oxazolidinones were discovered at DuPont in the 1970s and later developed by Pharmacia & 
Upjohn. They are a new class of compounds that are active against a variety of Gram-positive 
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bacteria, including M. tb. Linezolid 56 is the first oxazolidinone to be developed and approved 
by the FDA to treat single- or multiple-resistant Gram-positive bacterial infections (Figure 12).68 
 
N O
ON
O
F
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Figure 12: Structure of Linezolid. 
1.2.1.4 NITROIMIDAZOPYRAN 
A particularly promising candidate for TB treatment is nitroimidazopyran (PA824) 57, derived 
from 5-nitroimidazoles (Figure 13).69  
N O
O OCF3
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Figure 13: Nitroimidazopyran, PA824. 
PA824 is highly active, with a MIC as low as 0.015–0.250 µg/ml against M.tb and MDR-TB. 
PA824 is a prodrug that requires activation by a bacterial F420-dependent glucose-6-phosphate 
dehydrogenase and nitroreductase to activate components that then inhibit bacterial mycolic acid 
and protein synthesis.70  
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1.2.1.5 NEW ANTIMICROBIALS  
In most parts of Southern Africa, plants are used for medicinal purposes, including as 
antibacterial agents. The structure of biologically active compounds in plants varies; some 
compounds belong to classes of compounds such as alkaloids, terpenoids, coumarins/chromones, 
peptides and phenols. Naphthoquinones are among the compounds being investigated and they 
exhibit a range of pharmacological properties such as antibacterial,71 antiviral,72 trypanocidal,73 
anticancer,74 antimalarial75 and antifungal76 activity. A detailed study of a series of synthetic and 
plant-derived naphthoquinone derivatives of the 7-methyljuglone 58 (Figure 14) scaffold on 
antibacterial activity against M.tb was reported by Mahapatra and co-workers.77  
 
O
OOH
58
 
Figure 14: 7-Methyljuglone.  
 
The aim of their study was to examine the synthesis, antibacterial activity and cytotoxicity of a 
series of naphthoquinones.78 The naphthoquinone, 7-methyljuglone 58, has previously been 
isolated and identified as an active component of root extracts of Euclea natalensis which 
displays anti-tubercular activity. Mehapatra and co-workers showed that 7-methyljuglone 
exhibited the most potent and most selective anti-tubercular activity of all the compounds tested.  
 
It is well known that HIV increases a person’s susceptibility to TB infection due to the decline of 
CD4+ lymphocytes in number and function, resulting in a weakened immune system incapable 
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of preventing the growth and local spread of M.tb.79 A challenge arises in the interaction of HIV 
and TB drugs in HIV and TB patients. For example, rifampin has been recommended not to be 
used concurrently with almost all the anti-HIV nucleoside reverse transcriptase inhibitors 
NNRTIs and protease inhibitors due to drug-drug interactions.80 Therefore, there is an urgent 
need for new compounds that can target TB but do not interfere with drugs that are used to treat 
HIV.  Recent research for example that done by Xu has done an evaluation of anti-HIV active 
pyranocoumarin for their activity against M.tb.80 Focused libraries were synthesized 59-67 and 
evaluated for their anti-TB activity in primary screening assays (Figure 15). The structural 
framework of library is similar to one of our libraries called benzo[3,2]chromen-6-one and they 
are discussed in Chapter 4. 
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Figure 15: Pyranocoumarins evaluated for anti-TB activity. 
 
Although this library was biologically active none were potent and the compounds shown to be 
active were further assessed to determine their MIC values. The amino derivatives (68, 69 and 
70) exhibited MIC values of 16 µg/mL each (Figure 16).  
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Figure 16: The amino pyranocoumarin derivatives 68-70 most active against TB.80    
 
1.2.1.6 PHENOXYACETIC ACID DERIVATIVES 
A series of novel phenoxyacetic acid derivatives have also been synthesized and their in vitro 
activity was evaluated against M.tb H37Rv and an INH-resistant M.tb strain.81 Among the 
synthesized compounds, compound 71 was found to be the most active against the M.tb H37Rv 
and INH-resistant strains exhibiting a minimum inhibitory concentration (MIC) of 0.06 µg/ml 
(Figure 17). 
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Figure 17: Phenoxyacetic acid derivative 
 
 
Chapter  1                                                                            Bacteria and Cancer; An Overview 
 
 
27 | P a g e  
 
1.2.1.7 DIARYLQUINOLINES 
Koen et al has reported on the anti-mycobacterial properties of diarylquinolines (DARQs).82 
Chemical optimization of a lead compound led to a series of DARQs with potent in vitro activity 
against several mycobacteria, including M.tb. Molecules of the DARQ series have a MIC below 
0.5 µg/ml against M.tb H37Rv. Antimycobacterial activity was confirmed in vivo for three of 
these compounds and the most active compound of the class, R207910 72 (MIC99 = 0.06 
µg/mL), is a pure enantiomer with two chiral centres (Figure 18).  
.  
N
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(R)
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Figure 18: Diarylquinoline derivative. 
 
Compound R207910 72, has several properties, both in vitro and in vivo, that may improve the 
treatment of TB. In addition, it also appears to act on a new target providing an anti-
mycobacterial spectrum different from those of current drugs. Its clinical potential is currently 
being tested on patients.  
 
 
 
 
 
1.3 SUMMARY OF ANTIBIOTICS 
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In summary, the first-line antibiotics act either as bacteriostatics or as bacteriocides. Penicillins 
and cephalosporins act as bacteriocides. They are both β-lactams and their activity depends on 
disrupting the synthesis of the peptidoglycan layer of the bacterial cell walls by binding the β-
lactam ring to the enzyme called DD-transpeptidase, an enzyme responsible for catalysing the 
formation of the peptidoglycan cross-linkages. This then causes an imbalance between cell wall 
production and degradation, which lead rapidly cell death. On the other hand tetracyclines and 
erythromycin are both bacteriostatics. Erythromycin binds to the 50S subunit of the bacterial 70S 
rRNA complex; this then inhibits protein synthesis, which is critical for cell life and replication. 
Tetracyclines bind to the 30S ribosome of the bacteria and thereby preventing attachment of 
amino acyl tRNA to the RNA ribosome complex. Due to mutations and other factors, the search 
for new drug entities is an ongoing process. As mentioned in section 1.1 first-line antibiotics 
contain fused aromatic rings, quinones and hydroxyl moieties. This framework has the ability to 
undergo redox cycling, (ROS) such as hydrogen peroxide and superoxide which damages the 
cell.  
 
1.4 CANCER 
While it seems likely that the rise of antibiotic resistance may lead to an increase of infection 
related deaths, cancer is currently the leading cause of death worldwide and accounted for 7.6 
million deaths (13% of all deaths) in 2008.83 Among the most deadly cancers are lung, stomach, 
liver, colon and breast cancer. It is projected that worldwide annual deaths from cancer will 
continue to rise to an estimated 13.1 million by 2030.83 There are a number of prevention 
strategies that can be adopted in order to reduce the risk of cancer reaching the advance stage. 
These include early detection and curative treatment. 
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Cancer is a disease that occurs as a result of the suppression of apoptosis (programmed cell-
death) which leads to increased cell-proliferation. Proteins that sense cellular damage or growth 
signals normally arrest the cell-cycle so that the damage can be repaired or, if that is impossible, 
apoptosis is induced. Malfunction of this system leads to cancer by allowing cells to proliferate 
when they should either be repaired or die. Most human carcinogenesis was shown to have 
abnormalities in some component of the retinoblastoma protein (pRb) pathway.84 Mutations of 
the retinoblastoma gene result in a loss of functioning of the retinoblastoma protein, which leads 
to a wide range of human cancers, including osteosarcomas, small-cell lung cancer, lung cancer 
and breast cancer.  
 
The cell-cycle is controlled by proteins called cyclins and their catalytic partners.84 The 
miscoding mutations of a cyclin results in a loss of affinity for its catalytic protein. This can take 
place due to epigenetic inactivation by methylation in a variety of tumours. Other types of 
cancers can be due to chromosal rearrangement. In most human cancer cells, the cyclins that 
have been observed to mutate are cyclin-dependent kinase complex CDK4/6 cyclins. For 
example, it has been observed that a miscoding mutation of CDK4/6 resulted in a loss of cyclin-
dependent kinase inhibitor p16 binding. There have been attempts to exploit this by treating 
cancer patients with inhibitors that block CDK activity. Indirubicin, flavopiridol and UCN-01 
were the first CDK inhibitors tested in clinical trials in which benefits have been noted in some 
patients.84 
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Figure 19: Structures of indirubicin, flavopiridol and UCN-01 
 
1.5 THE CELL-CYCLE IN CANCER CELLS  
 
To ensure a proper progression through the cell-cycle, cells have developed a series of 
checkpoints that prevent them from entering into a new phase until they have successfully 
completed the previous one. As mentioned, this is controlled by cyclins and their corresponding 
catalytic enzymes. Critical regulators and check points of the cell-cycle progression are shown in 
Figure 20. 
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Figure 20: Critical regulators of a cell-cycle96 
                               
 
Growth factor signals stimulate the synthesis of D-type cyclins, which then form active 
complexes with CDK4 and CDK6 in the early G1 phase. The primary substrate of CDK4/6 is the 
retinoblastoma protein (pRb), which in its active hypophosphorylated form inhibits cell-cycle 
progression by binding and repressing the activity of the transcription factor, E2F.85 The 
transcription of several genes (including E-type cyclins) takes place in the G1-to-S transition by   
hyperphosphorylating the pRb, which causes it to disassociate from E2F. The activation of the 
cyclin E/CDK2 complex drives progression from the G1 to S phase. The appropriate completion 
of deoxyribonucleic acid (DNA) synthesis in its S phase requires the activity of A-type cyclins 
together with CDK2. The cyclin B/CDK1 complex regulates entry to mitosis, whereas 
proteolytic degradation of B-type cyclins regulates the exit from mitosis. Other CDK/ cyclin 
complexes are regulated as follows: (i) inhibiting or activating phosphorylation; (ii) inhibition by 
specific CDK inhibitors (CDKIs) such as p16, p21/WAF1, p27/KIP1 or (iii) by targeted 
degradation, mediated for example by the SCF (Skp1 – Cullin – F-box protein) ubiquitin ligase. 
It has been observed that, in tumour or cancer cells, the cyclin dependent kinase inhibitory 
proteins are either absent or mediated.85 
 
1.6 APOPTOSIS  
   
Apoptosis is an active, energy-dependent, genetically programmed process that occurs widely 
during mammalian development. It offers a practical way of getting rid of old, damaged or 
dangerous cells. Apoptosis is mediated by two major pathways known as the mitochondrial and 
the death-receptor pathways. The various interactions between the two pathways are summarized 
in Figure 19.84,853 The two pathways are intimately connected, and sometimes the death receptor-
mediated apoptotic stimulus is amplified by the mitochondrial loop. It begins when a death-
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ligand (such as tumour necrosis factor (TNF), Fas-ligand (FasL) or tumour necrosis factor-
related apoptosis-inducing ligand (TRAIL or Apo2L)) interacts with its corresponding receptor 
(TNF receptor, Fas receptor or KILLER/DR4 and DR5 respectively) leading to the activation of 
a caspase cascade pathway which includes caspase 8 and caspase 3 as shown in Figure 21. This 
results in the cleavage of proteins that are essential to cell viability.85  
      
                     
Figure 21: The mitochondrial and death-receptor pathway of apoptosis96 
 
The death receptor pathway is an extrinsic one that is triggered by extracellular cues such as 
growth factor withdrawal, matrix detachment and cytokine-mediated killing. The mitochondrial 
cascade is an intrinsic pathway and might be triggered by intracellular cues such as DNA 
damage or osmotic stress and it involves caspase 9 as shown in Figure 21 above. 
 
 The first genetic component of the human cell-death pathway to be identified was the B-cell 
CLL/lymphoma 2 (Bcl2) gene. This pathway is mediated by Bcl-2 family proteins, which consist 
of 20 members that have been recognised and described in humans.83 The relative ratios of anti- 
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and pro-apoptotic Bcl-2 family proteins dictate the ultimate sensitivity or resistance of cells to 
various apoptotic stimuli, including growth factor depletion, hypoxia, radiation and anticancer 
drugs. In response to apoptotic signals, pro-apoptotic Bcl-2 family proteins such as Bax 
translocate and alter the permeability of the mitochondrial membrane which leads to cytochrome 
C release and activation of the caspase cascade. Anti-apoptotic Bcl-2 family members such as 
Bcl-2 and Bcl-xL counter these effects.84  
 
1.7 CANCER IN AFRICA 
 
Cancer is an emerging public health problem in Africa. About 715,000 new cancer cases and 
542,000 cancer deaths occurred in 2008 on the continent.82 Despite its growing burden, cancer 
still receives low public health funding in Africa and this might be due to lack of infrastructure 
and other pressing public health problems.86 Lack of infrastructure (such as poor availability of 
diagnostic and screening services), low awareness of early signs, and limited availability of 
treatment are major challenges faced by the continent. When focusing on the African continent 
one has to take into account that the continent has a diverse population, culture, economic status 
and other sociodemographic characteristics, which affect the occurrence of cancer and its 
outcomes. For example, the Northern Africa region is dominated by Arabs, while the sub-
Saharan region is dominated by an indigenous black population with South Africa having as 
much as a 9% white population.87 These socio-demographics contribute to the variations of 
cancer in each region.  
 
The dominant type of cancers in the continent are cervical, liver, Kaposi sarcoma and urinary 
bladder, and all are a result of an infectious agent.87 The well-known infectious agents are 
viruses, bacteria and parasites. From the literature it has been reported that of the new diagnosed 
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cancers in females, 21% is due to cervical cancer.87 This is the leading cause of death (21,600) in 
women in Eastern Africa 2008, accounting for about 25% of the total new cancer cases and 
deaths.87 Countries like Malawi, Mozambique and Zambia have the highest toll of cervical 
cancer on a world scale. This is due to the high prevalence of human papillomavirus (HPV) 
infection and lack of screening.83 A different picture emerges when looking at Southern Africa. 
Breast cancer was the most diagnosed cancer and the leading cause of cancer death among 
women (9000 cases and 4500 deaths) in Southern Africa.87 It was found that breast cancer 
incidents were six times higher in whites than in blacks.87 The same trend is also observed in 
Northern Africa, where breast cancer is dominant among females.85 In the middle and Western 
Africa both breast and cervical cancers occurred with similar frequency. In sub-Saharan Africa 
cervical cancer still remains the leading cause of cancer deaths among women.87 
 
In males the dominant type of cancer was found to be liver cancer, and this has accounted for 
11% of all cases.83 Liver cancer was the leading cause of deaths among men in Middle and West 
Africa.88,89 When analyzing demographic data, Kaposi’s sarcoma was found to be the leading 
cause of cancer deaths among men in Eastern Africa. Kaposi’s sarcoma is a cancer commonly 
associated with infections of human herpes virus-8 and HIV.88,89 In sub-Saharan and Northern 
Africa chronic infections with hepatitis B virus (HBV) and hepatitis C virus (HCV) are the 
leading cause of deaths among men.90,91 Contamination of staple foods, such as maize and 
ground nuts, with aflatoxin B1, a known cancer-causing agent produced by moulds during 
inadequate storage of crops is the contributing factor.92, In Northern Africa it was lung cancer 
that was more dominant among males and the leading cause of deaths.88 However, the lung 
cancer incidents were only half as high as the rates in Southern Africa and this is due to smoking 
which accounts for 65% of the cases in South Africa. Egyptian men were found to have the 
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highest incidents of bladder cancer.93 About 40% of the disease is caused by a parasite, 
Schistosoma hematobium. The infection occurs when people come into contact with early 
development stage of the parasite which is released by snail larvae. Prostate cancer was 
commonly diagnosed among men in Southern Africa.85 The survival rate after diagnosis is much 
poorer on the continent, which might be due to the fact that most cases are diagnosed at the 
advanced stage. Incident and mortality rates are the two frequently used measures of cancer 
occurrence. They are usually expressed in 100,000 people per year and the mortality rate in 
Africa is high in both male and female when compared to North America. 
 
1.8 CANCER TREATMENTS 
The most feasible and cost effective approach to cancer control in Africa is prevention of 
exposure to cancer-causing agents or risk factors, including infections, tobacco use and obesity. 
The most commonly diagnosed cancers in Africa which are caused by infection are cervical, 
liver and bladder cancers. They are potentially preventable by vaccination, improved hygiene, 
sanitation and/or treatment. For example, the human papillomavirus (HPV) is a cancer causing 
infectious agent that can be prevented by vaccination. The vaccines are administered to 
adolescent girls.  
 
Tobacco use accounts for 20% of cancer deaths world wide and 6% are from Africa. Tobacco 
use shortens life expectancy by 10-20 years.85 The WHO established the Framework Convention 
on Tobacco Control (FCTC), this was due to the globalization of the tobacco epidemic. This 
includes raising the price of tobacco products, banning smoking in public places, restricting 
tobacco advertising and promotion, counter advertising and providing treatment and counselling 
for tobacco dependence. Obesity has also been associated with increased risks of several cancers, 
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including breast, colorectal, stomach, liver, kidney and uterine corpus. The prevalence of obesity 
and physical inactivity is increasing in some African countries thereby increasing obesity 
especially in urban areas. According to the Global School-Based Student Health Survey, more 
than 40% of 13-15 year-old teens in urban areas of Kenya and Zimbabwe spent three or more 
hours per day watching television and doing other sedentary activities.86 Methods that are 
commonly used in the treatment of cancers are chemotherapy, radiation therapy, targeted 
therapy, transplantation therapy, biological therapies and photodynamic therapies. These are 
further discussed below. 
 
1.8.1 CHEMOTHERAPY  
Chemotherapy is the treatment of cancer cells with drugs. The latter kills the cancer cells or 
makes them to be less active. The medicines are used in combination and together are called 
chemotherapy regimes. It can be given before or after surgery in order to shrink the cancer cells. 
If given before surgery it is called neoadjuvant chemotherapy. An example of the medicine used 
for this type of cancer is Abraxane which is albumin bound paclitaxel and called the Taxane 
chemotherapy. Taxane chemotherapy (paclitaxel/Taxol® 77 and decotexel/taxotere® 78) is one 
of the common chemotherapy drugs used for breast cancer (Figure 23). 
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Figure 23: Structure of Taxane and Taxotere 
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 It is given intravenously and it interferes with the ability of cancer cells to divide. These 
chemotherapy drugs are sometimes used in combinations with other drugs, for example 
Fluorouracil (5-FU) for breast cancer. Another example of a well-known anticancer drug is an 
etoposide also known as VP16 (Figure 24).  
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Figure 24: Etoposide 
Etoposide is used for Kaposi’s sarcoma, Ewing’s sarcoma, lung cancer, testicular cancer, 
lymphoma as well as in bone marrow and blood stem transplant.94 The mechanism is such that it 
forms a ternary complex with DNA and topoisomerase II enzyme, thereby breaking the DNA 
strand and promoting apoptosis.94 This is the drug we have selected as a positive control for our 
cancer screening as will be outlined in chapter 7. A vinca alkaloid used in chemotherapy is 
Vinblastine (Figure 25). It is used for breast cancer, head cancer, neck cancer and testicular 
cancer.95 
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Figure 25: Vinblastine 
It is a microtubule-disruptive drug and at low concentration it suppresses microtubule 
dynamics.95 At high concentration it reduce microtubule polymer mass. It also enhances 
microtubule detachment from spindle poles, thereby inducing apoptosis. A quinolone alkaloid 
which is composed of planar pentacyclic ring structure Camptothecin 81 also possesses 
anticancer activity (Figure 26).96 It inhibits the DNA enzyme called topoisomerase I and thereby 
inducing apoptosis.96 
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Figure 26: Camptothecin 
 
1.8.2 RADIATION THERAPY 
Radiation therapy is the use of high-energy radiation to kill cancer cells by damaging their DNA. 
The challenge with this type of treatment is that it can also damage normal cells, therefore 
treatment must be carefully planned to minimize side effects. This involves the use of either a 
radiation machine or a radioactive material placed near tumour cells or injected into the blood 
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stream, in theory using this method cancer cells whose DNA is damaged will die and be 
eliminated naturally by the body.97 
 
1.8.3 TARGETED THERAPIES  
Targeted therapy is the newer type of chemotherapy that use drugs or other substances that block 
the growth and spread of cancer by interfering with specific targets that are involved in tumour 
growth and progression (and is described in more detail in other parts of this Chapter).98 They 
mainly focus on proteins that are involved in cell signalling pathways and thereby help stop 
cancer progression. This induces cancer cell death through the process called apoptosis. 
 
1.8.4 TRANSPLANTATION 
This involves organ or tissue transplants and is dominated by hematopoietic stem cell transplants 
(HSCTs). These include bone marrow and peripheral blood transplants and the organs are mainly 
the liver and the lung. The biggest challenge in this type of cancer treatment is preventing 
rejection by the host. One of the methods used to prevent this is severe immunosuppression at a 
great risk of a variety of infections.99 
 
1.8.5 ANGIOGENESIS INHIBITORS 
Angiogenesis is the formation of new blood vessels. Tumour cells need new blood vessels in 
order to grow and spread. This process involves the migration, growth and differentiation of 
endothelial cells which line the inside wall of blood vessels. Inhibitors prevent the formation of 
new blood vessels in cancer cells, thereby stopping or slowing the growth or spread of tumours. 
For example, Avastin®is (bevazumab) the angiogenesis inhibitor is a monoclonal antibody which 
binds to the vascular endothelial growth factor (VEGF). The latter is then unable to activate the 
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VEGF receptor. Monoclonal antibodies are laboratory produced antibodies that bind to specific 
antigens expressed by cancer cells.100 
  
1.8.6 BIOLOGICAL THERAPIES 
Biological therapy uses living organisms, substances derived from living organisms or synthetic 
versions of such substances to treat cancer. Sometimes vaccines and bacteria are used to 
stimulate the body’s immune system to act against cancer cells. This therapy can be used to 
either treat cancer itself or for side effects of other cancer treatment.101 
 
1.8.7 PHOTODYNAMIC THERAPY 
Photodynamic therapy (PDT) combines a photosensitizer (drug) with a specific type of light in 
order to kill cancer cells. The photosensitizer is activated by light at a specific wavelength and 
produces oxygen that kills cancer cells. For example, Porfimer sodium and photofrin are used in 
PDT treatment as photosensitizers.102 
 
1.9 SUMMARY OF CANCER THERAPY  
In summary, cancer is a leading cause of death worldwide and accounted for 7.6 million deaths 
(13% of all deaths) in 2008. This disease occurs as a result of the suppression of programmed 
cell-death, which results in increased cell-proliferation.  Normally proteins that sense cellular 
damage or growth signals arrest the cell-cycle so that the damage can be repaired or, if that is 
impossible, apoptosis is induced. Malfunction of this system leads to cancer by allowing cells to 
proliferate when they should either be repaired or die. Most cancer deaths are due to late 
detection of the disease, due to a variety of reasons. Common human cancers include 
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osteosarcomas, small-cell lung cancer, melanoma cancer (a skin cancer) and breast cancer. Other 
types of cancers can be due to chromosomal rearrangement. As mentioned above the cost 
effective approach to cancer control is prevention to exposure. Cervical, liver and bladder 
cancers are the most diagnosed types of cancers in South Africa. They can be prevented by 
vaccination or improved hygiene, and can be treated. Methods that are mostly adopted in cancer 
treatment are; chemotherapy, radiation therapy, targeted therapy, transplantation therapy, 
biological therapies and photodynamic therapies. 
 
 In this work we screened our synthesised compounds against four cancer cell line namely; lung 
cancer, renal, breast cancer, melanoma cancer. As mentioned before the structural motif of a 
great number of biological compounds contain fused are aromatic rings, quinones and hydroxyl 
moieties. These moieties have the ability to undergo redox cycling, this process is when 
compounds catalytically cycle and generate ROS such as hydrogen peroxide and superoxide 
which damages the cell. ROS also inhibit active efflux which is responsible for moving 
antibiotics out of the cell. 
 
This study is divided into three sequential parts. The first part is the application of enzymes in 
synthetic chemistry (biocatalysis) to generate polyaromatic and substituted aromatic compounds. 
This is followed by derivitazation of selected compounds with isoniazid and thiosemicarbizide. 
The last section encompasses biological evaluation of the synthesised compounds as anti-
bacterial and anti-cancer agents. Biocatalysis and the objectives of the project will be discussed 
in depth in Chapter 2. 
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2.0 THE AIM OF THE PROJECT 
This study was divided into three distinct parts. The first part is the application of enzymes in 
synthetic chemistry (biocatalysis) to generate polyaromatic and substituted aromatic compounds. 
The reason is to employ green methods in the synthesis of organic compounds as discussed in 
section 2.3. The methodology adopted was C-H activation which is efficient in terms of atom 
and step economy. The latter involves the introduction of a C-H heteroatom bond without the use 
of a functional group such as triflate, halide, tin or palladium catalyst. This is followed by 
derivatazation of selected compounds with isoniazid and thiosemicarbizide. This will be 
discussed in details in chapter 6 of this dissertation. The last section encompasses the biological 
evaluation of the synthesised compounds as anti-bacterial and anti-cancer agents.  
 
The first objective identified was to investigate the use of the enzyme, laccase, in synthetic 
organic chemistry in order to develop novel as well as green synthesis methods for synthesis. As 
explained above green chemistry is environmentally friendly or sustainable chemistry. The 
specific commercial laccase, Suberase®, from Novozymes was selected for this investigation. In 
our investigation we used phenols and quinones as potential substrates for the laccase. 
Quinonoids have been noted in the literature to possess both anticancer and antibacterial activity 
due to their ability to undergo redox cycling which results in the generation of reactive oxygen 
species (ROS), Scheme 1.  
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Scheme 1: Oxidation of a phenolic structure to a quinonoid. 
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Laccase has the ability to oxidise phenols in situ to o-quinones. The quinones then react with 1,3-
dicarbonyls via Michael addition. This will be discussed in detail in Chapter 3. On the other hand 
when a quinone reacts with a 1,3-dicarbonyl it is reduced, resulting in a hydroxyl group. The 
hydroxyl group can be oxidised back to the quinone in the presence of laccase.  This will be 
discussed in more details in Chapter 5. The targeted products for this work are depicted in Figure 
2 below. 
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Figure 2: Targeted compounds. 
 
The second part of the project was to select a number of benzofurans for structural modification 
with isoniazid, a well-known anti-TB drug, and thiosemicarbizide as shown in Figure 3. The idea 
was to increase the potency of the benzofuran derivatives against bacteria and cancer cell-lines 
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by introducing a dual effect. This is observed when a drug is biologically active against two 
targets due to its structural design and is discussed in details in Chapter 5. 
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Figure 3: Structures of benzofuran derivatives 
 
Antibacterial resistance and cancer are major public health problems.  The third objective of our 
study was to evaluate the synthesized compounds for both anticancer and antibacterial activity. 
Several of the compounds were also screened against a range of both Gram positive and Gram 
negative bacteria namely:  Staphylococcus aureus (Gram-positive), Escherichia coli (Gram-
negative), Bacillus substilis (Gram-positive). The minimal inhibitory concentration (MIC) values 
were then determined. In particular we were targeting TB due to the fact that two African 
countries, South Africa and Nigeria, are in the top five countries with the highest toll of TB in 
the world. These were tested sequentially against Mycobacterium smegmatis and  M. 
tuberculosis. Compounds were also screened for anticancer activity against 3 cancer cell-lines; 
that is renal (TK10), melanoma (UACC62) and breast (MCF7).  
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2.1 BIOCATALYSIS  
 
Biocatalysis is the use of biological catalysts, such as enzymes, to perform chemical 
transformations. For this project the enzyme that was explored and utilized was laccase, as will 
be outlined later in this thesis. 
2.1.1 LACCASES 
Laccases (benzenediol: oxygen oxidoreductase, EC 1.10.3.2) are oxidoreductases that are part of 
the family of multinuclear copper-containing oxidases.121,122, They are also known as a blue 
copper oxidoreductase, because most purified laccases exhibit a characteristic blue color due to 
their electronic absorption around 600 nm.123 They catalyze the monoelectronic oxidation of 
substrates using molecular oxygen and release water as the only by-product in a four electron 
transfer process.124,125 The first plant laccase activity was discovered in 1883 by Yoshida in the 
sap of a Japanese tree, Rhus vernicifer.126 Plant laccases are believed to participate in the 
formation of polymer lignins via a radical-based mechanism.127 They can also be found in Rhus 
succedanea, Acer pseudoplatanus, Pinus taeda, Populus euramericana, Liriodendron tulipifera, 
Nicotiana tobacum, Lolium perenne and Zea mays.127 The discovery of fungal  laccases by 
Bertrand then followed in 1896.126 This type of laccase can be found in Trametes versicola, T 
hirsute, T ochracea, T. viloosa, T. gallica, Cerrena maxima, Coriolopsis polyzona, Lentinus 
tigrinus and Pleurotus eryngii. Laccase has also been found in various basidiomycetous and 
ascomycetous fungi.129,130 There are also laccase-like proteins in bacteria such as Azospirillum 
lipoferum, Bacillus sphaericus, Bacillus sp. (mnxG), Bacillus substilis (cotA), Escherichia coli 
(yacK), Marinomonas mediterranea (ppoA), Streptomyces antibioticus and Streptomyces griseus 
(epoA).131  
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2.1.2 THE ACTIVE SITE 
More than a hundred laccases have been isolated and characterised to date. Three laccases have 
been structurally characterized and they are C. cinereus and T. versicolar from Melanocarpus 
albomyces.132 Most fungal laccases are monomeric glycoproteins with an average molecular 
mass of 50-130 kDa. The carbohydrate moiety constitutes 10-45% of the protein mass and is 
comprised of galactose, mannose and N-acetylglucosamine, This enhances the stability of the 
enzyme as well as protecting it against proteolysis and inactivation by free radicals. The active 
site of laccase contains 4 copper atoms which are as follows: one type 1 (T1) copper and a three 
nuclear cluster (T2/T3) consisting of 1 type 2 (T2) and two type 3 (T3).132 
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Figure 4: The active site of laccase encoded by the gene cotA from Bacillus substilis. 
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2.1.3 LACCASE SUBSTRATES AND APPLICATION 
Laccase has a number of characteristics and applications. These range from ligninolytic activity 
of laccase in lignocellulose degradation to application in synthesis.133 They have 
biotechnological, chemical and industrial applications, as well as applications in Green 
Chemistry. Their biotechnological applications include delignification of lignocelluloses and 
desulfurization and solubilization of coal.134 In textile industries it is used for textile dye 
decolorization and remediation of coloured waste waters.135 Their use in enzyme-based 
biosensors allows for monitoring pollutants, and they can also be used in the transformation and 
inactivation of toxic environmental pollutants. Laccase activity has been modified by the use of 
laccase-mediated systems.136 Normally phenolic type laccase substrates also can include 
aromatic amines (Figure 2) and the reaction products are dimers and oligomers.137 
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Figure 5: Structures of laccase substrates. 
 
Scheme 2 show examples, applications and the examples include A. The biotransformation of ferulic 
acid 20 to vanillic acid 21 and vanillin 22,138 B. use in the oxidation of tetrahydro-2-naphthol to form 
a dimeric product as shown in Scheme 2 below and C. use in the coupling reaction of 
dihydrocaffeic acid and 4-amino benzoic acid. 
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Scheme 2: Coupling reaction of dihydrocaffeic acid and 4-amino benzoic acid. 
 
Laccases are similar to other phenol-oxidizing enzymes, but differ in that their substrates can 
extend to non-phenolic subunits of lignin by the inclusion of a mediator such as 2,2’-azinobis-(3-
ethylbenzthiazoline-6-sulfonic acid) (ABTS) 29 (figure 3).139a Other mediators include 
hydroxybenzotriazole (HOBT) 30, 2,2,6,6-tetramethyl-piperidin-1-yl)oxyl (TEMPO) 31, 
hydroxyanthanilic acid (HAA) 32. 
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Figure 3: Laccase mediators 
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Below are the examples of oxidation of indigo to isatin and oxidation of benzyl alcohol to 
aldehydes, using laccase using laccase mediator substrates (Scheme 3).136 The mechanism of the 
mediator substrate oxidation is suggested to occur via electron transfer (ET), radical hydrogen 
atom transfer (HAT)/ ionic oxidation depending on the structure. 
N
H
H
N
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2
N
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O
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33                                                              34
OH
R HR
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35                                                36
 
Scheme 3: oxidation of indigo to isatin and oxidation of benzyl alcohol to aldehydes using Laccase 
Mediator substrates 
 
2.1.3 MECHANISM OF ACTION OF LACASSE  
Laccase only attacks the phenolic subunits of lignin, leading to Cα oxidation to give compound 
38, Cα-Cβ cleavage, and aryl-alkyl cleavage to give compound 39, as shown in Scheme 4 
below.139 
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Scheme 4: Mode of action of laccase 
  
As previously mentioned the active site of laccase contains 4 copper atoms and these are: one 
type 1 (T1) copper and a three nuclear cluster (T2/T3) consisting of 1 type 2 (T2) and two type 3 
(T3).139 The mechanism of laccase has been attributed to three major steps (i) Type 1 copper is 
reduced by accepting electrons from the reducing substrate. (ii) Electrons are transferred from 
Type 1 copper to the trinuclear T2/T3 coppers (iii) Molecular oxygen is activated and reduced to 
water.  
The electron transfer from substrate to Type 1 copper is controlled by a redox potential 
difference. The Type 1 copper site has a shallow pocket whereas Type 2 and Type 3 appear to 
exclude all other oxidising agents except oxygen. Electron transfer from the substrate to the Type 
1 copper site is the rate-determining step.  
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2.2 SYNTHETIC ASPECTS 
   
Most of the published synthesis on Benzofurans involves the formation of annelated ring by 
intramolecular cyclisation of benzene ring.155 These procedures involved multi-steps, rigorous 
reaction conditions and expensive catalysts.155 At the beginning of this research the efficient 
synthesis for benzofurans was reported by Nematollahi and coworkers. It involved the 
electrochemical oxidation of catechols in the presence of 1,3-dicarbonyls (Scheme 5).161a 
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R
OH
OH
4e-, -4H+ O
O
OH
OH
R
43, R = H, 83%   
44, R = CH3, 87%
45, R = OMe,    93%
Yield obtained after consumption of about 3000C electricity
41                                 42                                                            43-45
 
Scheme 5: Electrochemical synthesis of Benzofurans 
 
This electrochemical study was achieved through the addition of a 1mM solution of catechol in 
aqueous solution containing 0.15M sodium acetate as a supporting electrolyte in cyclic 
voltammetry. The oxidation of a catechol occurs in the presence of 1,3-dicarbonyl to a quinone 
as shown in Scheme 6 below. The Michael acceptor 47 is attached at C-5 position yielding to a 
selective formation of benzofuran. 
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Scheme 6: Synthetic sequence for the electrochemical method 
 
 Another efficient method was reported by Wanzlic and Darbawar. This involved the oxidative 
coupling of catechol with 4-hydroxy-coumarins in the presence of ferricyanide.161b The chemical 
aspects were also investigated and with few positive outcomes. One procedure was reported by 
L-x Pei and coworkers, in their approach they used pyridine as a catalyst (Scheme 7).154  
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Scheme 7: Chemical synthesis of Benzofurans 
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This was achieved in ethanol, however if the is presence of water in ethanol it led to no reaction. 
Another disadvantage is that over reaction led to formation of polymers. The use of pyridine 
which is carcinogenic is also a disadvantage. The biocatalytical synthesis however remained 
scarce. The first biocatalytic study at accomplishing the preparation of polyhydroxylated 
benzofurans was reported in 2007 by Witayakran and coworkers (Scheme 15).155 They used 20 
mol% of sodium dodecyl sulfate (SDS) as their surfactant as well as scandium triflate (Sc(OTf)3) 
as a catalyst  in order to enhance Michael addition (Scheme 8).  
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Scheme 8: Biocatalytic synthesis of Benzofurans 
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Our methodology differs from all the published syntheses in that, it fulfills a number of green 
chemistry principles. It achieves selective, efficient transformation, at room temperature, in 
aqueous environment and without the use of an additional catalyst. Details of this methodology 
will be discussed in the chapters that follow. We also noted that there were no published reports 
on biocatalytic synthesis for substituted 1,3-diketones with catechols. To the best of our 
knowledge this is the first report to discuss the biocatalytic synthesis of Benzofuro[3,2-
c]chromen-6-one skeleton from fluorinated catechols and acid catechols with 1,3-dicarbonyls. It 
is also our first report to discuss the biocatalytic synthesis of naphthoquinones containing a 
substituent at position 2 (menadione) with a range of structurally diverse 1,3-dicarbonyls and 
coumarins. For the first time we were able to biocatalytically synthesise derivatives of juglone 
and 1,4-naphthoquinones from 1,3-dicarbonyls. 
 
2.3 BACKGROUND AND ORIGINS OF GREEN CHEMISTRY 
Green chemistry refers to the design and formulation of processes that minimize environmental 
pollution and thereby reduce hazards and risks to human beings. Its main objective is to 
eliminate the hazardous impact of chemicals over a chemical products’ life-cycle. The need for 
environmentally sustainable chemistry first became apparent to the public with a publication by 
Rachel Carson.103 Her publication titled ‘Silent Spring’ (1962) helped spread public awareness of 
the hazards of environmental pollution and pesticides to the environment. In 1969 President 
Richard Nixon established the citizen advisory committee on environmental quality.104 He 
subsequently appointed a White House Committee to determine whether an environmental 
agency should be established. The Environmental Protection Agency (EPA) was established in 
197083 and the Office of Pollution Prevention and Toxics was established in the 1980s. The EPA 
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implemented the Green Chemistry Programme in 1993105 which was followed by the 
establishment of the Presidential Green Chemistry Challenge award in 1995 by President Bill 
Clinton. The Green Chemistry Institute was launched in 1997 with the main objective to advance 
the broader chemistry enterprise and its practitioners for the benefit of the Earth and its people. 
Paul Anastas and John Warner published “The 12 Principles of Green Chemistry” in 1998, 
which codified how chemical process could be made greener. The California Green Chemistry 
initiative was established in 2000 and serves to develop policy options for green chemistry. In 
2001 Paul Anastas was appointed as head of Research and Development at the EPA.106   
 
2.4 The Twelve Principles of Green Chemistry 
These principles were published by Anastas and Warner in 1998 in a book titled: “Green 
Chemistry: Theory and Practice”.106 They serve as the basis of creating and implementing 
chemicals and processes. 
Principle 1: Prevention 
It is better to prevent waste than to treat or clean up waste after it has been created.  
Principle 2: Atom economy  
Synthetic methods should be designed to maximize the incorporation of all material used in the 
process into the final product. 
Principle 3: Less hazardous chemical synthesis  
Synthetic methods should be designed to use and generate substances that possess little or no 
toxicity to humans and the environment. 
Principle 4: Designing safer chemicals 
Chemical products should be designed to affect their desired function while minimizing their 
toxicity.  
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Principle 5: Safer solvents and auxiliaries 
The use of auxiliary substances (e.g. solvents, separation agents etc.) should be made 
unnecessary wherever possible and innocuous when used. 
Principle 6: Design for energy efficiency 
Energy requirements of chemical processes should be more recognized for their environmental 
and economic impacts and should be minimized. If possible, synthetic methods should be 
conducted at ambient temperature and pressure. 
Principle 7: Use of renewable feedstocks 
A raw material or feedstock should be renewable rather than depleting wherever technically and 
economically practicable.  
Principle 8: Reduce derivatization 
Unnecessary derivatization (use of blocking groups, protection/deprotection, and temporary 
modification of physical/chemical processes) should be minimized or avoided if possible 
because such steps require additional reagents and generate waste.  
Principle 9: Catalysts 
Catalytic reagents (as selective as possible) are superior to stoichiometric reagents.  
Principle 10: Design for degradation 
Chemicals should be designed so that at the end of their function they break down into innocuous 
products and do not persist in the environment.  
Principle 11: Real-time analysis for Pollution and Prevention 
Analytical methodologies need to be further developed to allow for real-time process monitoring 
and control to limit the formation of hazardous substances. 
Principle 12: Inherently safer chemistry for accident prevention 
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Substances and a form of a substances used in chemical processes should be selected to 
minimize the potential of chemical accidents including releases, explosions and fires. 
 
2.5 The importance of Green Chemistry 
Green chemistry focuses on meeting the needs of the present generation without compromising 
the needs of future generations. It also looks at methods for the prevention of primary pollution, 
not on remediation. It reduces waste, materials, hazards, risks, energy and cost. One of the good 
examples where a Green method is utilised is in the commercial synthesis of acetophenone 
(Scheme 9).107  
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Scheme 9: The commercial synthesis of acetophenone. 
 
The traditional synthetic method makes use of toxic chemicals that are in the EPA Toxic Release 
Inventory (TRI). This route generates a byproduct-chromium (III) sulfate that is a TRI chemical 
known to be a human carcinogen and its atom efficiency is only 42% whereas the green method 
provides a more user friendly method with only water as a byproduct at 87% atom efficiency. 
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2.6 GREEN CHEMISTRY IN PHARMACEUTICAL INDUSTRIES  
2.6.1 Background 
The practice of Green Chemistry has become a widespread protocol in some industry sectors. In 
2005 the Green Chemical Institute (GCI) and global pharmaceutical corporations established the 
GCI Pharmaceutical Roundtable.104,105 This was done to encourage innovation while catalyzing 
the integration of green chemistry and green engineering in the pharmaceutical industry for 
sustainable business. Sustainability in green chemistry can be defined as a step towards processes 
that are cleaner and/or that make better use of beneficial resources. Members of the Roundtable 
include the American Chemical Society (ACS), The Green Chemical Institute (GCI), Amgen, 
AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Codexis, Dr Reddy’s, DSM 
Pharmaceutical products, Eli Lilly and company, Genentech (a member of the Roche group), 
GlaxoSmithKline, Johnson & Johnson, Merck & Co Inc, Novartis, Pfizer Inc., Roche and 
Sanofi.106 In 2011 the medicinal chemistry subgroup of the roundtable was established.106 The 
main reason for this group is to encourage the intergration of green chemistry and engineering 
principles into discovery research. 
 
2.6.2 Drug Discovery 
There are a number of considerations when designing drug molecules and these include 
molecular property calculations, structure-based drug discovery (SBDD), in silico models, 
quantitative structure-activity relationship (QSAR) etc.109 The challenge with medicinal 
chemistry is that the chemistry selected when the compound is first synthesized can have a large 
influence on the chemistry of an ongoing project and a chemist might be under pressure to 
rapidly achieve a target for development of a process. However, the principles of green 
chemistry can always be implemented after synthetic route design. There are a number of 
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synthetic strategies that pharmaceutical companies have adopted or would like to adopt when 
applying green principles and are discussed below. 
 
2.6.2.1 C-H Activation 
This methodology is efficient in terms of both atom and step economy. It has become prominent 
in the past decade and is currently considered to be one of the very topical areas of research. It 
involves the introduction of a C-C or a C-heteroatom bond without requiring a functional group 
such as a halide, triflate, boron, tin and other metalation processes. For example, Prof Jin-Quan 
Yu, in collaboration with Pfizer, demonstrated C-H functionalization for late stage derivitization 
of the anti-inflammatory drug, Celecoxib, which has a sulfonamide moiety (Scheme 10).110 A 
wide range of new analogues were accessed in a single transformation that involves olefination, 
carboxylation, carbonylation, iodination, arylation and methylation (Scheme 10). Prior to the 
development of this methodology it would have required many steps, solvents, energy and 
generation of waste streams.  
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Scheme 10: Yu’s exemplification of C-H functionalization directed by a sulfonamide moiety. 
 
Another example where these mild and novel methods are applied is in the late stage 
derivitization of drug-like heterocycles. Zinc sulfinate reagents were adopted for fluoroalkylation 
and alkylation of unactivated C-H bonds on aryl, heteroaryl and aliphatic substrates by the Baran 
group.110 This one-pot sequential functionalization of a complex molecule, dihydroquinine, 
undergoes regioselective trifluoromethylation followed by isopropylation to regioselectively 
afford the doubly derivatized product in a 30% yield (Scheme 11).  
Chapter 2                     Laccases as catalysts for a sustainable route towards Benzofurans 
63 | P a g e  
 
N Hb
MeO
Ha
OH
N
Et
2.  R = iPr, TBHP
     one pot 30%
1. R = CF3, TBHP, TFA
    CH2Cl2/ H2O
S
O
O RZn
N
MeO
F3C
OH
N
Et
70                                                                                            71
 
Scheme 11: Baran’s sequential functionalization of dihydroquinine. 
 
This methodology is atom efficient, reduces time and energy, uses only Zn as a catalyst and the 
reaction is performed in the environmentally friendly solvent water. Although C-H activation is 
not applicable in all circumstances, chemists are encouraged to consider this and other synthetic 
improvements when designing routes to targets. 
 
2.6.2.2 Aqueous Chemistry 
Palladium-mediated reactions have been well known for the past two decades within the 
chemistry community. This was more evident by the award of the 2010 Nobel Prize to Heck, 
Suzuki and Negishi who pioneered the palladium-mediated processes that now bear their 
name.111 Advances have been made in the past years in order to adopt green methods in 
palladium catalyzed reactions.112 For example Lipshutz and co-workers developed a micellar 
catalysis using environmentally benign designer surfactants as shown in Scheme 12. The concept 
of the micellar catalysis relies on the ability to solubilize organic based reactants in aqueous 
media by the addition of a surfactant. 
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Scheme 12: A representative of a Lipshutz surfactant. 
 
The substrate becomes trapped within a nano-micelle within the water and the chemistry takes 
place within this compartmentalization. This approach has been utilised in a number of reactions 
including a designed surfactant linking a vitamin E derivative through a linker (succinic or 
sebacic acid) to a polyethylene glycol chain of varying lengths. Other success stories include 
transition metal mediated cross-couplings (from halide precursors and through C-H activation), 
olefin metathesis, 1,4-conjugate addition of hydride and Mitsunobu type reactions. With regards 
to Negishi reactions (Scheme 13, A), addition of tetramethylethylenediamine (TMEDA) and as 
an additional catalyst which is critical due to the conversion of organozinc reagents to pure 
aqueous reagents. In the absence of TMEDA and additional catalyst, there is an incompatibility 
of conventional organozinc reagents to purely aqueous conditions which is not in favor of the 
reaction. 
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Scheme 13: Surfactant methodology in common Palladium-mediated couplings. 
 
These methods often lead to reactions that have high regio and geometric selectivity, can occur at 
room temperature, reduces energy, have high efficiency, occur under remarkably mild conditions 
and avoid organic solvents. 
 
2.6.2.3 Telescoping 
Telescoping refers to multiple synthetic steps that are performed in one pot.114 Historically this 
application was more focussed on multicomponent reactions as opposed to sequential orthogonal 
reactions. This application reduces time, energy, solvent, as well as product extraction and work 
up time. This has been succesfully adopted for application of methyliminodiacetic acid (MIDA) 
boronates toward the preparation of drug-like arrays. Protected borates were developed by 
Burke.115 A one-pot sequential reduction-amination Suzuki-Miyaura cross coupling (SMCC), 
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heterocycle formation SMCC and Buchwald-Hartwig-SMCC were also achieved (scheme 
14).116-118      
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Scheme 14: A one-pot sequential reduction-amination Suzuki-Miyaura cross coupling (SMCC) 
 
2.6.2.4 Flow Chemistry 
The new and developing area of flow chemistry, which involves continuous reactions rather than 
batch reactions, is favorable in the pharmaceutical industries since it can result in higher yields, 
increased safety, less solvent usage, reuse of solid supported catalysts, less waste generation and 
the possibility of automation.119 Flow chemistry is now found at all stages of drug discovery and 
development processes. 120 It is used for safety, as only limited quantities of unstable 
intermediates were present at any one time in, for example, the azide synthesis.120 Azide 
synthesis is toxic and can cause an explosion due to the presence of hydrazoic acid produced 
from sodium azide, Flow chemistry shortens the duration of the synthesis and prevents potential 
reactive intermediates produced.120 Also it is safer for reactions where extreme pressure and 
temperature are required. From the literature it has been noted that 40-50% of all reactions 
recently hypothesized in pharmaceutical industries are suitable for continuous flow chemistry, 
and that it requires 10% less solvent usage.119 An example where reactions takes place above the 
boiling point is in the use of a channel flow reactor for the synthesis of an azide which mitigates 
the toxicity and explosion risks associated with hydrozoic acid produced from sodium azide 
(Scheme 15a). Another example is the Claisen rearrangement reaction that takes place at 230°C 
as shown in (Scheme 15(b)). 
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Scheme 15: Reactions enabled by operation in thermal tube flow reactors. 
 
A challenge arises when the product precipitates in the channel reactor. In order to address this 
challenge, co-solvents are introduced in flow chemistry in order to promote solid formation post 
reaction. This is not feasible for all reactions, but for most reactions it does prevent clogging. For 
heterogeneous mixtures, continuous stirred tank reactors (CSTRs) have been a solution. The 
Schotten Bauman acylation and crystallization adopts this method in three disposable continuous 
stirred tanks. This type of reaction solves the challenges that chemists face when scaling up. 
 
The chapters that will follow will discuss the laccase-based synthesis of the desired compounds 
in more detail, including Benzo[b]furans, Benzo[3,2-c]chromen-6-ones, quinone derivatives, as 
well as an imine/Schiff base family.  
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3.0 INTRODUCTION 
   
Benzofurans are attractive to chemists because they possess a broad range of biological 
activities. Anti-allergic and anti-inflammatory activities have been exhibited by 5-benzofuranol 
1, while benzofuran fused benzocarbazoles 2 (Figure 1) exhibit antitumor and antibiotic 
activities.140, 141 Benzofurans, of which machicendiol 3 is an example, are used in the treatment 
of asthma, rheumatism and ulcers.142 Amiodarone hydrochloride 4, an ideal antiarrhythmic drug, 
contains a 2,3-substituted benzofuran moiety.143 It has also been noted that benzofurans that 
possess an hydrazide group exhibit a broad spectrum of pharmacological and biological 
properties, such as analgesic, anticancer and anti-inflammatory properties that may be due to a 
the azomethine linkage.144 It has been observed that compound 5, a Schiff-base bearing several 
methoxy groups has pronounced antimicrobial activities.145 
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Figure 1: Biologically active benzofuran derivatives 
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Benzofurans 7 and 8 possess anticancer activity, while both 10 and 11 exhibit antibacterial 
activity as shown in Figure 2. Usnic acid 6 and 9 are particularly interesting as they exhibit either 
anticancer activity or antibacterial activity depending on the isomer synthesized. This metabolite 
showed activity against the wild-type p53 breast cancer cell line MCF7 (IC50/GI50 = 18.9 µM), 
and the lung cancer cell line H1299 (IC50/GI50 = 22.3 µM). This was one of the motivations for 
screening our synthesised benzofuran derivatives for both anticancer and antibacterial activity as 
discussed in Chapter 8. 
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Figure 2: Benzofurans exhibiting anticancer and antibacterial activity.   
 
The strategies for the construction of benzofurans varies from the ring closing metathesis 
reaction. In 1978 Takia reported that a reagent prepared from Zn, TiCl4 and CH2Br2 can 
olefinate carbonyl in a manner that is similar to the Tebbe-like reagents as shown in Scheme 1 
below. 
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Scheme 1: Olefination of a carbonyl to a benzofuran 
Another example is the coupling of conjugated dienynes with Fisher carbene complexes, anion-
accelerated palladium-mediated intramolecular cyclization. In the synthesis of benzofurans 
Fischer carbene complexes are coupled with aldehydes 15 which results in furan derivatives 16 
as shown in Scheme 2. This ring system can undergo Diels-Alder reactions to give compound 
18. 
O
H
Cr(CO)5
OMe O
R
OMe
+
MeOOC
COOMe
R
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O
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COOMe
 15                                                    16                         17                                                    18
   
Scheme 2: Diels-Alder reaction in the synthesis of a benzofuran 
 
 
This reaction sequence serves as a cornerstone for preparation of pharmaceutically important 
structures, for example estrogen like structures.146-159 Biologically important furopyridines can be 
prepared by this approach in high yields. The detailed mechanism is such that it involves 
cyclisation of vinyl bromide by heating bromide with CS2CO3 in dimethyacetamide (DMA) in 
the presence of catalytic amounts of Herrmann’s palladacyclic catalyst (HC) as shown in Scheme 
3. 
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Scheme 3: Palladium-catalyzed intramolecular coupling of aryl halides with phenols 
 
 
The main side product of this reaction, which was not observed in the aryl coupling process, is 
resorcinol. The exact mechanism for this side chain elimination is not clear. Another example 
from literature is utilization of o-hydroxyphenyl ketones or o-(1-hydroxy-2,2-
dimethylpropyl)phenol 23 with 1-benzotriazol-1-ylalkyl chloride 25 . These reactions undergo a 
two or three steps mechanism as shown in Scheme 4. 
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Scheme 4: Synthesis of benzofuran derivatives from o-(1-hydroxy-2,2-dimethylpropyl)phenol 23 and 1-
benzotriazol-1-ylalkyl chloride 25 
 
 
The mechanism is similar to the one described in Scheme 3 with the exception of oxidizing an 
alcohol to a ketone using Sir Ewart Jones reagents (pyridium chlorochromate in DMF). 
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The goal of our research was to develop green methods of synthesis of the 5,6-dihydroxylated 
benzo[b]furans 27 using laccase biocatalysis (Scheme 5).  
O
R1
O
R2
R
OH
OH
Oxidation OR1
OR2
R
O
O
27                                                               28
 
 Scheme 5: Oxidation of a phenol to a 1,2-quinonoid 
Since quinonoid compounds display potent biological properties such as antibacterial, anticancer, 
antifungal and antimalarial activity,160  we anticipated that the 5,6-dihydroxylated benzo[b]furans 
27 could have similar pharmacological activities because the ortho phenolic substituents 
(hydroxyl groups) could be oxidized to the corresponding o-quinone 28 within the cell. This 
study, which we published in 2013,161 was the first on the synthesis of a variety of 5,6-
dihydroxylated benzo[b]furans 27 and catechol derivatives using the commercial laccase, 
Suberase®, as well as the first report on the anticancer activity of the synthesised compounds (see 
the Appendix). The published manuscript is included in the dissertation, and is appended after 
the references. 
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3.1 RESULTS AND DISCUSSION 
 
3.1.1 SYNTHESIS 
 
Our interest was in both cyclised and un-cyclised 1,3-diketones. We explored a number of 
different methods as shown in Scheme 6 below. 
 
The method used for the synthesis entailed reacting one equivalent of the catechol with one 
equivalent of the 1,3-dicarbonyl at room temperature using the laccase Suberase® in a vessel 
open to air at pH 7.15 (Scheme 6). A pH of 7.15 was chosen because it would make the reaction 
medium sufficiently basic to deprotonate the alpha-proton from the 1,3-dicarbonyls and thus 
facilitate the Michael addition reaction with the in situ-generated o-quinone. This is then 
followed by oxidation, which is then followed by cyclisation. 
 
OH
OH
O
OLaccase
atmospheric O2 H2O
R1 R1
Oxidation
O
O
R1O
R3R2 +
O
OH
R1
R2
R3 O
O O
OH
R1
R2
R3 O
OH
O
R1
OH
OH
R2
OR3
Cyclisation
Michael addition Enolization
OH
29 30
31                               30                                                          32                                                      33
34-47
 
Scheme 6. Synthesis of the 5, 6-dihydroxylated benzo[b]furans 34-47. 
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The catechols (29a–e) and the 1,3-dicarbonyls (31a–e) used in this study are depicted in Figure 
3. 
 
O O
O
O
O
O
O
O
O
O
OH
OH
OH
OH
O
OH
OH
29a                    29b                     29c                            29d                    29e
31a                       31b                   31c                   31d                              31e
F
OH
OH
O OH
OH
OH
 
Figure 3. The catechols 29a–c and 1,3-dicarbonyls 31a–f used in this study. 
 
The first approach, Method A, entailed reacting the catechols 29a–e with the 1,3-
dicarbonyls 31a–e at room temperature (rt) at pH 7.15 for 24 h. The second approach, Method B, 
entailed conducting the reaction under the same conditions but for a longer time (44 h) to 
determine whether a longer reaction time would improve the yield of the product. In the third 
approach, for Method C, DMF was added to the reaction mixture as a co-solvent to improve the 
solubility of the organic substrates. The number of equivalents of the 1,3-dicarbonyl was also 
increased so that a ratio of 1,3-dicarbonyl to catechol was 4:1. These reactions were conducted 
for 42 h. We were able to successfully synthesise compounds 34-47 shown in Figure 4. 
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34  (48, 49)%                          35  50%                         36 65%                          37 (62, 67)%
38 70%                                     39 (59, 30)%                            40  (78, 71)%                       41 (37%)
42 (58, 40)%                     43 (98, 59)%                                  44  26%                           45 27%
46  29%                                                             47 30%
 
Figure 4: Structures of the 5, 6-dihydroxylated benzo[b]furans 34-47 synthesised at rt. 
 
For fluorinated catechols 29d the desired product was not formed. We were also unable to form 
benzofuran derivatives with the acid catechol 29e. Interestingly, we observed in the 1H NMR 
spectrum the effect of chirality in the neighbouring hydrogens for compounds with a stereogenic 
centre as shown Figure 5 below. The reason for this is that Ha and Hb are in different 
environments or diastereotopic due to the presence of the stereogenic centre. 
O OH
OH
O
Hb
Ha
Chiral centre
39
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Figure 5: Structure of 7,8-Dihydroxy-3-methyl-3,4-dihydrodibenzo[b,d]furan-1(2H)-one  
The 1H nuclear magnetic resonance (1H NMR) for compound 39, for example, shows two 
doublet of doublets  at 2.30 (1H, dd, J 4.6, 12.8 Hz, CHa) and 3.01 (1H, dd J 4.6, 12.8 Hz, CHb) 
 
The results of the investigations with Methods A to C are depicted in Table 1. 
 
Table 1. Synthesised benzo[b]furans 34-47, 49, 50 (yield in parentheses) at rt in phosphate buffer at pH 7.15 
________________________________________________________________________________________ 
Entry Catechol Dicarbonyl Reaction   Method   Product Yields of other Yield of 
                                                              time (h)                    (%Yield)           enzymatic     other syntheses   
___________________________________________________________________________________________  
1 29a   31a  24 A 34(48) 60153  47154 
2 29a   31a  44 B 34(49) 
3 29b   31a  24 A 35(50) 76155, 62153 
4 29a   31b  24 A 36(65) 87156  22157  
5 29b   31b  24 A 37(62) 70156   
6 29b   31b  44 B 37(67) 
7 29c   31b  24 A 38(70) 89156 
8 29a   31c  24 A 39(59) 85156, 39158   
9 29a   31c  42 C 39(30) 
10 29b   31c  24 A 40(78) 71156 
11 29b   31c  42 C 40(71) 
12 29c   31c  24 A 41(37) 97156 
13 29a   31d  24 A 42(58) 91156   90159,90160,82161,66162 
14 29a   31d  42 C 42(40) 
15 29b   31d  24 A 43(98) 92156  87161 
16 29b   31d  42 C 43(59) 
17 29c   31d  24 A 44(73) 95156  93161,80162 
18 29c   31d  44 B 44(77)  
19 29a   31e  24 A 45(76) 96156, 44158 
20 29a   31e  42 C 45(50) 
21 29b   31e  24 A 46(80) 91156 
22 29c   31e  24 A 47(43) 97156 
23 29c   31e  42 C 47(15) 
24 29b   48  24 A 49(80) 
25 29c   48  24 A 50(55) 
________________________________________________________________________________________________________ 
Method A –Suberase® (8.0 mL), catechol (2.0 mmol), 1,3-dicarbonyl(2.0 mmol, 1 eq), phosphate buffer (20.0 mL, 0.10 M, pH 
7.15), stirring time at rt = 24 h. 
Method B – Suberase® (8.0 mL), catechol (2.0 mmol), 1,3-dicarbonyl (2.0 mmol, 1 eq), phosphate buffer (20 mL, 0.10 M, pH 
7.15), stirring time at rt = 44 h 
Method C – Suberase® (4.5 mL), catechol (0.60 mmol), 1,3-dicarbonyl (2.4 mmol, 4 eq), phosphate buffer (4.0 mL, 0.10 M, pH 
7.15) and DMF (2.0 mL), stirring time at rt = 42 h. 
 
From these results it can be seen that 5,6-dihydroxylated benzo[b]furans can be accessed using 
all three synthesis methods. For Method A the highest yield that was obtained is 98% 
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for 43 (Entry 15, Table 1) and the lowest is 37% for 41 (Entry 12, Table 1). For Method B the 
highest yield was 77% for 44 (Entry 18, Table 1) and the lowest 49% for 34 (Entry 2, Table 1). 
In the case of Method C, the highest yield was 71% for 40 (Entry 11, Table 1) and the lowest 
15% for 47 (Entry 23, Table 1). When comparing the yield of product using Method A to that 
obtained using Method B, it can be seen that there was not a significant increase in yield even 
though the reaction time has almost doubled (Entries 1 and 2, 5 and 6, 17 and 18, Table 1). It was 
therefore concluded that there was a limit to the quantity of product that can be formed in the 
reaction. The presence of DMF (Method C) may have deactivated the laccase, Suberase®, 
resulting in a lower yield of the product. As explained by Müller et. al the higher volume of 
organic solvent increases the solubility of a substrate but significantly decreases the overall 
reaction rate by deactivating the enzyme.127 The optimum conditions for synthesising these 5,6-
dihydroxylated benzo[b]furans using Suberase® were thus that used under Method A.  
 
The biocatalytic synthesis of 5,6-dihydroxylated benzo[b]furans has been reported previously, 
with the  first enzymatic synthesis of compound 35 being reported in 2007 by Witayakran et 
al.153 using Trametes villosa laccase in phosphate buffer (pH 7.0) with a Lewis acid, scandium 
tris(trifluoromethanesulfonate), and sodium lauryl sulfate at 20ºC and afforded it in 76% yield 155 
as shown in Table 1. In 2009, Witayakran et al. also reported on a laccase–lipase co-catalytic 
system for the synthesis of compounds 34 and 35 using phosphate buffer (pH 7.0) with lipase.153 
Although lipase is used to catalyse the hydrolysis of esters and bromohydrin esters it was used in 
their study as a co-catalyst, wherein the Michael addition step was enhanced by lipase addition 
providing improved yields. Compound 34 was obtained in 60% yield using Candida rugosa 
lipase and laccase from T. villosa at 23°C. Compound 35 was obtained in 62% yield using 
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Candida antarctica (CALB) lipase and laccase from T. villosa at 23ºC.153 We have synthesised 
compounds 34 and 35 without the use of scandium tris(trifluoromethanesulfonate) or lipase and 
achieved a 49% yield of compound 34 (Entry 2, Table 1) and a 50% yield of compound 34 
(Entry 3, Table 1) Hajdok et al.154 was the first to report on the synthesis of compounds 36–47 
using laccase initiated oxidative domino reactions. One method entailed using a commercial 
laccase from Trametes versicolor in an acetate buffer (pH 4.38) at room temperature while the 
other method used laccase from Agaricus bisporus in phosphate buffer (pH 5.96) also at rt. The 
latter method was found to be better since it gave the product in higher yield and purity with 
yields ranging from 71 to 97%. The yields of compounds 34–35 using our methods are 37–98%, 
however all the purity yields are above 90%. The commercial fungal laccase, Suberase® from 
Myceliophthora thermophila, was overall less effective than the laccase from A. bisporus which 
was used by Hajdok et al.154 Compounds 39 and 45 (entry 8 and 19 respectively, Table 1) have 
also been synthesised by employing tyrosinase and laccase from A. bisporus and were obtained 
in 39 and 44% yields, respectively.156 Our method was higher yielding since compound 39 was 
obtained in 59% yield and compound 45 in 76% yield (Entries 8 and 19, respectively, Table 1). 
There have also been literature reports on the chemical syntheses of 5,6-dihydroxylated 
benzo[b]furans. The first report of compound 34 was a chemical synthesis which afforded 34 in 
47% yield using pyridine and sodium metaiodate in ethanol at 20ºC.154 Our methods afforded 
similar yields for compound 34 (48 and 49%, Entries 1 and 2, respectively, Table 1). Duthaler 
and Scherrer reported on the chemical synthesis of compound 36 which was obtained in 22% 
yield using sodium acetate in water.157 We were able to obtain compound 36 in 65% yield (Entry 
4, Table 1). Electrochemical syntheses have also been reported for the synthesis of 5,6-
dihydroxylated benzo[b]furans. The first report on the synthesis of 42 was by Grujic´ et al.159 In 
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1976 and afforded it in 90% yield. Later Tabaković et al.160 also reported on the electrochemical 
synthesis of 42 in 90% yield in water.160 Another electrochemical synthesis of 42 using sodium 
acetate in water by Nematollahi et al.161 afforded it in 82% yield. The electrochemical synthesis 
of 42 by Davarani et al.162 only afforded a 66% yield. We could only obtain a 58% yield 
for 42 (Entry 13, Table 1). Nematollahi et al.161 also reported on the electrochemical synthesis 
of 43 and 44 (entry 15 and 17) which were obtained in 87 and 93% yields, respectively, also 
using sodium acetate in water as a reaction medium. The electrochemical synthesis 
of 43 and 44 in a sodium acetate solution by Davarani et al.162 afforded these compounds in 
slightly lower yields, 81 and 80%, respectively. Compound 43 was obtained in 98% yield (Entry 
15, Table 1) which is higher than the yields obtained by electrochemical synthesis, while 
compound 44 was obtained in 77% yield (Entry 18, Table 1) which was lower than that obtained 
by electrochemical syntheses.  
  
Two reactions, using derivatives with the 1,3-diketone containing an extra methyl substituent, 
gives insights into the oxidative catalytic mechanism of laccase on benzofurans. In this approach, 
as expected we formed an intermediate that could not cyclize due to the presence of methyl at 
position 2 as shown in Scheme 2 below. This then supports the reaction mechanism in the 
synthesis of benzofurans. 
HO
HO
R
+
O O
R
OH
OH
O
OSuberase
Phosphate buffer, 
pH 7.15, rt, 24h
49=R = Me, 80%
50=R =  OMe, 55%
29b, 29c                           48                                                       49-50
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Scheme 7 
The proposed mechanism involving an o-quinone intermediate of 29b and 29c is shown in 
Scheme 5 below. The mechanism is such that the catechol is oxidised to an ortho-quinone. The 
quinonoid undergoes a Michael addition reaction with a substituted 1,3-diketone. However since 
it is substituted the second enolization cannot take place and instead a subsequent re-
aromatization takes place as shown in Scheme 8 below. 
 
O O
HO
HO
R
O
O
R OH O
HO
O
R
O
O
H
H
-H+
HO
O
R
O
O
H
HO
HO
R
O
O
48
29b, 29c
49; R = Me
50; R = OMe
Oxidation
 
Scheme 8: A proposed mechanism for C-C bond formation for the catechol derivatives 29b and 29c. 
 
These reactions were conducted using Method A which was used for the synthesis of the 5,6-
dihydroxylated benzo[b]furans 34–47. In this case, the aim was to synthesize one carbon-carbon 
bond using the 1,3-dicarbonyl 48 without subsequent cyclisation. This reaction is of crucial 
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significance as cross coupling of an enolates cannot take place with unactivated sp2-hybridized 
electrophiles without a transition-metal catalyst (Scheme 6). 
OH O
+ R
O O
R
 
Scheme 9: Showing unactivated sp2-hybridized electrophiles not reacting with enolates. 
 
These types of reactions can only take place through the enolate arylation reaction and it 
proceeds via the classical cross-coupling mechanism which includes; oxidative addition, 
transmetalation and reductive elimination as shown in Scheme 7 below. 
OH O
+ R
O O
R
Pd(0)/Pd(II)L
base
 
LnPd(0)
ArPd(Ln)xAr(Ln)Pd
R1
O
R2
Arx
oxidative addition
transmetalation
reductive 
elimination
Ar O
R1R2
 
Scheme 10:  Showing activated sp2-hybridized electrophiles reacting with enolates. 
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We have successfully demonstrated that the enzyme Suberase® can be utilised in cross coupling 
of enolates to unactivated sp2-hybridized electrophiles without the use of a transition-metal 
catalyst. 
3.2 CONCLUSION 
The fungal laccase from M. thermophila, which is commercially available as an inexpensive 
preparation known as Suberase®, can be used in the catalytic synthesis of benzofurans under 
mild and environmentally friendly reaction conditions. A pH of 7.15 was chosen because it 
would make the reaction medium sufficiently basic to deprotonate the alpha-proton from the 1,3-
dicarbonyls and thus facilitate the Michael addition reaction with the in situ-generated o-
quinone. This is then followed by oxidation which is then followed by cyclisation to give us our 
desired 5,6-dihydroxylated benzo[b]furan. Evidence for this catalytic mechanism comes from the 
use of 1,3-diketone blocked at carbon 2, where it was evident that under these conditions we 
were unable to cyclise the intermediate to a benzofuran and rather achieved a C-C monocoupled 
product. The yields achieved in the present study are, in some cases, similar to or better than that 
obtained by other enzymatic, chemical, or electrochemical synthesis. This method has eliminated 
the use of the Lewis acid, scandium tris (trifluoromethanesulfonate), and lipase which was used 
in previous laccase methods.A proposed mechanism involves an o-quinone intermediate and the 
mechanism is such that the catechol is oxidised to a quinonoid. The quinonoid undergos a 
Michael addition reaction with a substituted 1,3-diketone. However since it is substituted the 
second reduction cannot take place. This opened the question as to what other reactants could be 
included to yield a wider range of products. We successfully demonstrated that the enzyme 
Suberase® can be utilised in cross coupling of enolates to unactivated sp2-hybridized 
electrophiles without the use of a transition-metal catalyst. 
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4.0 INTRODUCTION 
 
As discussed in Chapter 3 natural products with a benzofuran skeleton are well known for their 
broad range of biological activities.163 Coumestan 1, which contains a benzofuro [3,2-c]chromen-
6-one skeleton, belongs to an important class of natural oxygenated aromatic products (Figure 1), 
the flavonoid category of phytoestrogens.163 These compounds  exhibit antibacterial, anticancer 
antifungal, antihepatotoxic, and phytoalexin activities.163,164  In China compounds with 
benzofuro[3,2-c]chromen-6-one skeleton are used in the treatment of septic shock.165 They are 
found in a variety of plants including split peas, pinto beans, lima beans, alfalfa and clover 
sprouts. 
 
O
O R3
R4
O
R2
R1
A
D
1
 
Figure 1: The structure of a coumestan. 
 
 
 
HCV, a major human pathogen that causes non-A and non-B hepatitis, is also associated with the 
development of chronic disease such as steatosis, liver cirrhosis and hepatocellular carcinoma. 
HCV infection is estimated to be four to five times more prevalent than the Human 
Immunodeficiency Virus-1 (HIV-1).166 Although there is currently no vaccine for HCV, five 
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coumestan analogues, Wedel lactone 2, LQB16 3, LQB34 4, LQB93 5 and LQB96 6 have been 
reported to inhibit HCVNS5B which is required for viral RNA replication in HCV (Figure 3).  
 
O
O OH
OH
O
OH
HO
A
D
O
O OCH3
OH
O
OH
HO
A
D
O
O
O
OH
HO
A
D
O
O OCH3
OH
O
OH
CH3O
A
D
O
O OH
OH
O
OH
CH3O
A
D
HO
HOH3CO
O
O
2 3
4 5 6
 
Figure 2: Five coumestan analogues that inhibit HCVNS5B. 
 
In the literature it has been reported that benzofuro[3,2-c]chromen-6-ones can be synthesized by 
electrochemical oxidation, tyrosinase-catalyzed oxidation, as well as chemical oxidation using 
ferricyanide.  In light of the biological activity exhibited by the coumestans and the structural 
similarity (ortho phenolic substituents) to the 5,6-dihydroxylated benzo[b]furans 7 (Chapter 3) we 
were interested in developing a green, efficient one-pot synthesis using laccase as the catalyst.    
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Figure 3: Showing a structure of a coumestan and benzo[b]furans 
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4.1 RESULTS AND DISCUSSION 
 
4.1.1 SYNTHESIS 
 
The catechols 8a–e and the coumarins 9a–d used in this study are depicted in Figure 5. The 
method used for the synthesis entailed reacting one equivalent of the catechol 8a–e with one 
equivalent of the coumarin 9a–d shown in Scheme 1 using Suberase® in a vessel open to air at 
pH 7.15. A pH of 7.15 was chosen because it would make the reaction medium sufficiently basic 
to allow for deprotonation of the acidic hydrogen of the coumarin and thus facilitated the 
Michael addition reaction with the in situ-generated o-quinone. 
 
OH
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 8a                          8b                       8c                      8d                       8e
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Figure 4: The catechols 8a–e and coumarins 9a–d used in this study. 
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Scheme 1. Synthesis of the 5,6-dihydroxylated benzo[b]furans 10-29. 
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From the twenty compounds that were successfully synthesized (Figure 6), five are known 
(compound 10, 11, 12, 15 and 16) and 15 are novel (compounds 13, 14, 17-29). Bhalerao et al 
have reported a synthesis for 15 in 94% yield using  a mushroom tyrosinase enzyme at ambient 
temperature in phosphate buffer (pH 6.8).166 Leutbecher et al. reported the synthesis of 
compound 15 in 94% yield with  Trametes versicolor laccase in  acetate buffer (pH 4.37) at 
20°C.167 They also reported the synthesis of 16 in 96% yield after 49 h using  Agaricus bisporus 
laccase in acetate buffer (pH 6.0) at 20°C.167 Bhalerao et al also demonstrated the synthesis of 18 
in 96% yield after 1 h  using mushroom tyrosinase  at ambient temperature in phosphate buffer 
(pH 6.8).166 Compound 13 could also be synthesized in 99 % by using T. versicolor laccase in  
acetate buffer (pH 4.37) at 20°C to.166 The synthesis of 16 could be accomplished by using 
sodium acetate and potassium hexacyanoferrate(III) in  water for 1 hr to afford a 96% yield.170  
Compound 15 could be synthesized via heterocyclic chemistry with  sodium acetate; potassium 
hexacyanoferrate(III) in  water 1 h through Michael addition reaction; 96%.170   
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Figure 5: Structures of the biocatalytically synthesized benzofuro[3,2-c]chromen-6-ones 10-29.  
 
In the first approach, Method A was used, which entailed reacting the catechols 8a–e with the 
heterocyclic 1,3-dicarbonyls 9a-d at room temperature (rt) at pH 7.15 for 24 h. All the 
compounds could be synthesized at rt except for the acid derivatives 14, 19, 24 and 29. As a 
consequence, it was decided to increase the reaction temperature. The second approach, Method 
B, thus entailed reacting 8d with catechols 9a-d at 40°C for 24hr. The results of the reactions are 
shown in Table 1. 
For compounds with a fluorinated catechol, we observed splitting of the peaks in the 13C NMR 
spectra, indicating carbon-fluorine coupling. The splitting is obviously only observed in the 
spectra of compounds prepared from the fluorinated substrate, 3-fluorocatechol. The percentage 
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purity for all the synthesized compounds was more than 90%. The yields of the compounds are 
indicated in Table 1. 
 
Table 1. Synthesised benzofuro[3,2-c]chromen-6-one 10-29 (yield in parentheses) at rt in phosphate buffer at pH 
7.15. 
___________________________________________________________________________________________ 
Entry Catechol      Dicarbonyl   Reaction      Method       Product                  Yields of           Yields of 
                                                                    time(h)              (%Yield)              enzymatic     other syntheses   
___________________________________________________________________________________________  
1 8a  9a          24                     A  10(86)              96166 85167        95168,96169 
2 8b  9a          44      A  11(76)         99166                        
3 8c  9a          24      A  12(74)    64166                     98168 
4 8d  9a          24      A  13(72)   
5 8a  9b          24      A  14(78)      
6 8b  9b          44      A  15(79)         94166, 94167       
7 8c  9b          24      A  16(78)      96167 
8 8d  9b          24      A  17(72)   
9 8a  9c          42      A  18(78) 
10 8b  9c          24      A  19(74)  
11 8c  9c          42      A  20(74) 
12 8d  9c          24      A  21(70)  
13 8a  9d          24      A  22(73)        
14 8b  9d          42      A  23(78) 
15 8c  9d          24      A  24(78)  
16 8d  9d          42      A  25(70) 
17 8e  9a          24      B  26(78)                                            
18 8e  9b          44      B  27(76)  
19 8e  9c          24      B  28(74)  
20 8e  9d          42      B  29(76) 
________________________________________________________________________________________________________ 
Method A  - Suberase® (8.0 mL), catechol (2.0 mmol), coumarin (2.0 mmol, 1 eq), phosphate buffer (20.0 mL, 0.10 M, pH 7.15), 
stirring time at rt = 24 h. 
Method B - Suberase® (4.0 mL), catechol (1.0 mmol), coumarin (1.0 mmol, 1 eq), phosphate buffer (8.00 mL, 0.10 M, pH 7.15), 
stirring time at 40°C = 24 h. 
 
 
 
 
Proposed mechanism of formation for the coumestans 
It is assumed that the first step of these domino reactions is the laccase-catalysed oxidation of a 
catechol with O2 to give o-benzoquinone as shown in Scheme 4. The o-benzoquinone 30 then 
undergoes a 1,4- addition with the coumarin 9a-e under basic conditions to afford 31, which is a 
transitory intermediate. 
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Scheme 4: A proposed mechanism for the synthesis of benzofuro[3,2-c]chromen-6-one derivatives 10-29 
 
After a second laccase-catalyzed oxidation, a final intramolecular oxa-1,4-addition, involving the 
formation of a tricycle, takes place. This reaction is highly regioselective since the initial 1,4-
addition exclusively occurs at the more electrophilic carbon atom of the corresponding o-
benzoquinone. Interestingly, for benzofuro[3,2-c]chromen-6-one, both the acid 8d and the 
fluorinated 8e catechols reacted to afford 23 and 24. This was not observed for the 1,3-diketones 
discussed in Chapter 3 where the fluorinated and acid catechols did not react. 
 
4. 1. 2 SPECTROSCOPIC EVIDENCE THAT SUPPORTS CYCLIZATION 
In order to confirm that a furan ring has been formed through the second oxa-1,4-Michael 
addition  we selected compound 15 as an example for careful scrutiny by NMR. If the reaction 
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had undergone a C-C coupling addition we would then expect to see 1,2,4-trisubstituted benzene 
ring 33 as shown in Figure 7 below. However if the further cyclisation, had occurred then we 
will expect to obtain a product displaying two aromatic protons in the 1H NMR spectra 15. 
 
O
O
OH
OH
OO
OH
OH
OH
O
A B
C
A B
C D
33 17
 
 
Figure 6: Two possible structures 
 
 
Both compounds would have the same number of protons and carbons. However 33 has an 
additional OH group making a total of 3 OH protons that are expected in the 1H NMR spectra. 
We observed from the 1H NMR spectra that we have 2 OH protons that are at 9.61ppm (2H, s, 2 
x OH). This can only be possible if we have formed 15 not 33. In addition, if we had synthesized 
compound 33we would expect to see 3 aromatic signals in the 1H NMR from C ring in the 
aromatic region, whereas if compound 15 has been synthesized, we expect 2 aromatic signals in 
the 1H NMR spectra from ring D and these signals should be singlets, which we can indeed see 
at 7.21 ppm (1H, s, ArH) and 7.28 (1H, s, ArH). Therefore 1H NMR confirms that we have 
synthesized 15. We then proceeded to examine the 13C NMR and mass spectroscopy data for 
further analysis. Sixteen signals matched that of 15 in structure; 13C NMR (100 MHz, DMSO-
d6): δ = 20.4, 98.9, 104.9, 105.3, 112.0, 113.9, 116.8, 120.6, 132.1, 134.3, 144.7, 146.5, 149.4, 
150.5, 157.6, 157.7. Mass spectroscopy also confirmed that it was 15 (M+H+ Found: 283.0512, 
C16H11O5 requires M+H+, 283.0606). Although 33 would have the same mass spectrometry data 
the NMR data would have differed from that of 15. We can then conclude that the reaction 
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undergoes a 1,4-Michael addition followed by a second oxa-Michael addition. For compounds 
with a fluorinated catechol, we observed splitting of the peaks in the 13C NMR spectra.  
 
 
 
4.2 CONCLUSION 
Twenty benzofuro [3,2-c]chromen-6-one compounds could be synthesized by exposure of 
catechols and coumarins to laccase under basic conditions at rt. Unlike in the synthesis of 5,6-
dihydroxybenzo[b]furans in Chapter 3 we could access all the acid derivatives of benzofuro[3,2-
c]chromen-6-ones (14, 19, 24 and 29) when the temperature was raised to 40°C. For compounds 
with the fluorinated catechol 10e we observed a confirmatory splitting of the peaks in the 13C 
NMR spectra which is also observed in the spectra of the fluorinated substrate, 3-fluorocatechol. 
Five compounds are known (compound 10, 11, 12, 15 and 16) while fifteen are novel 
(compound 13, 14, 17-29). 
Chapter 5                                                                                Naphthoquinone derivatives 
97 | P a g e  
 
   
 
 
 
 
 
 
 
 
 
NAPHTHOQUINONE 
DERIVATIVES 
 
 
 
 
 
 
 
Chapter 5                                                                                Naphthoquinone derivatives 
98 | P a g e  
 
5.0 INTRODUCTION 
A 1,4-naphthoquinone is a two planar benzene ring system, fused together with two 
carbonyls in one ring that are in a para-position to each other (Figure 1). These compounds 
can undergo electrophilic aromatic substitution like benzene, although, they are more reactive 
than benzene, and also have the ability to undergo 1,2- or 1,4 addition reactions that are 
enabled by the carbonyl functionalities.  
O
O
R1
R2
1  
Figure 1: Structure of a 1,4-naphthoquinone. 
Herein, we report on the synthesis of 1,4-naphthoquinone derivatives, by using biocatalytic 
procedures as one of the key steps.  A number of the synthesised derivatives were screened 
for both anti-cancer and anti-bacterial activities, and the biological screening results will be 
discussed in Chapter 7. The two classes of compounds that were investigated were substituted 
1,4-naphthoquinones 2-5 (a two ring system) and anthraquinone 6 (a three ring system) as 
shown in Figure 2 below.   
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Figure 2: Structures of 1,4-naphthoquinones (2-5) and 1,4-dihydroxyanthracene-9,10-dione (6).  
In summary we wanted to determine whether 1,4-naphthoquinones substituted at the 2-
position with either an electron-donating or an electron-withdrawing group could be used in 
biocatalytic reactions to synthesise 1,4-naphthoquinone derivatives. The idea was to increase 
conjugation and ring size when compared to those of the 5,6-dihydroxylated benzo[b]furans 
and benzofuro[3,2-C] chromen-6-ones discussed in Chapters 3 and 4, respectively. By 
increasing the number of fused rings the lipophilicity also increases, which could result in an 
enhancement of absorption through biological membranes.  
5.1 BACKGROUND 
The search for novel drugs that are effective against both cancer and bacteria is a continuing 
process.171 The molecular framework of a great number of pharmaceuticals and biological 
compounds contain a quinone moiety.172 It has been noted from literature that the quinone 
moiety possesses both anticancer and antibacterial activity.173 This is due to their ability to 
undergo redox cycling which results in the generation of reactive oxygen species (ROS) as 
shown in Scheme 1.171 Redox cycling is a process in which compounds catalytically cycle 
and generate ROS such as hydrogen peroxide and superoxide which then damages the cell. 
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ROS also inhibits the drug efflux mechanism in drug resistant bacteria, which allows 
intracellular accumulation of potent drug molecules.171 
O
O
O
O
R1
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R
R2
R3
R1R
R2
H2O2
NADPH + H+
O2
NADP+
O2-.
Superoxide
anion radical
Hydrogen
peroxide
 
Scheme 1: Redox cycling of NADH or NADPH and a quinone to produce ROS.163 
 
The anticancer activity of quinones is also believed to be due to alkylation when quinones are 
activated inside the cells.  This alkylation process involves covalent attachment to proteins, 
DNA or other targets, which leads to the inhibition of cell growth. For example, the 
furanonaphthoquinone 7 is an example of a biologically active 1,4-naphthoquinone.171 It has 
been shown to possess antibacterial activity against drug resistant bacteria. Chlamydia is a 
genus of bacteria, including the species C. trachomatis, C. pneumonia and C. psittaci that are 
obligate intracellular parasites that are resistant to existing drugs, 171 (C. pneumonia and C. 
psittaci have recently been reclassified under the genus Chlamydophila). The 
furanonaphthoquinone 7 derivative depicted in Figure 3 has been screened against 14 strains 
of methicillin resistant Staphylococcus aureus (MRSA) and 12 strains of methicillin 
susceptible Staphylococcus aureus (MSSA) as a control.171 Koyama found that the MIC of 7 
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against MRSA was 5.36 µg/ml and the MIC against MSSA, 11.98 µg/ml. This shows that 
compound 7 exhibits stronger antibacterial activity against MRSA. 
O
O
O
OH
7  
Figure 3:  A furananophthoquinone derivative exhibiting activity against MRSA. 
 
When compound 7 was screened against Fluconazole-resistant Candida albicans (FRCA) it 
exhibited the same degree of antibacterial activity as in MSSA and MRSA.  
Other naphthoquinones, for example the compounds, Diospyrin 8 and Methyljuglone 9 
(Figure 4), isolated from the South African medicinal plant Enatalensis, were found to be 
effective against Mtb. They inhibit several antibiotic resistant as well as antibiotic susceptible 
strains of Mtb. 
R1
R O
OR1
R O
O
R1
R O
O
R = H, R1 = CH3 R = OH, R1 = CH3
 8                                                   9  
Figure 4: Compounds isolated from the plant Enatalensis. 
Crassiflorone, a new 1,4-naphthoquinone, from the stem bark of the Diospyros crassiflora 
tree, has been shown to exhibit antimicrobial activity.174 The Grassiflorone derivatives 10 and 
11 (Figure 5) were studied using a microdilution assay against six microbial cultures.175,176  
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Figure 5: Crassiflorone derivatives 
The cultures were the bacteria Escherichia coli (LMP0101U), Shigella dysenteriae 
(LMP0208U), Salmonella typhi (LMP0209U), and Staphylococcus aureus (LMP0206U), and 
the yeasts Candida krusei (LMP0311U) and Candida albicans (LMP0204U). The 
antimicrobial activity was evaluated on the basis of MIC. Compound 11 showed the greatest 
activity against S. dysenteriae (MIC 4.88 µg/ml) and S. typhi (MIC 4.88 µg/ml), whilst 
compound 10 showed weaker activity (MIC 78.12 µg/ml and 19.53 µg/ml, respectively). 
Other important examples of quinones that are known for inhibition of special proteins such 
as bacterial topoisomerase II, DNA gyrase (antibacterial), mammalian topoisomerase I and II 
(antitumor), HIV integrase and HIV protease (antiviral) are the important anticancer drugs  
doxorubicin 12 and mitoxanthrone 13 (Figure 6).177-179 These anthracyclines are well known 
for their anticancer activity.174 The mechanism of action is believed to involve topoisomerase 
II inhibition. Naphthoquinone analogues such as shikonin 14, naphthazarin 15, plumbagin 16, 
and β-lapachone 17 are believed to also inhibit similar enzymes.180 
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Figure 6: Naphthoquinone derivatives exhibiting anticancer activity. 
 
 
5.2 RESULTS AND DISCUSSION 
 
5.2.1 SYNTHESIS OF MENADIONE ANALOGUES FROM 1,3-DIKETONES 
 
In this section we proceeded by reacting naphthoquinones containing a substituent at position 
2 and reacted these substrates with 1,3-diketones. Menadione 18 was initially selected as the 
monosubstituted 1,4-napthoquinone to react with a range of structurally diverse diketones 
19a-h (Figure 7). 
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Figure 7: Menadione 18 and the 1,3-diketones 19a-h. 
 
The synthesis of C-C coupled menadione derivatives was achieved by reacting laccase 
(Suberase) with one equivalent of the 1,3-diketone (1.0 mmol) and one equivalent of 
menadione  in a mixture of DMF (1.0 mL) and phosphate buffer (0.10 M, pH 7.15) in a test 
tube. The reaction mixture was stirred in an open vessel (providing oxygen) at 40°C. DMF 
was added to the reaction mixture to improve the solubility of the organic substrates in the 
reaction medium.  The mixture was vigorously stirred under air until the substrates were 
consumed as judged by TLC. The product was extracted with ethyl acetate, purified by 
column chromatography and, if not pure, recrystallization. Characterization of the 
compounds was achieved by 1H NMR, 13C NMR and mass spectrometry.  
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Scheme 2: Biocatalytic synthesis of menadione derivatives 
The results of the investigation are depicted in Table 1 below. 
Table 1. Synthesised C-C coupled menadione analogues 20–27 (yield in parentheses) from diketones 
at 40oC in phosphate buffer at pH 7.15. 
_______________________________________________________________________________________ 
Entry     Naphthoquinone               Diketone      Reaction time (h)                Product (%Yield)   
   1  18   19a   24        20 (76)  
   2  18   19b   24        21 (82) 
   3  18   19c   24        22 (88)    
   4         18   19d   24        23 (88)  
   5  18   19e   24        24 (84)  
  6  18   19f   24        25 (92) 
  7  18   19g   24        26 (70) 
  8  18   19f   24        27 (83) 
____________________________________________________________________________________________________           
        Method - Suberase® (4.0 mL), diketone (1.0 mmol), naphthoquinone/naphthohydroquinone (1.0 mmol, 1 eq), phosphate buffer  
         (8.0 mL, 0.10 M, pH 7.15), stirring time at 40°C = 24 hrs 
 
From these results it can be seen that the menadione analogues can be accessed using the 
above method. The synthesis afforded yields of products ranging from 70-92%. The highest 
yield that was obtained is 92% for 25 (Entry 6, Table 1) and the lowest is 70% for 26 (Entry 
7, Table 1). The structures of the products 20-27 are depicted in Figure 8 below. 
Chapter 5                                                                                Naphthoquinone derivatives 
106 | P a g e  
 
O
O O
OH
O
O
O
O
O
O
O
O
20(76%)                                        21(82%)                                22(88%)
23(88%)                                       24(84%)                                      25(92%)
OH
O
OH
O
OH
O
OH
O
O
O O
OH
F FF
O
O O
OH
F FF
S
26(70%)                                        27(83%)
O
O O
OH
 
Figure 8: Structures of the menadione analogues 20-27 synthesised from 1,3-diketones.  
 
5.2.2 MECHANISM OF FORMATION OF THE MENADIONE ANALOGUES FROM 
1,3-DIKETONES 
Analysis of quinones 20-27 using 1H NMR, 13C NMR and mass spectroscopy showed that the 
attack of the nucleophilic 1,3-dicarbonyl 22a-h takes place at C-3 of the monosubstituted 1,4-
naphthoquinone. C-3 is the most electrophilic carbon suitable for the 1,4-addition. Addition 
cannot take place at the C-2 position due to the higher energy transition state and the presence 
of the methyl group as shown in Scheme 3 below. 
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Scheme 3: Proposed mechanism for the formation of the menadione analogues from 1,3-diketones.  
 
Several studies of monosubstituted quinones with nucleophiles have been previously 
reported.170 One of them examined the influence of the first substituent on the course of the 
reaction. For example the reaction of methylquinone with anilines 2:1 to give 2,5 and 2,6-
disubstituted products in a 2:1 ratio.178 It has also been reported that the reaction between 
electrochemically generated formyl-p-benzoquinone and 3-hydroxy-1H-phenalen-1-one starts 
with the formation of a 2,5-disubsituted bis-adduct which then undergoes cyclization to the 
corresponding benzofuran derivatives. The synthesised compounds were easily accessible, and we 
observed almost complete conversion of the starting materials as determined by TLC monitoring and 
analyses of the reaction mixtures. We then decided to investigate whether the coumarins would react 
in a similar manner to the 1,3-diketones with menadione. 
 
5.2.3 SYNTHESIS OF MENADIONE ANALOGUES FROM COUMARINS  
Menadione 21 successfully reacted with the coumarins 32a-d to give the expected mono-
substituted menadione analogues. 
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Scheme 4. Synthesis of menadione analogues from coumarin. 
The synthesis of the C-C coupled menadione analogues was accomplished by following the 
same method as that used for the reaction with the diketones to produce compounds 33-36.   
The results of the reaction of menadione 21 with each of the coumarins is shown in Table 2 
below. 
Table 2. C-C coupled menadione analogues 33–36 (yield in parentheses) synthesized from coumarins 
at 40oC in phosphate buffer at pH 7.15.. 
_______________________________________________________________________________________ 
Entry    Naphthoquinone               Coumarin      Reaction time (h)                Product (%Yield)   
1  21   32a   24        33 (86)  
2  21   32b   24        34 (80) 
3  21   32c   24        35 (85)    
4         21   32d   24        36 (88)  
____________________________________________________________________________________________________           
        Method - Suberase® (4.0 mL), diketone (1.0 mmol), naphthoquinone/naphthohydroquinone (1.0 mmol, 1 eq), phosphate buffer  
         (8.0 mL, 0.10 M, pH 7.15), stirring time at 40°C = 24 h. 
From these results it is evident that the synthesis afforded products in high yields, ranging 
from 80-88%. The highest yield was obtained for 36 (88% (Entry 4, Table 2) and the lowest 
for 34 (80% (Entry 2, Table 2). The structures of the synthesised products are shown in 
Figure 9 below. 
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Figure 9: The structures of the menadione analogues 33-36 synthesised from coumarins.   
The synthesis of menadione analogues from coumarins was achieved by oxidation of 37 
which is formed after coumarin 32a-d reacts with menadione 21 as shown in Scheme 5 
below. 
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Scheme 5. Proposed mechanism for the synthesis of menadione analogues from coumarins. 
The final step is oxidation resulting in the formation of the 2-monosubstituted p-
naphthoquinone. In this transformation ring cyclisation does not occur as it did for the 
formation of the benzofurans and chromenes in Chapters 3 and 4 respectively.  
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Similar to the diketones discussed in Section 5.2.2 we could access the coumarin derivatives 
easily with no side products. This prompted us to investigate the reaction of the unsubstituted 
1,4-naphthoquinones with 1,3-diketones to determine whether the initial 1,4-addition reaction 
would be followed, after oxidation, with a second oxa-Michael reaction, resulting in 
furanonaphthoquinone formation.  
 
5.3 FORMATION OF 2,3-DIALKYLATED NAPHTHOQUINONES, 
THROUGH CONSECUTIVE C-C COUPLING REACTIONS. 
 
In this study we expected the formation of a furanonaphthoquinone 38 (Figure 10) from the 
reaction of a 1,4-naphthoquinone with a diketone. Our interest in furan formation was 
inspired by the biological results of compound 7 shown in Figure 3. However, we observed 
that consecutive C-C bis-coupling reactions occurred resulting in the 2,3-dialkylated 
naphthoquionones ring structure 39 instead of the anticipated ring cyclisation which would 
have afforded 38 ( Figure 10). The formation of 39 was initially not obvious from the NMR 
spectra, but was confirmed through mass spectrometry. 
R1O
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O
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38                                                          39  
Figure 10: The targeted compound 38 and the actual naphthoquinone derivative 39 obtained. 
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5.3.1 SYNTHESIS OF 1,4-NAPHTHOQUINONE AND JUGLONE ANALOGUES 
FROM 1,3-DIKETONES 
The reactants and substrates for this investigation are depicted in Figure 11 below.  
OH
OH
OH O
O
O O
O
O
O
O
O
O
O
O
O O
O
2 3
19a                              19b                       19c                         19d                        19e                        19f  
Figure 11. 1,4-Naphthohydroquinone 2, juglone 3 and the 1,3-dicarbonyls 21a–f used in this study. 
The synthesis of C-C bis-coupled 1,4-naphthquinone derivatives was achieved by reacting 
one equivalent of the 1,4-naphthohydroquinone 2 with one equivalent of the 1,3 dicarbonyl 
compounds 19a-f. 
The reaction for the synthesis of C-C bis-coupled products from the reaction of 1,3-diketones 
with 1,4-naphthoquinones is depicted in Scheme 6 below. 
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Scheme 6. Synthesis of C-C bis-coupled 1,4-naphthquinone derivatives 
Table 3 shows the results that were obtained when  1,4-naphthohydroquinone 2 and juglone 3 
were each reacted with a 1,3-diketone in a 1:1 ratio.  
 
 
Table 3. The synthesised C-C coupled 1,4-naphthoquinone derivatives 40-44 (yield in parentheses) 
__________________________________________________________________________________________ 
Entry  NQ/NHQ      Dicarbonyl     Reaction time (h)  Product(%Yield) 
__________________________________________________________________________________________ 
    1              2       19i   24    40 (50)  
    2              3       19i   24    41 (52) 
   3              2       19c   24    42 (55)                     
   4              3       19d   24    43 (50)  
   5              3       19e   24    44 (53)  
____________________________________________________________________________________________________ 
         Method - Suberase® (4.0 mL), diketone (1.0 mmol), naphthoquinone/naphthohydroquinone (1.0 mmol, 1 eq), phosphate buffer  
         (8.0 mL, 0.10 M, pH 7.15), stirring time at 40°C = 24 h; NQ = naphthoquinones; NHQ = naphthohydroquinone. 
 
The products were obtained in moderate yields (50-53%) as can be seen from the results in 
Table 3. After discovering that the expected furan was not formed it was decided to increase 
the quantity of the diketone to improve the yield of the bis-coupled product. Instead of a 1:1 
diketone:naphthoquinone ratio, a a 2:1 ratio was used. It was then observed that the yields 
increased as shown in Table 4 below.   
Table 4. Synthesised C-C coupled naphthoquinone derivatives using a 2:1 stoichiometric ratio of 
diketone to naphthoquinone. 
_______________________________________________________________________________________ 
Entry Naphthoquinone     Dicarbonyl  Reaction time (h)      Product (%Yield) 
  
__________________________________________________________________________________________ 
1  2   20e   24   42 (60)  
2  3   20d   24   43 (65) 
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3  3   20e   24   44 (73)           
____________________________________________________________________________________________________           
Method - Suberase® (4.0 mL), diketone (2.0 mmol), naphthoquinone/naphthohydroquinone (1.0 mmol), phosphate 
buffer  (8.00 mL, 0.10 M, pH 7.15), stirring time at 40 °C = 24 h; ratio of diketone:naphthoquinone is 2:1. 
 
It is evident from the results in Table 4 that an increase in the amount of the 1,3-diketone 
resulted in a higher yield of product. The structures of the products are shown in Figure 12 
below. 
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Figure 12: Structures of the C-C bis-coupled 1,4-naphthoquinones 40-44 synthesized at 40ºC. 
 
This outcome was a surprise because in the literature most of the reactions between a 1,3-
dicarbonyl and a p-quinone affords  the benzofuran as the product.170-172 However, Hadjok et 
al reported a similar result to ours for  benzoquinone.180 They reacted a 1,3-diketone with a 
hydroquinone in a 1:1 ratio and the product formed was also a bis-adduct. They also observed 
that even when the stoichiometry is changed to a 2:1 ratio the resulting product is still a bis-
adduct, but the yield was better. In another example from literature a reaction of a p-
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benzohydroquinone with a 1,3-diketone resulted in a mixture of both mono- and bis-
adduct.181 An imidazole reacted with a benzoquinone (1:1 ratio) led to the formation of  
mono-substituted, 2,3-disubstituted and 2,5-disubstitued products. Another interesting 
example is the domino processes between p-benzoquinone that is electrochemically generated 
from a hydroquinone and 2 equivalents of a cyclic 1,3-dicarbonyl (3-hydroxy-1H-phenalen-
1-one). Under specific reaction conditions a bis-adductformed. This adduct could not be 
isolated and underwent cyclisation to a benzofuran derivative.182  
 In this project, these compounds were the most challenging class of compounds to purify as 
they seemed to be unstable during purification by silica gel chromatography. In some cases 
despite observing one spot on TLC, after column purification the product was still impure as 
could be seen by 1H NMR spectroscopy.  
   We hypothesised that the acidic nature of silica gel (silicon dioxide) used in silica gel 
chromatography allowed for decomposition. 
SiO2            +             Base SiO anion  
Figure 14: Reaction of silicon dioxide under basic conditions 
Mass spectrometry results indicated that the reaction mechanism was that of a C-C bis-
coupling. In Figure 15 are two possible naphthoquinone derivatives. 
R1O
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O
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R1
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38                                                          39  
Figure 15: Structures of two possible naphthoquinone derivatives 
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From the 1H NMR spectra it could not be determined whether a furan ring had formed based 
on the splitting pattern of peaks. However, when integration was taken into consideration it 
was evident that a C-C bis-coupling had occurred.  
 
5.4. SYNTHESIS OF 1,4-NAPHTHOQUINONE AND JUGLONE ANALOGUES 
FROM COUMARINS 
We were then interested to determine whether the same reaction would occur with a 
coumarin 32a-d when it reacted with a naphthoquinone. The substrates and reactants used are 
shown in Figure 16 below. 
OH
OH
OH OH
OH
2 3
   32a                       32b                          32c                            32d
O O O O
OH
O
OH
O
OH
O
Cl
O
OH
 
Figure 16: The 1,4-naphthohydroquinone 2, juglone 3 and coumarins 32a-d. 
As previously mentioned the benzopyrone skeleton 32a-d is a natural product like benzofuran  
and has shown to possess both anticancer and antibacterial activities.139 We followed the same 
method as discussed in Section 5.4.1 with an intention of forming either compounds 45 or 46 
(Scheme 7). 
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Scheme 7. Synthesis of coumarin derivatives 
The attempted synthesis was such that 1,4-naphthohydroquinone 2 (1.0 mmol) and juglone 3 (1.0 
mmol) was  added to laccase (Suberase) with one equivalent of the coumarin (1.0 mmol)  in a 
mixture of DMF (1.0 mL) and phosphate buffer (0.10 M, pH 7.15) in a test tube. The reaction 
mixture was stirred in an open vessel (providing oxygen) at 40°C. Further attempts were at 
room temperature with DMF, and then without DMF. 
The reactions (Figure 16) were conducted initially at room temperature and then at 40ºC. 
These reactions were unsuccessful since neither a novel compound nor the desired product 
was formed. From TLC it appeared that a number of new spots had formed but after column 
chromatography no characterisable product could be isolated. A possible reason for the 
unsuccessful reaction is that the coumarin may not have been sufficiently soluble in the 
reaction mixture when compared to the 1,3-diketone. 
 
 
Chapter 5                                                                                Naphthoquinone derivatives 
117 | P a g e  
 
5.5 LACCASE-MEDIATED SYNTHESIS OF 2-HYDROXY-1,4-
NAPHTHOQUINONE ANALOGUES UTILIZING 1,3-DIKETONES AS MICHAEL DONOR 
SUBSTRATES 
In Section 5.2.1 we explained how we achieved the synthesis of menadione analogues. We 
were interested in a substrate having an electron-withdrawing group at C-2 of the quinone 
and lawsone (2-hydroxy-1,4-naphthoquinone)  was a suitable substrate. The reaction of 
lawsone 46 with diketones 21a-f was investigated (Scheme 9). In the presence of lawsone 46 
it was anticipated that a 1,4-addition would be the first step which would then be followed by 
oxidation to afford 48 as shown in Scheme 9 below. 
 
O
O
46
+R1
OH
R2
O
1,4-addition
O
OH
OH
oxidation
-2e-, -2H+
O
O
OH
OH
21a-f
R1HO
R2
O
47
R1O
R2
OH
48
Suberase
 
Scheme 9: Proposed mechanism for the formation of C-C bis-coupled 1,4-naphthoquinones. 
  
The reaction was unsuccessful at both room temperature and 40°C. The co-solvent, DMF, 
was used at both temperatures for the reaction, the pH was also adjusted from 7.15 to 4.50 in 
order to increase the acidity in the reaction mixture but still we were unable to obtain the 
desired product using Suberase. 
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5.6 SYNTHESIS OF ANTHRACENEDIONE ANALOGUES FROM 1,3-DIKETONES 
Our interest in synthesising anthracenedione analogues was inspired by drugs such as 
doxorubicin and mitoxantrone. We were interested in investigating the reaction of the 1,4-
dihydroxyanthracene-9,10-dione 49 with each of the 1,3-diketones 21a-f. A possible product 
of the reaction is shown in Scheme 10 below. 
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oxidation
-2e-, -2H+
49
50
Scheme 10: Proposed mechanism for the formation of possible C-C bis-coupled 1,4-  
dihydroxyanthracene-9,10-dione  analogues from1,3-diketones. 
 
Initially we used Method C, this involves the addition of DMF to the reaction mixture as a co-
solvent to improve the solubility of the organic substrates. The number of equivalents of the 1,3-
dicarbonyl was also increased so that a ratio of 1,3-dicarbonyl to catechol was 4:1. These reactions 
were conducted for 42 h. To react 1,4-dihydroxyanthracene-9,10-dione 49 with the 1,3-
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diketones 21a-f. After 24 h it was observed that only starting materials were present in the 
reaction vessel. Extending the reaction time to 72 h and subsequently elevating the reaction 
temperature to 40ºC failed to generate any products. The reaction was also investigated at 40 
ºC at pH 4.5 while all the other conditions were kept the same.  
After much experimentation we could not get the 1,4-dihydroxyanthracene-9,10-dione 49 to 
react with a diketone (Scheme 11). 
R1 R2
O O
O
O
49
, ,
OH
OH
+
O
O O
R2
O
R2
O
O
O
R1 O
R1
Suberase
oxidation
-2e-, -2H+
50
 
Scheme 11. Synthesis of 1,4-dihydroxyanthracene-9,10-dione analogues from 1,3-diketones. 
 It might be due to the fact that the 1,4-dihydroxyanthracene-9,10-dione 49 is not sufficiently 
soluble in the reaction mixture or it could be too large for the active site of the laccase, 
Suberase, to oxidise to the corresponding quinone. 
5.7 CONCLUSION 
All the synthesised compounds in this chapter are novel: 7 menadione derivatives 22-29 from 
1,3-diketones, 4 menadione derivatives 32-35 from coumarins and 5 C-C bis-coupled 1,4-
naphthoquinones derivatives 40-44 from 1,3-diketones.  
Our interest in naphthoquinones was inspired by the the quinone moiety which posseses a 
range of biological activities including both anticancer and antibacterial activities.161  
The reaction of menadione with the 1,3-diketones and coumarins at 40°C at pH 7.15 using 
DMF as a co-solvent affords C-C coupled naphthoquinone derivatives  substituted at position 
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3.  The reaction of 1,4-naphthohydroquinone and juglone (well-known compounds with 
antibacterial activity) with 1,3-diketones produced unexpected C-C bis-coupled 1,4-
naphthoquinone derivatives. These compounds showed some instability and degraded on a 
silica-gel column. The degradation was attributed to the acidic nature of silica (silicon 
dioxide) which can catalyse the degradation.  Lawsone 46 and 1,4-dihydroxyanthracene-9,10-
dione 49 did not react with  the 1,3-diketones.   
O
O
OH
O
O
46 49
OH
OH
 
Figure 19: Substrates for which no reaction was observed with Suberase. 
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6.0 INTRODUCTION  
In light of the previous chapters, we were interested in synthesising derivatives of the first-
line anti-TB drug, isoniazid 1, as well as thiosemicarbazide 2 derivatives (Figure 1) from the 
previously synthesised 5,6-dihydroxylated benzo[b]furans (Chapter 3). The goal of these 
derivatizations was to develop drugs directed at multiple targets and to improve the biological 
activity against both cancer and bacteria. The detail of the synthetic approach is in the section 
that follows.  
 
N
N
H
O
NH2 H2N N
H
NH2
S
1                                    2
 
Figure 1: Structures of isoniazid 1 and thiosemicarbazide 2. 
 
The emerging area of multi-target drug discovery is one of increasing interest to members of 
the drug discovery community.181 The potential advantages of drugs that modulate several 
targets are that there could be an improved balance of efficacy in addition to safety when 
compared to single target agents.181 A number of drugs have been successfully synthesised 
that possess dual inhibitory activity, which is observed when a drug is biologically active 
against two targets due to its structural design. For example, Donepezil 3, Galanthamine 4, 
and Rivastigmine 5 (Figure 2) are drugs that can be used to treat Alzheimer’s disease which 
is an age-dependent progressive brain disease that slowly destroys memory and thinking 
skills and eventually the ability to carry out the simplest tasks.182-183 The main cause is not 
known yet but the disease is associated with a decrease in hippocampal acetylcholine (Ach) 
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in the cholinergic system. Acetylcholinesterase (AChE) is responsible for the hydrolysis of 
acetylcholine in the synaptic cleft.184 The three drugs 3-5 (Figure 1) are AChE inhibitors and 
are therefore helpful in increasing the level of acetylcholine in the damaged cholinergic 
neurons. This, however, increases the butyrylcholinesterase (BuChE) activity that causes 
hydrolysis of acetylcholine in a new way.185  
NO
O
O
O
N
OH
O N O
O
N
3
4 5
Donepezil
Galanthamine Rivastigmine
 
Figure 2: Three well known AChE inhibitors.  
 
As a result the design and synthesis of dual AChE/BuChE inhibitors were considered.186,187 
Since benzyl pyridinium derivatives 6 have previously been reported to be  excellent 
acetylcholinesterase inhibitors, while coumarin moiety 7 has been previously reported to 
possess anticholinesterase activity they were linked (Figure 3) in order to investigate the dual 
effect.188,189 
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Figure 3: Structural framework of potent anticholinesterase 6 and antiacetylcholinesterase 7 
inhibitors. 
An assay for inhibitory activity was then performed using Donepezil 3 as a positive control. 
The derivatives were able to inhibit both acetylcholinesterase and butyryl cholinesterase. 
Compound 8 showed superior ability (0.11 nm) when compared to the control 3 (14 nm). 
O O
O
N ARR
8
R = Br
Ar = Me
 
Figure 4: Structure of a potent derivative. 
Another example of multi-target drugs is that of histamine receptors. Histamine is an organic 
compound that is involved in a local immune response and also regulates physiological 
activities. The histamine receptors belong to class A of the superfamily of the G-protein-
coupled receptors (GPCRs).190 These receptors are involved in the inflammatory response 
and the response to foreign pathogens, they are produced by basophils and mast cells. H1R 
mediates numerous pathophysiological responses to histamine such as vasodilation via nitric 
oxide release, increase in capillary permeability, and contraction of smooth muscles in the gut 
and bronchi.190 The first H1R blockers were described as ‘antihistamines’ more than 70 years 
ago and are now widely used in the treatment of allergic conditions.191 H2R is mostly 
Chapter 6                                                                                           Schiff-Base Derivatives                                                                                          
125 | P a g e  
 
associated with simulation of gastric acid and ulcers.192 The development of H2R in the 1970s 
revolutionised the treatment of gastric and duodenal ulcers.192 The development of a 
combined H1R and H2R antagonist 9 was also accomplished (Figure 5).  
N N (CH2)2-7
CH3 H
N
H
N
N CN
H3CO
spacer
Mepyramine
various
H2-partial
structure
9 Cyanoguanine
 
 Figure 5: The structure of a spacer-linked combined H1/H2 receptor antagonist 9.  
The result is a combination of Mepyramine (H1R antagonist) through a spacer to 
cyanogaunine (H2R antagonist) and results in dual activity.190 It is used as an as anaesthetic in 
operations to prevent hypertensive reactions to drugs. It can also be used in cancer 
chemotherapy and for the treatment of skin diseases.191-198  
 
6.1 ISONIAZID DERIVATIVES 
Schiff-base compounds possess a number of biological activities. For example, 10 is an 
intestinal antiseptic while 11 and 12 (Figure 6) exhibit antibacterial activity against both S. 
aureus ATCC 29213 and M. tb H37Rv.198  
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Figure 6: Schiff-base compounds exhibiting biological activity. 
Isoniazid 8, also known as isonicotinylhydrazine, is a first-line prodrug for TB treatment. 
This prodrug activates the KaTG enzyme to form the INH-nicotinamide adenine dinucleotide 
(NAD) adducts as previously discussed in Chapter 1. The emergence of multi-drug and new 
TB cases led to renewed research interest in new anti-TB treatments as well as the idea of 
derivatization of the clinically available drugs.199 Isoniazid derivatives are considered an 
important class of compounds for the development of new drugs, and a number of isoniazid 
derivatives have been successfully synthesised through the Schiff-base reaction of an 
isoniazid with Carl-Mannich bases. 200,201 The latter are β-amino-ketones that are formed in 
the reaction of an amine, formaldehyde/aldehyde and an enolizable carbonyl compound. All 
the compounds were then evaluated for antimicrobial activity against Bacillus substilis, 
Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Candida albicans and 
Candida gabrata.202 Amoxicillin, an antibiotic, was used as the positive control in the study. 
Compounds 13-18 (Figure 7) exhibited better growth inhibitory activity against all strains 
when compared to amoxicillin as shown in Table 1 below.  
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 Figure 7: The biologically active Schiff-base derivatives 13-18.202 
 
Table 1: Zone of inhibition (mm) of the Schiff-base derivatives 13-18 
__________________________________________________________________________________
Compound  Concentration of      B. substilis   S. aureus  E.coli  P. aeruginosa  C. albicans  C. gabrata           
                   the compound(µg/ml) 
13  100  26 31 22 32  21  22 
14  100  23 25 20 25  16  16 
15  100  22 26 20 27  18  19 
16  100  27 32 22 31  21  21 
17  100  27 34 23 33  24  23 
18  100  26 33 22 32  22  20 
  
Amoxicillin 50  25 30 21 30  -  - 
__________________________________________________________________________________________ 
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The biological activity exhibited by the isoniazid Schiff-base derivatives 13-18 led us to 
pursue the synthesis of isoniazid derivatives of the 5,6-dihydroxylated benzo[b]furans 
discussed in Chapter 3. 
  
6.2 RESULTS AND DISCUSSION 
 
6.2.1 SYNTHESIS 
The compounds that were used in this study, isoniazid 8 and the 5,6-dihydroxylated 
benzo[b]furans 19–27 (the synthesis of which was described in Chapter 3) are depicted in 
Figure 8. 
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Figure 8. Isoniazid 5 and the 5,6-dihydroxylated benzo[b]furans 19-27 used in this study. 
The synthesis of the isoniazid derivatives was conducted by reacting one equivalent of 
isoniazid 8 with one equivalent of each of the 5,6-dihydroxylated benzo[b]furan (16-23) and 
stirring in methanol under reflux in the presence of glacial acetic acid  for 24 hours as shown 
in Scheme 1 (Method C).  
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Scheme 1: Synthesis of isoniazid derivatives of 5,6-dihydroxylated benzo[b]furans. 
 
Acetic acid was added in order to make the hydroxyl group of the hemiamine intermediate a 
good leaving group. This intermediate is depicted in the mechanism of the reaction below. 
The second reason was to make the alpha carbon to be more electrophilic and susceptible to 
the lone pair of the nitrogen group. The reaction was monitored by TLC and the 
disappearance of the 5,6-dihydroxylated benzo[b]furan was followed. The reaction afforded 
an imine that migrated further up the TLC plate in comparison to the starting material. The 
resulting product was purified by flash chromatography. In some cases the product required 
further purification by either washing with EtOAc or recrystallizing from a mixture of MeOH 
and EtOAc. The yields of the reactions are shown in Table 1, and the structures of the 
products 19-27 are shown in Figure 9.  
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Table 1. The isoniazid derivatives 19-27 synthesised in methanol at 50°C. 
________________________________________________________________________________________ 
Entry  benzo[b]furan       Reaction time [h]              Product (%Yield)                                                              
__________________________________________________________________________________________ 
1   28   24   19 (65) 
2   29   24   20 (63)  
3   30   44   21 (70) 
4   31   24   22 (76)  
5   32   24   23 (72)  
6   33   42   24 (70) 
7   34   24   25 (70)  
8   35   42   26 (74) 
9   36   24   27 (74) 
____________________________________________________________________________________________________ 
Method C  – isoniazid (1.0 mmol, 1 eq), 5,6-dihydroxylated benzo[b]furan (1.0 mmol), methanol (10.0 mL), stirring time at 
50°C = 24-44 h. 
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Figure 9: The structures of the isoniazid derivatives 19-27. 
 
6.2.2 MECHANISM OF FORMATION OF SCHIFF-BASE PRODUCTS  
The Schiff-base product was obtained from the condensation reaction between a carbonyl 
group and and the hydrazine amino group via an intermediate hemiaminal, generating water 
as a by-product as shown in Scheme 2.  
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Scheme 2: Mechanism for synthesis of isoniazid derivatives of 5,6-dihydroxylated benzo[b]furans. 
 
The isoniazid derivatives were successfully synthesised using the Schiff-base reaction in 63-
76% yield. The highest yield that was obtained was 76% for 22 (Entry 4, Table 1) and the 
lowest was 63% for 20 (Entry 2, Table 1).   
  
 
 
6.3 THIOSEMICARBAZIDE DERIVATIVES 
 
Thiosemicarbazide 2 is a versatile intermediate which is mostly used for preparing various 
heterocyclic derivatives such as 37,  38, and 39 among others (Figure 10).203-206  
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Figure 10: Thiosemicarbizide 2 and heterocyclic derivatives 28-30 prepared from it. 
 
Thiazole, which contains both sulfur and nitrogen, is a component of the vitamin, thiamine 
B1. Thiosemicarbazide 2 has displayed a wide range of biological activities such as 
anticancer, antiHIV, antitubercular, antiviral, antitumor, antiprotozoal, anticonvulsant, 
antidepressant, antimalarial, antifungal, pesticidal and antibacterial activity, antimicrobial, 
analgesic, sodium channel blockers and antiallergic agents.207-210 It has also found application 
in drug development for the treatment of central nervous system disorders. 210 Methyl 
hydrazine carbodithioate 31 and hydrazine-carbothionamide analogue 32, which are both 
thiosemicarbazide derivatives, possess antibacterial activity against Gram positive and Gram 
negative bacteria (Figure 11). Compound 32 has activity that is as potent as that of the 
standard, that was used. Therefore we thought it will be useful to incorporate 
thiosemicarbazide into the 5,6-dihydroxybenzo[b]furan. 
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Figure 11: The hydrazine derivatives that 31 and 32 exhibited antibacterial activity. 
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6.4 RESULTS AND DISCUSSION 
 
6.4.1. Synthesis 
The thiosemicarbazide 2 and the 5,6-dihydroxylated benzo[b]furans  19, 20, 22, 25-27, 33 
and 34  (the synthesis of which was described in Chapter 3) used in this study are depicted in 
Figure 12 below. 
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Figure 12: The thiosemicarbazide 2 and the 5,6-dihydroxylated benzo[b]furans 19, 20, 22, 25-27, 33 
and 34 used in this study. 
 
The synthesis of the thiosemicarbazide derivatives entailed  reacting one equivalent of each 
of the 5,6-dihydroxylated benzo[b]furans 19, 20, 22, 25-27, 33 and 34 with one equivalent of 
the thiosemicarbazide 9 at 50ºC in methanol for 24 hours (Method C) as shown in Scheme 2. 
This was achieved in the presence of a catalytic amount of glacial acetic acid. The products 
were purified by flash chromatography. 
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Scheme 2: General synthesis of the thiosemicarbazide derivatives 35-42. 
 
The synthesis of the thiosemicarbazide derivatives was accomplished by employing the 
Schiff-base reaction and afforded the products in 66-80% yield. The highest yield that was 
obtained was 80% for 38 (Entry 4, Table 4) and the lowest was 66% for 35 (Entry 1, 
Table 4). The presence of a signal for a primary amine (NH2) at about 4.50 ppm and a 
secondary amine (NH) at 8.60 ppm in the 1H NMR spectrum, provided evidence for the 
structure of the compounds (Figure 12).   
Table 4: The thiosemicarbazide derivatives 35-42 synthesised at 50oC in methanol for 48 h. 
Entry                   benzo[b]furans          Reaction time (h)                    Product (%Yield) 
    1    33   24    35 (66)  
    2    19   24    36 (68) 
    3    20   24    37 (76) 
    4    34   48    38 (80)  
    5    22   48    39 (78) 
    6    25   48    40 (73) 
    7    26   48    41 (72) 
    8     27                                       48                           42 (70) 
_________________________________________________________________________________ 
Method C – thiosemicarbazide (1.0 mmol, 1 eq), 5,6-dihydroxylated benzo[b]furan (1.0 mmol), methanol (10.0 mL), stirring 
time at 50°C = 24 -48 h. 
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Figure 12: The structures of the synthesized thiosemicarbazide derivatives 35-42. 
 
6.5 CONCLUSION 
This part of the project was inspired by the idea of multi-target drug discovery. The focus is 
on potential drug candidates that can modulate several targets which could improve efficacy 
and safety when compared to single target agents. Our goal was to react benzofurans with the 
well-known first-line anti-TB drug, isoniazid, as well as thiosemicarbazide through a Schiff-
base reaction. The purpose of this derivatisation was to improve the biological activity 
against cancer and bacteria. All the synthesised compounds (9 isoniazid derivatives 19-27 
and 8 thiosemicarbazide derivatives 35-42) are novel with potential increased potency when 
compared with our 5,6-dihydroxybenzo[b]furans. The results of the biological screening of 
the compounds are discussed in Chapter 7.   
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7.0 BIOLOGICAL EVALUATION 
The synthesized compounds, as described in Chapters 3 to 6, were screened for their ability to inhibit cell growth of renal (TK10), 
melanoma (UACC62), breast (MCF7) and cervical (HeLa) cancer cell lines. The cell lines were obtained from the National Cancer 
Institute (NCI) in a collaborative research program between the South African Council for Scientific and Industrial Research (CSIR) 
and the NCI.    
   The synthesized compounds were initially screened against four different bacterial strains i.e. M. smegmatis MC2155, methicillin-
sensitive Staphylococcus aureus (MSSA) 32710, Bacillus substilis 168 and E. coli DH10B and then against M. tb. The minimum 
inhibitory concentrations (MIC) was recorded. M. smegmatis was used as a model for further screening against M. tb. All the strains 
were from the International Centre for Public Health (ICPH), New Jersey, USA. This work was performed over a three month period 
during my PhD through a Fogarty Fellowship from the Aurum Institute that was awarded to myself, Tozama Qwebani-Ogunleye. The 
anticancer screening was done at the CSIR. 
 
7.1 EVALUATION OF THE ANTICANCER ACTIVITY  
We will first discuss the anticancer activity of the screened compounds. Screening was conducted against renal (TK10), melanoma 
(UACC62), breast (MCF7) and cervical (HeLa) cancer cell lines using the Sulforhodamine B (SRB) assay to determine the growth 
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inhibitory effects of the compounds. These cell lines have been used routinely at the U.S. National Cancer Institute for screening for 
new anticancer agents and were derived from tumors that have different sensitivities to chemotherapeutic drugs. Etoposide, a well-
known anticancer agent, was used as a positive control. It is known to be an inhibitor of topoisomerase, particularly topoisomerase II, 
and aids in DNA unwinding which causes the DNA strands to break. The results of a five dose screening were reported in three 
parameters: 50% cell growth inhibition (GI50), total cell growth inhibition (TGI) and the lethal concentration that kills 50% of cells 
(LC50). The 5,6-dihydroxylated benzo[b] furans were the first compounds to be screened and are shown in Figure 2 below. 
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Figure 2: 5,6-Dihydroxylated benzo[b] furans screened for anticancer activity.  
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The screening results are shown in Table 1 and it is evident that several compounds exhibited potent cytostatic effects. 
Table 1: In vitro anticancer screening of the compounds against renal (TK10), melanoma (UACC62), breast (MCF7) and cervical (HeLa) cancer 
cells expressed as GI50, TGI and LC50 values (µM). 
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
Entry Compound           Renal (TK10)   Melanoma (UACC62) Breast (MCF7)   Cervical (HeLa)   
          GI50      TGI       LC50         GI50       TGI      LC50       GI50        TGI        LC50      GI50        TGI      LC50 
1 11a 68.02 >100 >100 45.00  >100   >100   52.41 >100 >100 a   a a 
2 11b 38.14 75.72 >100 15.18 46.22 77.26 27.34 64.31  >100 a   a a 
3 11c 51.63 96.98 >100 23.64 50.26 76.87 27.55 60.68 93.81 a   a a 
4 12 41.05 69.94 98.82 32.74 60.84 88.94 35.10 66.12 97.14   60.70  >100   >100 
5 13 65.00 >100 >100 37.73 68.65 99.57 35.53 64.19 92.85 49.09 >100 >100 
6 14 24.25 54.74 85.23 23.63 51.06 78.49 25.97 61.87 97.78 44.55 >100 >100 
7 15 52.47 >100 >100 6.04 33.15 >100   15.85 54.74 93.63 54.46   >100  >100 
8 16 16.56 55.32 94.09 6.50 33.85 74.35 25.55 68.82 >100  25.93 >100 >100 
9 17 26.54 51.65 76.75 0.78 18.32 60.32 8.79 48.79 95.11 26.68 69.67  >100 
10 18 18.69 46.14 73.59 6.79 28.93 66.27 28.44 60.90 93.35 34.37 62.15 89.93 
11 19 18.60 48.25 77.90 9.76 >100    >100  17.96 60.79 >100   47.28 >100 >100 
12 20 9.73 47.15 85.35 0.77 23.60 64.58 9.30 46.93 86.93 22.32 73.19 >100 
13 21 86.99 >100 >100  51.29 >100   >100   68.03 >100 >100  a   a  a 
14 Etoposide 7.19 49.74 >100 0.89 52.71   >100   0.56 >100  >100   3.56 40.18 87.54 
_________________________________________________________________________________________________________________________________
Inactive, I: GI50 or TGI > 100 µM; weak activity, w: > 30 µM GI50 or TGI < 100 µM; moderate activity, m: < 30 µM GI50 or TGI > 10 µM; potent activity, p: 
GI50 or TGI < 10 µM. a  Not screened. 
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The GI50 values of the catechols 11a–c and selected benzo[b]furans were compared to that of 
etoposide, a well-known anticancer drug. Screening against the TK10 cell line showed that only 
compound 20 had potent activity (GI50 = 9.73 µM, Entry 12), which was not as good as that of 
etoposide (GI50 = 7.19 µM, Entry 14). Most of the compounds exhibited potent growth inhibitory 
activity against the UACC62 cell line. The potent activity exhibited by 17 (GI50 = 0.78 µM, Entry 
9) and 20 (GI50 = 0.77 µM, Entry 12) was slightly better activity than that of etoposide 
(GI50 = 0.89 µM, Entry 14). Moreover, the same two compounds, 17 (GI50 = 8.79 µM, Entry 9) 
and 20 (GI50 = 9.30 µM, Entry 12), also exhibited potent growth inhibitory activity against the 
MCF7 cell line but this was not as good as that of etoposide (GI50 = 0.56 µM, Entry 14).  
   Most compounds exhibited weak TGI activity and three were inactive against the TK10 cell 
line. The activities of 18, 19 and 20 (Entries 10–12, respectively) were slightly better 
(TGI = 46.14–48.25 µM) than that of etoposide (TGI = 49.74 µM, Entry 14). The compounds 
also exhibited moderate to weak activity against the UACC62 cell line with most 
compounds, 14, 15, 16, 17, 18 and 20, exhibiting better activity (TGI = 18.32–51.06 µM) than 
that of etoposide (TGI = 52.71 µM, Entry 14). The best activity was observed for 
17 (TGI = 18.32 µM, Entry 9) which was almost threefold better than that of etoposide. The test 
compounds exhibited weak activity against the MCF7 cell line, but the cytostatic effects of these 
compounds were better than that of etoposide which was inactive (TGI > 100 µM, Entry 14).  
 
The LC50 values of the compounds were also compared to that of etoposide to get an idea of the 
cytotoxic effects of these compounds against the different cell lines. Screening against the TK10 
cell line showed that most of the compounds were more lethal than etoposide (LC50 > 100 µM) 
with 18 (LC50 = 73.59 µM, Entry 10) being the most lethal.  
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   Again, most of the compounds were more lethal than etoposide (LC50 > 100 µM) against the 
UACC62 cell line and 17 (LC50 = 60.32 µM, Entry 9) was the most lethal. Apart from 18, none 
of the test compounds were lethal for HeLa cells, indicating a degree of selectivity between cell 
lines.  
   The compounds also exhibited more lethal cytotoxic effects against the MCF7 cell line than 
that of etoposide (LC50 > 100 µM, Entry 14) and 20 (LC50 = 86.93 µM, Entry 12) was the most 
lethal.  
   Apart from 17, none of the test compounds were lethal against HeLa cells indicating a degree 
of selectivity between cell lines. The catechols 11a–c and the catechol derivative 21 (Entry 13) 
did not exhibit any significant anticancer activity. From the results it can be seen that the 
GI50 concentrations of benzo[b]furan 12 (Entry 4) are almost half of those of 21 (Entry 13) 
against the renal (TK10), melanoma (UACC62) and breast (MCF7) cancer cell lines. It may thus 
be concluded that the presence of the furan ring enhances anticancer activity.            
 
The benzo[b]furans were most effective against the melanoma (UACC62) cell line. Only one 
benzo[b]furan, 20, exhibited growth inhibitory activity against all three cancer cell lines which 
may be attributed to the presence of the methoxy group on the benzene ring. When the methoxy 
group was replaced with a methyl group, as in 19, growth activity against the renal (TK10) and 
breast (MCF7) cell lines was diminished. The benzo[b]furan 17 exhibited activity against 
melanoma (UACC62) and breast (MCF7) cell lines. The replacement of the methoxy-group with 
that of a methyl, as in 16, also resulted in diminished activity and in this case against the breast 
(MCF7) cancer cell line. When comparing the structure of 19 to that of 17 it appears that the 
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replacement of the methyl group with that of a phenyl specifically affords growth inhibitory 
activity against the renal (TK10) cancer cell line.  
   It was concluded that the phenyl and methoxy-groups are essential for activity against all three 
cancer cell lines.  We observed that the benzo[b]furans having the methoxy catechol were more 
biologically active and the activity increased with size as well as with hydrophobicity as shown 
in Figure 3. The benzo[b]furans having a methoxy catechol and a phenyl group showed 
enhanced activity when compared to the ones without the phenyl group. 
O
O
OH
OH
O
O
OH
OH
O
O
OH
OH
OO
ANTICANCER ACTIVITY
         INCREASES
O
O
O
OH
OH
O
         15                                      17                                               18                                                        20
 
 
Figure 3: Evaluation of the anticancer activity of benzo[b]furan derivatives. 
The benzofuro[3,2-c]chromen-6-one derivatives were the second class of compounds screened 
for anticancer activity and are shown in Figure 4 below. 
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Figure 4: Benzofuro[3,2-c]chromen-6-one derivatives screened for anticancer activity. 
The screening results of the catechols 22a-d, coumarins 23a-d and benzofuro[3,2-c]chromen-6-
ones 24-41 were again compared to that obtained for etoposide.  
   It was evident that screening against the TK10 cell line showed that only compound 30 had 
potent activity against both melanoma (GI50 = 5.32 µM, Entry 14, Table 2) and breast cancer 
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(GI50 = 7.96 µM, Entry 14, Table 2). Most of the compounds exhibited moderate to weak 
activity. All the results are tabulated in Table 2 below. 
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Table 2. In vitro anticancer screening of the compounds against renal (TK10), melanoma (UACC62) and breast  
(MCF7) cancer cells expressed as GI50, TGI and LC50 values (µM). 
________________________________________________________________________________________ 
                 Renal (TK10)                               Melanoma (UACC62)                   Breast (MCF7) 
Entry 
                        
Cpd 
 
        GI50         TGI         LC50         GI50         TGI         LC50         GI50         TGI         LC50              
______________________________________________________________________________________________________________________ 
          
 
          
1 22a 68.02 >100   >100 45.00   >100   >100 52.41     >100 >100 
2 22b 38.14 75.75    >100 15.18 46.22 77.26 27.34 64.31   >100 
3 22c  51.63 96.98    >100 23.64 50.26 76.87 27.55 60.68 93.81 
4 22d 84.68    >100    >100 35.24 78.43     >100 57.55      >100    >100 
5 22e a   a    a a   a    a a      a     a 
5 23a >100    >100    >100 83.60    >100     >100 95.34      >100     >100 
6 23b >100    >100    >100 84.66    >100     >100 84.40      >100     >100 
7 23c >100    >100    >100 80.48    >100     >100 82.26      >100     >100 
8 23d N/A    >100    >100 88.72    >100     >100 83.31      >100     >100 
9 24 28.73 88.41    >100 33.26 61.88 90.56 39.40 77.31    >100 
10 25 >100    >100    >100 55.57    >100     >100 54.92       >100     >100 
11 26 >100    >100    >100 67.63    >100     >100 87.31        >100      >100 
12 27 >100    >100    >100 67.57    >100     >100 53.06        >100      >100 
13 30 51.96    >100   >100 11.16 50.94 90.71 54.70        >100      >100 
14 29 48.81    >100    >100 5.35 9.82 89.94 7.96 78.16    >100 
15 31 88.59    >100   >100 49.90    >100     >100   65.76         >100      >100 
16 32 >100    >100   >100 >100   >100     >100   69.67         >100      >100 
17 34 53.26    >100   >100 38.28 8.01     >100 45.97 86.34     >100 
18 35 >100    >100   >100 67.63   >100     >100 87.31       >100      >100 
19 36 26.81 66.41   >100 18.12 46.70 75.28 29.51 95.42    >100 
20 37 >100    >100   >100 91.84 >100     >100 77.73        >100      >100 
21 39 53.38    >100   >100 36.29 68.57     >100 47.54 89.75     >100 
22 40 58.14    >100   >100 39.66 73.59     >100 63.14  >100        >100 
23 41 >100    >100   >100 83.70   >100    >100 70.34 >100        >100 
24 Etoposide  7.19 49.74   >100 0.89 52.71    >100 0.56 >100       >100 
 
Inactive, GI50 or TGI > 100 mM; weak activity,  > 30 mM GI50 or TGI < 100 mM; moderate activity: < 30 mM GI50 or TGI > 10 mM; potent activity, GI50 or 
TGI < 10 mM. a  Not screened. 
 
Chapter 7                                                                                                    Biological evaluation 
146 | P a g e  
 
 
Compounds 24 (GI50 = 28.73 µM, Entry 9, Table 2) and 36 (GI50 = 26.81 µM, Entry 19, Table 2) 
showed moderate activity against the renal (TK10) cancer cell line.  
 Methyl-catechol 22b (GI50 = 15.18 µM, Entry 2, Table 2) and methoxy-catechol 22c (GI50 = 
23.64 µM, Entry 3, Table 2) exhibited moderate activity against the melanoma (UACC62) cancer 
cell line. Compounds 30 (GI50 = 11.16 µM, Entry 13, Table 2) and 36 (GI50 = 18.12 µM, Entry 
19, Table 2) also showed moderate activity against the melanoma cancer (UACC62) cell line. 
Compound 29 was the only compound that exhibited potent activity (GI50 = 5.35 µM, Entry 14, 
Table 2) against melanoma (UACC62) cancer cell line. This compound also exhibited potent total 
growth inhibition (TGI = 9.82 µM, Entry 14, Table 2) 
Moderate activity was observed for methyl catechol 22b (GI50 = 27.34 µM, Entry 2, Table 2), 
methoxy catechol 22c (GI50 = 27.55 µM, Entry 3, Table 2) and compound 36 (GI50 = 29.51 µM, 
Entry 19, Table 2) against the breast (MCF7) cancer cell line while compound 30 (GI50 = 7.96 
µM, Entry 14, Table 2) was the only compound to exhibit potent activity.   
Compound 30 is the only compound that has exhibited potent activity against both melanoma 
(UACC62) and breast (MCF7) cancer cell lines. 
 
The last class of compounds screened were the naphthoquinone derivatives as shown in Figure 5 
below. 
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Figure 5: Naphthoquinone derivatives screened for anticancer activity. 
The screening results of the naphthoquinone derivatives are in Table 3 below.  
Table 3. In vitro anticancer screening of the compounds against renal (TK10), melanoma (UACC62), breast 
(MCF7) and cervical (HeLa) cancer cells expressed as GI50, TGI and LC50 values (µM). 
__________________________________________________________________________________ 
  Entry   Compound                      renal (TK10)                    melanoma (UACC62)                breast (MCF7)                   
                                         GI50                TGI         LC50      GI50         TGI        LC50        GI50         TGI        LC50       
_____________________________________________________________________________________________________________  
      1       45         49.57 >100 >100 32.96 63.16 93.36 44.02 80.96 >100 
      2              46         >100  >100 >100 27.31 56.00 84.69 52.88 >100 >100 
       3             47          3.75  6.70  9.66  1.43  4.73  8.04  4.09  8.28 98.71 
      4              48         >100   >100 >100 28.02 55.85 83.69 50.25 >100 >100 
      5              49         32.52 55.35 78.18  6.28 27.31 64.71 31.94 64.00 96.07  
      6 Etoposide        7.19  49.74 >100  0.89        52.71 >100  0.56 >100 >100 
 
  
 
  
 
  
_____________________________________________________________________________________________________________ 
Inactive, GI50 or TGI > 100 mM; weak activity,  > 30 mM GI50 or TGI < 100 mM; moderate activity: < 30 mM GI50 
or TGI > 10 mM; potent activity, GI50 or TGI < 10 mM. 
 
Compound 47 showed excellent activity against all three cancer cell lines. 
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7.2 EVALUATION OF THE ANTIBACTERIAL ACTIVITY 
As previously mentioned in Section 7.1, it has been reported in the literature that benzofurans 
exhibit antibacterial activity.108b The benzo[b]furans synthesized in the present study were 
therefore screened against four different bacterial strains i.e. M. smegmatis MC2155, methicillin-
sensitive Staphylococcus aureus (MSSA) 32710, Bacillus substilis 168 and E. coli DH10B. The 
minimum inhibitory concentrations (MIC) were recorded. M. smegmatis was used as a model for 
further screening against M.tb. If good growth inhibitory activity was obtained against M. 
smegmatis then screening would be conducted against M.tb. Although this model is not 
completely precise we had to adopt it due to the time constraints as M.tb is a slow growing 
bacterium. Kanamycin and Rifampicin, which are well known antibiotics, were used as positive 
controls. The results are shown in Table 4 below and compound structures are shown in Figure 6. 
 
 Table 4.  MIC values (µg/mL) of the 5,6-dihydroxylated benzo[b]furans screened against four bacterial 
strains. 
_____________________________________________________________________________________ 
  Entry     Compound          M. smegmatis                         S. aureus            B. subtilis               E. coli 
________________________________________________________________________________________________________ 
1          11a   100   >100    >20  >100 
2         11b   100   >100    >20      50 
3         11c   25   >100    >20  >100 
4          12   >100     100  >100  >100 
5          13   >100   >100  >100  >100 
6          14   >100   >100  >100    100 
7         15   >100   >100  >100    100 
8          16   >100   >100  >100  >100 
9          17   >100   >100  >100  >100  
10          18   >100   >100  >100  >100  
11          19   >100   >100  >100  >100 
12          20   >100   >100  >100  >100 
13          21   >100   >100  >100    100 
14       Kanamycin    1.56       -      -     - 
15       Rifampicin     _                  <0.78  <0.78  <0.78 
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Figure 6: Benzo[b]furan derivatives screened for antibacterial activity. 
From the results shown in Table 4 it is evident that the benzo[b]furans were not active against 
the four bacterial strains since no growth inhibition was observed. Since none of the compounds 
exhibited potent activity against M. smegmatis they were not screened against M.tb. We then 
proceeded to evaluate the antibacterial activity of benzofuro[3,2-c]chromen-6-ones against the 
same bacterial strains. The structures are shown in Figure 7 below. 
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Figure 7: Benzofuro[3,2-c]chromen-6-one derivatives screened for antibacterial activity. 
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Table 5.  In vitro antibacterial screening results of the catechols, coumarins and benzofuro[3,2- 
c]chromen-6-one derivatives against M. smegmatis, S. aureus, B. subtilis and E. coli expressed as 
MIC values (µg/mL). 
_____________________________________________________________________________________ 
  
 Entry               Compound          M. smegmatis                          S. aureus           B.  subtilis               E. coli 
                                                   (MC2155)                 (32710)                  (168)                (DH10B) 
________________________________________________________________________________________________________ 
1                   22a   100   >100  >20  >100 
2       22b   100   >100  >20      50 
3     22c   25   >100  >20  >100 
4      22d   50   >100  >20  >100 
5     23a     50   >100  >20  >100 
6    23b   25   >100  >20  >100  
7      23c   50   >100  >20  >100  
8     23d  100   >100  >20  >100 
9     24  >100   >100                 < 20  >100 
10     25               >100   >100  >20  >100 
11     26               >100   >100  >20  >100 
12     27  >100   >100  >20  >100 
13     28               >100   >100  >20  >100 
14     29  >100   >100  >20  >100 
15     30  >100   >100  >20  >100 
16     31  >100   >100  >20  >100 
17     32  >100   >100  >20  >100 
18     33   >100   >100  >20  >100 
19     34   >100   >100  >20  >100 
20     35  >100   >100  >20  >100 
21     36   >100   >100  >20  >100 
22     37  >100    6.25  >20  >100 
23     38  >100   >100  >20  >100 
24     39   >100   >100  >20  >100 
25  Kanamycin 1.56       -      -     - 
26   Rifampicin -   <0.78  <0.78  <0.78 
_________________________________________________________________________________________________________________ 
 
Compound 37 (MIC = 6.25 µg/mL, Entry 37, Table 5) showed some activity against S. aureus.  
However, since none of the derivatives were potent against M. smegmatis it was decided not to 
screen benzofuro[3,2-c]chromen-6-one derivatives against M.tb.  
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We then proceeded to screen the naphthoquinone derivatives (Figure 8) against all four bacterial 
strains (Table 6). Compound 48 exhibited potent antibacterial activity (MIC = 6.25 µg/mL, Entry 
4, Table 6) against M. smegmatis and we decided to proceed and screen it against three 
susceptible M.tb strains.  
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Figure 8: Naphthoquinone derivatives screened for antibacterial activity. 
 
Table 6.  MIC values (µg/mL ) of compounds screened against four bacterial strains. 
__________________________________________________________________________________ 
  Entry   Compound    Mycobacterium smegmatis   Staphylococcus aureus  Bacillus subtilis   Escherichia coli 
_____________________________________________________________________________________________________________  
1 45                   >100   >100             >20  >100 
2 46     >100   >100  >20  >100 
3 47                   >100   >100  >20  >100 
4 48     6.25   >100  >20  >100 
5 49    >100   >100  >20  >100 
___________________________________________________________________ 
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Compound 48 was left in M. smegmatis for a number of days in order to determine if it was 
acting as a bactericidal or bacteriostatic agent. On the tenth day the bacterium started to slowly 
grow and this confirmed that this compound was acting as a bacteriostatic agent. 
 
 
7.2.2 SCREENING OF COMPOUND 48 AGAINST THREE SUSCEPTIBLE 
M.tb STRAINS 
 
Compound 48 was screened against three M.tb strains. Strain 4 is a MDR unique 001 strain with 
D516Y mutation in rpoB gene. Strain 5 is a MDR LL strain with S531L mutation in rpoB gene. 
Strain 10 is the drug susceptible strain called BE. Figure 9 shows two plates; the first one (Plate 
A) is the control which has three M. tb strains. The second one (Plate B) has three M. tb strains 
with compound 48 at different concentrations. 
 
      
                                 A                                                                 B 
Figure 9: Plate A, the control and 3 M.tb strains. Plate B, 3 M.tb strains with compound 48 at different 
concentrations. 
 
The growth of the bacteria took three weeks at 37ºC in 7H11 media. As depicted above 
compound 48 was active against resistant and susceptible clinical M.tb strains at 10, 50 and 100 
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mM as shown in Figure 9. This is evident as the bacteria were unable to grow at those 
concentrations.  
 
7.2.3 ISONIAZID AND THIOSEMICARBAZIDE DERIVATIVES 
In this section we will discuss the derivatized compounds that were screened for both anticancer 
and antibacterial activity. Because of time constraints we were unable to screen all the 
compounds. The compounds that were screened are shown in Figure 10 below. 
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Figure 10: Benzo[b]furan isoniazid derivative 50 and thiosemicarbazide derivatives, 51 and 52, screened 
for antibacterial and anticancer activity. 
 
7.2.3.1 Evaluation of the anticancer activity 
The results of the cancer screening are shown in Table 7 below. 
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Table 7: In vitro anticancer screening of compounds 17, 50, 51, 52, 53  
and 54 against renal (TK10), melanoma (UACC62) and breast (MCF7)  
cancer cell lines expressed as GI50, TGI and LC50 values (µM). 
__________________________________________________________ 
Entry   Cpd     Renal (TK10)         Melanoma (UACC62)      Breast (MCF7)                                               
                            GI50     TGI     LC50           GI50    TGI     LC50        GI50   TGI     LC50        
_____________________________________________________________________   
      
     1         17          26.54      51.65     76.75        0.78     18.32    60.32       8.79  48.79 95.11  
     2 50          37.25      84.01     >100        17.12    60.11    >100       56.87    >100      >100        
     3 51          45.56      82.44     >100         4.38      8.32     >100       33.22    78.55     >100         
     4 52          30.72      61.21     91.69        0.65      4.32     94.85       9.27   61.61     >100 
     5  53          19.41      47.00     74.59       29.56    59.48    89.39      44.55   80.91 >100 
     6 54          26.69      56.49     83.29       40.41    77.13    >100      52.63   98.60 >100        
     7   Etoposide    7.19       49.74     >100         0.89     52.71    >100         0.56     >100     >100        
_____________________________________________________________________ 
Cpd = compound; Inactive, I: GI50 or TGI > 100 µM; weak activity, w: > 30µM GI50  
or TGI < 100µM; moderate activity, m: < 30µM GI50 or TGI > 10µM; potent activity,  
p: GI50 or TGI < 10µM. 
 
The results were compared to its precursor 53, 54 and 17 (Figure 11) as well as to that of 
etoposide.  
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Figure 11: Structures of the precursors, benzo[b]furans 53, 54 and 17. 
 
Both compounds 52 (GI50, = 0.65 µM) and 17 (GI50 = 0.78 µM) exhibited potent activity against 
both melanoma and breast cancer cell lines. The precursor 17 was less potent than that of the 
derivative 52 against the melanoma cancer cell line. However, it was observed that the GI50 of 
the precursor 17 (GI50 = 8.79 µM) was better than that of the derivative 52 (GI50 = 9.27 µM) 
against the breast cancer cell line. These findings imply that the synthesized benzo[b]furan 17 is 
more biologically active and that derivitisation did not improve the biological activity against the 
breast cancer cell line.  
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Benzo[b]furans 53 and benzo[b]furans 54 exhibited moderate to weak activity as shown in Table 
7 above. The GI50 values were compared to that of anticancer drug, etoposide. Compound 50 
exhibited moderate to weak activity against the three cancer cell lines.  
   It was observed that 51 exhibited potent activity against the melanoma cell line (GI50 = 4.38 
µM) but it was not as good as that of etoposide (GI50 = 0.89 µM, Entry 5, Table 7). The activity 
of 52 (GI50, = 0.65 µM) against the melanoma cell line was better than that of etoposide (GI50 = 
0.89 µM, Entry 5, Table 7).  The activity of etoposide (GI50 = 0.56 µM, Entry 5, Table 7) was 
better than 52 (GI50 = 9.27 µM) against the breast cancer cell line. The difference between 51 
and 52 is the methoxy group which enhanced the activity of compound 52 against all three 
cancer cell lines.  
 
7.2.3.2 Evaluation of the antibacterial activity 
7.2.3.2.1 Isoniazid derivatives  
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Figure 12: Structures of the selected isoniazid derivatives screened against  M. smegmatis. 
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The selected isoniazid derivatives  that were screened were inactive against the four bacterial 
strains since no growth inhibition was observed. Since none of the compounds exhibited potent 
activity against M. smegmatis the derivatives were not screened against M.tb. 
 
7.2.3.2.2 Thiosemicarbazide derivatives 
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Figure 13: Structures of the selected thiosemicarbazide derivatives screened against M. smegmatis. 
The selected thiosemicarbizide derivatives were also like isoniazid derivatives inactive against 
the four bacterial strains since no growth inhibition was observed. Since none of the compounds 
exhibited potent activity against M. smegmatis the derivatives were not screened against M.tb. 
 
7.3 CONCLUSION 
 
 
It was possible to establish a structure-activity relationship for the 5,6-dihydroxylated 
benzo[b]furans that were screened against  four cancer cell lines.   It was observed that the 
phenyl and methoxy-groups in the 5,6-dihydroxylated benzo[b]furans are essential for activity 
against renal, melanoma breast and cervical cancer cell lines. Compounds; 15, 17, 18 and 20 
were the most biologically active of the benzo[b]furans (Figure 11).  
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Figure 12: Structures of the biologically active benzo[b]furans. 
The methoxy catechol derivatives were more biologically active and the activity increases as the 
size of the 1,3-diketone  increases as shown in Figure 11 above. The 5,6-dihydroxylated 
benzo[b]furans having both a methoxy catechol and a phenyl group showed enhanced activity 
when compared to the ones without the phenyl group.  
   The benzo[3,2-c]chromen-6-ones did not exhibit a similar activity  to that of the 5,6-
dihydroxylated benzo[b]furans. Only benzofuro[3,2-c]chromen-6-one 29 exhibited potent 
activity against the melanoma cancer cell line (GI50 = 5.35 µM). Interestingly, compound 29 also 
has a methoxy group (Figure 13). Only compound 37 exhibited antibacterial activity, it has 
potent activity against S. aureus (MIC = 6.25 µg/mL). 
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Figure 13: Benzofuro[3,2-c]chromen-6-one 29 exhibiting potent anticancer activity and 37 exhibiting  
potent antibacterial activity. 
 
Compound 51 exhibited potent activity (GI50 = 4.38 µM) against the melanoma cell line (Figure 
14). Compound 52 exhibits potent activity against two cell-lines, melanoma (GI50 = 0.65 µM) 
and breast cancer (GI50 = 9.27 µM), and its activity was better than that of etoposide (GI50 = 0.89 
µM) against the melanoma cell-line.  
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Figure 14: Thiosemicarbazide derivatives exhibiting potent anticancer activity. 
The methoxy group enhanced the activity of compound 52.  The isoniazid derivatives were 
inactive against the three cancer cell lines since no growth inhibition was observed, and the 
thiosemicarbizide derivatives did not show any significant increase in anticancer activity when 
compared to their precursors, the 5,6-dihydroxylated benzo[b]furans. For the antibacterial 
evaluation compound 48 (Figure 15) is the only compound that exhibited significant biological 
activity (MIC = 6.25 µg/mL) against M. smegmatis (MC2155). 
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Figure 15: The juglone derivative exhibiting anti-TB activity. 
 Compound 48 is active against both susceptible and resistant clinical M.tb strains.  
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CONCLUSION 
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8.0 CONCLUSION 
8.1 BIOCATALYTIC SYNTHESIS  
A new and broadly applicable synthetic sequence that is concise and cost effective has been 
successfully developed for the synthesis of benzo[b]furans 1, methyl substituted 1,3-
diketones catechol derivatives 2, benzofuro[3,2-c]chromen-6-ones 3, naphthoquinone 
menadione analogues 4 and C-C Bis coupled naphthoquinones 5 , 6 (Figure 1).  
O
R2
O
R3
OH
OH
R1
R1
OH
OH
O
O
O
O
OH
OH
O
R1
R2
R3
R2
O
O
O
O
OH
R1
O
O
1                                                        2                                                    3
4                                                 5                                          6
R1
R2
R1
 
Figure 1: Structures synthesized compounds 
The biocatalytic synthesis that entailed reacting a catechol or naphthohydroquinone with an 
equivalent of the 1,3-dicarbonyl, was based on the use of an enzyme, a laccase, which is 
marketed as Suberase®. The methodology utilised was environmentally friendly with high 
atom economy in that it was performed in an aqueous solvent at room temperature with 
atmospheric oxygen as a co-reactant, and generated water as the only by-product. No 
mediator compounds were required for these reactions. This broadly applicable biocatalytic 
method permitted the synthesis of a total of seventy compounds in this study, of which fifty 
one were novel.  
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We were able to synthesise fluorinated and acid derivatives of benzofuro[3,2-c]chromen-6-
one 3,which has not been reported in literature previously. We also demonstrated that the 
enzyme Suberase® can be utilised in cross coupling of enolates to unactivated sp2-hybridized 
electrophiles without the use of a transition-metal catalyst (compound 2).  
 
8.2 SYNTHESIS OF ISONIAZID AND THIOSEMICARBIZIDE 
DERIVATIVES 
Our interest was in synthesising derivatives of the first-line anti-TB drug, isoniazid, as well as 
thiosemicarbazide derivatives from the previously synthesised 5,6-dihydroxylated 
benzo[b]furans 1, with the aim to improve the biological activity against both cancer and 
bacteria. Schiff base methodology was utilised to give nine novel isoniazid derivatives and 
eight novel thiosemicarbizide derivatives. 
 
8.3 BIOLOGICAL EVALUATION 
Anti-cancer activity: The synthesised compounds were evaluated as anti-cancer compounds 
against cancer cell panels comprised of renal (TK10), melanoma (UACC62), breast (MCF7) 
and cervical (HeLa) cancer lines. A number of the benzo[b]furans 1, (compounds 7, 8, 9 and 
10, Figure 2) had a comparable potency to that of the anticancer drug etoposide on the 
melanoma cell line (etoposide (GI50 = 0.89 µM), compound 7 (GI50 = 6.04 µM), 8 (GI50 = 
0.78 µM), 9 (GI50 = 6.79 µM) and 10 (GI50 = 0.77)). 
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Figure 2: Structures of the benzo[b]furans with anti-cancer activity. 
The methoxy catechol derivatives of the benzo[b]furans were more biologically active on 
melanoma cancer cell line and the activity increased as the size of the 1,3-diketone as 
increased. This observed increase in activity of these analogues was attributed to an increased 
lipophilic character. The benzo[3,2-c]chromen-6-ones 3 did not generally exhibit a similar 
anti-cancer activity to that of the 5,6-dihydroxybenzo[b]furans, and. only benzofuro[3,2-
c]chromen-6-one 11 exhibited potent activity against the melanoma cell-line (GI50 = 5.35 
µM)  (Figure 3).  
O
O
OH
OH
O
11
O OH
OH
N
H
N NH2
S
OO OH
OH
N
H
N NH2
S
12                                         13
 
Figure 3: A benzofuro[3,2-c]chromen-6-one 11 and two thiosemicarbazide derivatives 12, 13 
exhibiting potent anticancer activity.. 
 
A thiosemicarbizide analogue 12 exhibited potent activity (GI50 = 4.38 µM) against the 
melanoma cell line, while 13 exhibited potent activity against both melanoma (GI50 = 0.65 
µM) and breast cancer (GI50 = 9.27 µM), the former being similar in potency to etoposide 
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(GI50 = 0.89 µM) against the same melanoma cell-line. However, the thiosemicarbizide 
derivatives did not show superior anticancer activity when compared to their chemical precursors, the 
5,6-dihydroxyl benzo[b]furans. It is evident among the thiosemicarbizide derivatives that the 
methoxy group enhanced the activity of compound 13.   
Antibacterial activity: A selected number of compounds were evaluated for antibacterial 
properties against a range of bacteria which included the Gram positive bacteria Bacillus 
subtilis and Staphylococcus aureus, the Gram negative Escherichia coli, and the acid fast 
bacteria Mycobacterium smegmatis, and Mycobacterium tuberculosis. Compound 14 (Figure 
4) exhibited antibacterial activity, against S. aureus (MIC = 6.25 µg/mL). Only compound 15 
exhibited significant biological activity (MIC = 6.25 µg/mL) against M. smegmatis 
(MC2155), but was active against both drug susceptible and drug resistant clinical M.tb 
strains. 
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Figure 4: A benzofuro[3,2-c]chromen-6-one 14 that exhibited  potent antibacterial activity and a 
juglone derivative 15 that exhibited anti-TB activity . 
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8.3 CLOSING COMMENTS 
 
In conclusion, this research has thoroughly explored the application of a laccase, one 
that is commercially available and accessible to chemists, for the synthesis of a broad 
range of benzofurans and structurally related compounds. These compounds were  
demonstrated  to have biological activities,  specifically relating to anti-cancer and anti-
microbial properties, with potencies that are comparable with existing prescription 
medicines. The biocatalytic synthetic technique used here permitted the synthesis of many 
novel compounds, opening the way to access synthetic spaces that have not been 
previously accessed by non-biocatalytic methods. 
 
The future work should include further studies of benzo[b]furans (7-11) and 
thiosemicarbizide (12-13) for their application in anticancer therapy. This encompasses 
further synthesis of 7-11, 12,13 and evaluation of their anticancer activity in addition to 
structural modification of hits in order to determine whether the anticancer activity can be 
optimised. The results also warrant further derivatisation of the promising compounds 14 
and 15 in order to enhance their antibacterial properties. The influence of other laccases 
on the synthetic profile and reaction yield should be explored, including those laccases 
with higher redox potentials or with differing active site configurations. 
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9.1 EXPERIMENTAL 
 
9.1 SUMMARY OF THE EXPERIMENTAL 
 
9.1.1 General 
Proton nuclear magnetic resonance (1H NMR) spectra were recorded on a Varian Mercury 
400 MHz spectrometer. Carbon-13 nuclear magnetic resonance (13C NMR) spectra were recorded 
on the same instrument at 100 MHz. Chemical shifts are reported in parts per million (ppm) relative 
to the solvent peaks and coupling constants are given in Hertz (Hz). A Waters UPLC coupled in 
tandem to a Waters photodiode array (PDA) detector and a SYNAPT G1 HDMS mass 
spectrometer was used to generate accurate mass data. The PDA detector was used for all purity 
determinations (Maxplot 200–500 nm). All chemicals for UPLC-MS work were of ultra-pure LC-
MS grade and purchased from Fluka (Steinheim, Germany) while ultra-pure solvents were 
purchased from Honeywell (Burdick & Jackson, Muskegon, USA). Ultra-pure water was 
generated using a Millipore Elix 5 RO system and Millipore Advantage Milli-Q system (Millipore 
SAS, Molsheim, France). Reactions were monitored by thin layer chromatography (TLC) on 
aluminium-backed Merck silica gel 60 F254 plates. Gravity column chromatography was 
performed using Merck Silica Gel 60 (70–230 mesh). Melting points were determined using a 
Glassco melting point apparatus and are uncorrected. All other chemicals were reagent grade 
materials. The 1,3-dicarbonyls were purchased from Sigma–Aldrich, South Africa. Suberase® 
(10757.8 PCU/mL) is a fungal laccase from M. thermophila produced by submerged fermentation 
of a genetically modified Aspergillus oryzaestrain. The enzymatic preparation is supplied as a 
brown liquid which is completely miscible with water. Suberase® was obtained from Novozymes 
in South Africa. 
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9.1.2 METHODS FOR THE SYNTHESIS OF THE 5,6-DIHYDROXYLATED 
BENZO[B]FURANS 
 METHOD A 
The laccase (Suberase®, 2.0 mL) was added to a mixture of the catechol (2.0 mmol), 1,3-
dicarbonyl (2.0 mmol) and phosphate buffer (20.0 mL, 0.10 M, pH 7.15) in a 250-mL round-
bottom flask stirred under air at rt. More laccase (2.0 mL) was added after 2, 18 and 20 h. The 
mixture was vigorously stirred under air until the substrates were consumed as judged by TLC. 
After stirring the reaction mixture was acidified with 32% HCl to pH 4.0. The mixture was 
extracted with EtOAc and washed with water (20.0 mL). The organic phases were then combined 
and the solvent evaporated. The residue, a powder, was purified by washing with EtOAc or 
recrystallizing from a combination of MeOH and EtOAc. 
METHOD B 
Same as Method B except that more laccase (2.0 mL) was added after 4, 24 and 28 h. 
METHOD C 
The laccase (Suberase®, 1.5 mL) was added to a mixture of the catechol (0.60 mmol), 1,3-
dicarbonyl (2.40 mmol), phosphate buffer (4.0 mL, 0.10 M, pH 7.15) and DMF (2.0 mL) in a test 
tube stirred under air at rt. More laccase (1.5 mL) was added after 2 h and then again after 4 h. The 
mixture was vigorously stirred under air until the substrates had been consumed as judged by TLC. 
After stirring the reaction mixture was transferred to a separating funnel and the mixture extracted 
with EtOAc and washed with water (20.0 mL). The organic phases were combined, the solvent 
evaporated and the residue (a powder) purified by flash chromatography. 
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Synthesis of 7,8-Dihydroxy-6-methyl-3,4-dihydrodibenzo[b,d]furan-1(2H)-one 4 
O OH
OH
O
 
Method A 
Stirring time 24 h.should really say how much you started with.for all of the experimental. The 
product was recrystallized from 5% MeOH in EtOAc solution at 35°C to afford a brown powder 
(288 mg, 62%) (Found: M–H+, 231.0683. C13H11O4 requires M–H, 231.0657). UPLC 99.7%. 
Rf 0.48 (EtOAc/hexane, 1:1). mp 250°C. 1H NMR (400 MHz, DMSO-d6): δ 2.14 (2H, m, CH2), 
2.26 (3H, s, CH3), 2.45 (2H, t J 6.1 Hz, CH2), 2.98 (2H, t J 6.1 Hz, CH2), 7.11 (s, 1H, ArH); 13C 
NMR (100 MHz, DMSO-d6): δ 9.0, 22.2, 23.3, 37.9, 102.4, 107.9, 113.5, 115.9, 142.2, 143.4, 
147.6, 169.6, 194.6. 
 
Method B 
Stirring time 44 h. The product was washed with EtOAc to afford a brown powder (311.0 mg, 
67%). 
Synthesis of  3-(3,4-Dihydroxy-5-methylphenyl)-3-methylpentane-2,4-dione 16 
OH
OH
O
O
 
Method A 
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Stirring time 24 h. The product was washed with EtOAc to afford a dark-brown powder (1.60 g, 
80%) (Found: M–H+, 235.0926. C13H14O4 requires M–H, 235.0970. UPLC 98.0%. Rf 0.48 
(EtOAc/hexane, 1:1). mp 82–85°C. 1H NMR (400 MHz, DMSO-d6): δ 1.60 (3H, s, CH3), 2.03 
(6H, s, CH3), 2.08 (3H, s, CH3), 6.43 (1H, d J 2.0 Hz, ArH), 6.46 (1H, dJ 2.4 Hz, ArH), 8.36 (1H, 
br s, OH), 9.29 (1H, br s, OH); 13C NMR (100 MHz, DMSO-d6): δ 16.2, 19.0, 27.2, 30.7, 68.8, 
112.4, 120.1, 124.7, 127.7, 143.0, 144.8, 207.8. 
 
9.1.3 METHODS FOR THE SYNTHESIS OF Benzofuro[3,2-c]chromen-6-one 
 
METHOD A 
The laccase (Suberase®, 2.0 mL) was added to a mixture of the catechol (2.0 mmol), coumarin 
(2.0 mmol) and phosphate buffer (20.0 mL, 0.10 M, pH 7.15) in a 250 mL round bottom flask 
stirred under air at rt. More laccase (2.0 mL) was added after 2, 18 and 20 h. The mixture was 
vigorously stirred under air until the substrates were consumed as judged by TLC. The mixture 
was extracted with EtOAc and washed two times with water (20.0 mL). The organic phases were 
then combined and the solvent evaporated. The residue, a powder, was purified by washing with 
EtOAc, flash chromatography or recrystallization from a combination of MeOH and EtOAc. 
Products were characterized by 1H NMR, 13C NMR, and MS. 
 
METHOD B 
 
The laccase (Suberase®, 1.0 mL) was added to a mixture of the catechol (1.0 mmol), coumarin 
(1.0 mmol) and phosphate buffer (8.0 mL, 0.10 M, pH 7.15) in a 250 mL round bottom flask stirred 
under air at 40°C. More laccase (1.0 mL) was added after 2, 18 and 20 h. The mixture was 
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vigorously stirred under air until the substrates were consumed as judged by TLC. The solvent 
mixture was left for a day to allow the product to precipitate to the bottom and filtered. The residue, 
a powder, was purified by washing with EtOAc. Products were characterized by 1H NMR, 13C 
NMR, and MS. 
 
Synthesis of 8,9-Dihydroxy-6H-benzofuro[3,2-c]chromen-6-one 17 
 
O
O
OH
OH
O
 
 
Method A. Stirring time = 24 h. Purification by a wash with EtOAc and the flash chromatography 
(silica: EtOAc/hexane, 1:5, 1:4, 1:3, 1:2 and EtOAc) to afford a light-brown solid (0.4600 g, 
86.0%). (M-H+ Found: 267.0216. C15H7O5 requires M-H+, 267.0293). UPLC 99.8 %.   Rf 0.54 
(EtOAc/Hex, 1:2).  mp 300oC. 1H NMR (400 MHz, DMSO-d6): δ = 7.24 (1H, s, ArH). 7.31 (1H, 
s, ArH), 7.48 (1H, t, J 8.0  Hz, ArH), 7.58 (1H, d, J  8.0 Hz, ArH), 7.66 (1H, ddd, J 1.6, 8.0, 15.6  
Hz, ArH), 8.00 (1H, dd, J 1.6, 8.0 Hz, ArH; 13C NMR (100 MHz, DMSO-d6): δ = 98.9, 104.9, 
105.5, 112.4, 113.8, 117.0, 121.1, 124.8, 131.2, 144.7, 146.6, 149.4, 152.3, 157.4, 157.7.    
       
Synthesis of 10-Fluoro-8,9-dihydroxy-2,3-dimethyl-6H-benzofuro[3,2-c]chromen-6-one 30 
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Method A. Stirring time = 24 h. Purification by washing with EtOAc to afford a brown solid (0.500 
g, 76.0%). (M+H+ Found: 314.0588. C17H11O5F requires M+H+, 314.0591). UPLC 93%.  Rf 0.58 
(EtOAc/hexane, 1:1).  mp = 174 oC; 1H NMR (400 MHz, DMSO-d6): δ = 2.26 (3H, s, CH3), 2.30 
(3H, s, CH3), 5.46 (1H, s, ArH), 7.15 (1H, s, ArH), 7.56 (1H, s, ArH); 13C NMR (100 MHz, DMSO-
d6): δ = 18.7, 19.6, 62.5, 63.4, 68.8, 71.4, 72.3, 73.7, 89.9, 113.6, 116.7, 123.0, 132.1, 142.1, 152.0, 
162.3, 166.2.  
 
Synthesis of 2-chloro-8,9-dihydroxy-6-oxo-6H-benzofuro[3,2-c]chromene-10-
carboxylic acid 34 
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Method B. Stirring time = 24 h. Purification by a wash with EtOAc to afford a yellow solid (0.527 
g, 76.0%). (M+H+ Found: 346.9887 C16H8O7Cl requires M+H+, 346.9959). UPLC 98.1%. Rf  0.31 
(EtOAc/Hex, 2:1). mp 152oC; 1H NMR (600 MHz, DMSO-d6): δ =  7.13 (1H, s, H-Ar), 7.52 (1H, 
d, J 8.8  Hz, H-Ar), 7.60 (1H, dd, J 2.4, 8.8 Hz, H-Ar), 7.96  (1H, d,  J 2.4 Hz, H-Ar), 13C NMR 
(100 MHz, DMSO-d6): δ =  98.1, 107.6, 109.0, 111.9, 113.7, 118.3, 120.1, 128.1, 130.1, 147.5, 
147.9, 150.5, 154.6, 155.6, 168.4. 15  
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9.1.4 SYNTHESIS OF 1,4-NAPHTHOQUINONE DERIVATIVES 
METHOD 
The laccase (Suberase1, 1.0 mL) was added to a mixture of the catechol (1.0 mmol), coumarin (1.0 
mmol) and phosphate buffer (8.0 mL, 0.10 M, pH 7.15) in a test tube stirred under air at 40°C. 
More laccase (1.0 mL) was added after 2, 18 and 20 h. The mixture was vigorously stirred under 
air until the substrates were consumed as judged by TLC. The mixture was extracted with EtOAc 
and washed two times with water (20.0 mL). The organic phases were then combined and the 
solvent evaporated. The residue, a powder, was purified by flash chromatography. Products were 
characterized by 1H NMR, 13C NMR, and MS.  
 
Synthesis of 2-(2-hydroxy-4,4-dimethyl-6-oxocyclohex-1-enyl)-3-methylnaphthalene-1,4-
dione 41 
O
O
OH
O
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a brown 
solid (0.296g 88% yield), (M-H+ Found: 309.1012, C22H13O2 requires M-H+, 309.0916). UPLC 
99.6%. Rf  0.52.  (EtOAc/Hex, 1:2). mp 230ºC 1H NMR (400 MHz, DMSO-d6): δ = 1.09 (3H, s, 
CH3), 1.16 (3H, s, CH3), 1.90 (3H, s, CH3),2.36 (4H, s, 2 x CH2), 7.85 (2H, dd, J 3.4, 5.4 Hz, ArH), 
7.96 (1H, dd, J 3.4, 5.4 Hz, ArH), 8.04 (1H, dd, J 3.4, 5.4 Hz, ArH), 10.8 (1H, s, OH). 13C NMR 
(100 MHz, DMSO-d6): δ = 13.9, 27.7, 28.0, 31.9, 108.9, 125.8, 125.8, 131.6, 132.0, 133.7, 133.9, 
141.6, 145.4, 182.5, 184.6. 
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Synthesis of 2-(6-chloro-4-hydroxy-2-oxo-2H-chromen-3-yl)-3-methylnaphthalene-1,4-
dione 46 
O
O
O
O
HO
Cl
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a brown 
solid (M-H+ Found: 365.0299, C20H10ClO5 requires M-H+, 365.0300). UPLC 90.1%. Rf  0.40  
(EtOAc/Hex, 1:2). mp 260-261ºC 1H NMR (400 MHz, DMSO-d6): δ = 2.12 (3H, s, CH3), 3.90 
(1H, br s, OH),  6.98 (1H, s, ArH), 7.55 (1H, dd, J 7.50, 15.6 Hz, ArH), 7.64 (1H, m, ArH), 7.86 
(2H, dd, J 3.60, 4.80 Hz, ArH), 7.97 (1H, t, J 4.50 Hz, ArH), 8.02 (1H, t, J 4.50 Hz, ArH). 13C 
NMR (100 MHz, DMSO-d6): δ = 14.2, 95.9, 116.6, 116.7, 122.8, 122.9, 124.8, 125.4, 125.8, 130.2, 
131.8, 133.0, 133.1, 133.3, 143.2, 146.2, 154.0, 161.8, 171.5, 183.1, 189.2.  
Synthesis of 5-hydroxy-2,3-bis(4,4-dimethyl-2,6-dioxocyclohexyl)naphthalene-1,4-dione 50 
O
O
O
O
O
O
OH
 
Stirring time = 48h.  The product was washed with EtOAc to afford light brown solid (0.292g 48% 
yield), (M_H+ Found: 449.1595 C26H25O7 requires M-H, 449.1600). UPLC 91.2%.  Rf = 0.51 
(EtoAc) Mp = 170 oC. 1H NMR (400 MHz, DMSO-d6) 0.99 (3H, s, CH3), 1.07 (3H, s, CH3), 2.13 
(2H, s, 2 X CH), 2.15 (2H, s, CH2), 2.26 (2H,s,CH2), 7.33 (1H, dd, J 1.0, 8.7 Hz, H-Ar), 7.50 (1H, 
dd, J 1.20, 7.60 Hz, H-Ar), 7.75 (1H, t, J 8.0 Hz, H-Ar), 12.0 (1H, s, OH); 13C NMR (100 MHz, 
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DMSO-d6): δ  28.8, 29.3, 31.8, 31.6, 109.9, 125.8, 128.6, 129.3, 132.3, 134.6, 135.3, 139.8, 146.6, 
183.6 
9.1.5 SYNTHESIS OF ISONIAZID DERIVATIVES 
METHOD 
The synthesis of the isoniazid derivatives was conducted by reacting one equivalent of isoniazid 
with one equivalent of the 5,6-dihydroxylated benzo[b]furan and stir in methanol at 60ºC  for 24-
44 hours. The reaction was followed by TLC, the disappearance of the 5,6-dihydroxylated 
benzo[b]furan was monitored. The resulting product was purified by flash chromatography. In 
some cases the product required further purification by either washing with EtOAc or 
recrystallizing from a mixture of MeOH and EtOAc. 
Synthesis of isoniazid derivative 56 
O OH
OH
N
HN O
N
 
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a brown 
solid (MeOH/EtOAc 1:2). mp 240°C. (M+H+ Found: 365.1511, C20H20N3O4 requires M+H+, 
365.1566)  Rf = 0.35 (2:1 EtoAc: MeOH). 1H NMR (400 MHz, DMSO-d6): δ 1.14 (3H, d, J 6.4 Hz, 
CH3), 2.26 (3H, s, CH3), 2.29 (1H, dd, J 4.7, 12.4 Hz, CH2), 2.43 (2H, dd J 3.4, 12.8 Hz, CH2), 
2.68 (1H, m, CH), 3.03 (1H, dd J 4.7, 12.4 Hz, CH), 7.11 (1H, s, ArH), 7.72 (2H, dd, J 1.6, 4.4 
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 Hz, ArH), 8.40 (1H, br s, OH), 8.70 (2H, d, J 6.0 Hz, ArH),9.31 (1H, br s, OH), 10.01 (1H, br s, 
NH); 13C NMR (100 MHz, DMSO-d6): δ 2.0, 23.1, 37.3, 60.3, 99.8, 114.8, 115.5, 120.9, 133.3, 
136.1, 140.2, 144.9, 150.1, 163.8, 169.8, 194.4. 
 
9.1.6 SYNTHESIS OF THIOSEMICARBIZIDE DERIVATIVES 
Method A  
The benzofuran  (1.0 mmol) was added to a solution of the thiosemicarbazide  (1.0 mmol) in 
methanol (10 ml). The resulting mixture was stirred at 40ºC for 48 h. The reaction mixture was 
extracted with EtOAc and washed with water (20.0 mL). The product was left to precipitate when 
the reaction vessel was left standing at room temperature. The residue, a powder, was purified by 
washing with EtOAc or recrystallizing from a mixture of MeOH and EtOAc.  
Method B  
This method is the same as Method A except that the resulting mixture was refluxed for 48 h in 
the presence of a catalytic amount of glacial acetic acid. After completion of the reaction, the 
reaction mixture was first extracted with EtOAc and then the organic phases were combined, the 
solvent evaporated and the residue (a powder) purified by flash chromatography. 
Synthesis of thiosemicarbizide derivative 65 
O OH
OH
N
H
N NH2
S
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Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a light 
brown solid (MeOH/EtOAc 1:2). (M+H+ Found: 306.0904, C14H16N3O3S requires M-H+, 
306.0912).  mp 240°C. Rf = 0.30 (2:1 EtoAc: MeOH).  1H NMR (400 MHz, DMSO-d6): δ 1.12 
(3H, d, J 6.40 Hz, CH3), 2.31 (1H, dd, J 4.6, 12.8 Hz, CH), 2.44 (2H, dd, J 3.6, 12.8 Hz, CH2), 2.70 
(1H, m, CH), 3.03 (1H, dd J 4.6, 12.8 Hz, CH), 4.49 (1H, s, NH), 6.97 (1H, s, ArH), 7.21 (1H, s, 
ArH) and 8.60 (2H, br s, OH), 9.05 (2H, s, NH2), 13C NMR (100 MHz, DMSO-d6): δ 20.6, 30.2, 
30.6, 30.9, 45.6, 98.4, 105.3, 114.3, 115.2, 143.6, 144.3, 148.1, 169.2, 193.8. 
 
9.1.7ANTICANCER EVALUATION 
The growth inhibitory effects of the compounds were tested in a 3-cell line panel consisting of 
TK10 (renal), UACC62 (melanoma) and MCF7 (breast) cancer cells using the Sulforhodamine B 
(SRB) assay. The SRB assay was developed by Skehan and colleagues to measure drug-induced 
cytotoxicity and cell proliferation. Its principle is based on the ability of the protein dye, 
sulforhodamine B (Acid Red 52), to bind electrostatically in a pH-dependent manner to protein 
basic amino acid residues of trichloroacetic acid-fixed cells. Under mild acidic conditions it binds 
to the fixed cellular protein, while under mild basic conditions it can be extracted from cells and 
solubilised for measurement. The SRB assay is performed at CSIR in accordance with the protocol 
of the Drug Evaluation Branch, NCI, and the assay has been adopted for this screen. 
 
 MATERIALS AND METHOD 
The human cell lines TK10, UACC62 and MCF7 were obtained from the NCI in a collaborative 
research program between the CSIR and the NCI. cell lines were routinely maintained as a 
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monolayer cell culture at 37°C, 5% CO2, 95% air and 100% relative humidity in RPMI containing 
5% fetal bovine serum, 2 mM L-glutamine and 50 µg/mL gentamicin. For the screening 
experiment the cells (3–19 passages) were inoculated in a 96-well microtitre plate at plating 
densities of 7–10 000 cells/well and were incubated for 24 h. After 24 h one plate was fixed with 
TCA to represent a measurement of the cell population for each cell line at the time of drug addition 
(T0). The other plates with cells were treated with the experimental drugs which were previously 
dissolved in DMSO and diluted in medium to produce five concentrations (0.01–100 µM). Cells 
without drug addition served as control. The blank contains complete medium without cells. 
Etoposide was used as a reference standard. The plates were incubated for 48 h after addition of 
the compounds. Viable cells were fixed to the bottom of each well with cold 50% trichloroacetic 
acid, washed, dried and dyed by SRB. Unbound dye was removed and protein-bound dye was 
extracted with 10 mM Tris base for optical density determination at a wavelength of 540 nm using 
a multiwell spectrophotometer. Optical density measurements were used to calculate the net 
percentage cell growth. The optical density of the test well after a 48 h period of exposure to test 
drug is Ti, the optical density at time zero is T0, and the control optical density is C. Percentage 
cell growth is calculated as: 
 
. 
 
 
 
 
  
[(Ti – T0)    x  100 for concentrations at which Ti ≥ T0 
(C – T0)] 
 
[(Ti – T0)    x  100 for concentrations at which Ti <T0 
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The results of a five dose screening were reported as TGI (total growth inhibition). The TGI is the 
concentration of test drug where 100 × (T − T0)/(C − T0) = 0. The TGI signifies a cytostatic effect. 
The biological activities were separated into four categories: inactive (GI50 or TGI > 100 µM), 
weak activity (30 µM < GI50 or TGI < 100 µM), moderate activity (10 µM < GI50 or TGI < 30 µM) 
and potent activity (GI50 or TGI < 10 µM). For each tested compound, three response parameters, 
GI50 (50% growth inhibition and signifies the growth inhibitory power of the test agent), TGI 
(which is the drug concentration resulting in total growth inhibition and signifies the cytostatic 
effect of the test agent) and LC50 (50% lethal concentration and signifies the cytotoxic effect of the 
test agent), were calculated for each cell line. 
 
 
9.1.8 ANTIBACTERIAL SCREENING 
 Mycobacterium smegmatis - (MC2 155) 
The MICs of the compounds against the four different bacteria were determined in 96 well 
microtiter plate. A 10.00 mg/mL stock solution of each compound was prepared by dissolving it 
in 1 mL of DMSO. The stock solution was kept in a refrigerator at +4 ⁰C.  Kanamycin was used 
as a positive control. The negative control was a well with 7H9 media and bacterial dilutions. The 
second negative control was wells with only the media in order to check for contamination. A 1:2 
serial dilution of the tested compound was prepared. The initial concentration was 100 µg/ml of 
the stock solution in well 1 and a final concentration of 0.78 µg/mL in the well. A bacterial 
suspension was prepared by scraping a small amount of fresh bacteria from a plate onto a wet 
cotton stick. 7H9 media was used to wet the cotton wool. The bacterium was dispensed by rubbing 
the wet cotton wool with the bacterium against the walls of a tube with 2.5 mL of 7H9 media. The 
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tube was vortexed and the OD measured at 600 nm. The standard for OD is 0.3 = 5 x 108 CFU/mL, 
Serial dilutions of the bacterial suspension were made up to the required concentrations(for our 
experiment: C1 = 1x102/well = 2 x103 CFU/mL and C2 = 1x103/well = 2 x106 CFU/mL ). A volume 
of 100 µL of the required concentrations of the bacteria was dispensed into each well to have a 
total volume of 200 µL per well. The concentrations of the bacteria in the wells were determined 
using a microtitre plate reader. The 96 well plates were then placed in a plastic bag which was 
incubated at 37°C. The concentrations of the bacteria were read daily for 4-5 days. 
 
7H9 Medium Preparation (7H9 + 0.2% glycerol + 0.05% Tween 80 + ADC)                                                                                                                               
Middlebrook 7H9 broth base (4.7 g) was added to a 2 L flask to which water (900 mL) was added.  
Tween 80 (0.5 g) was added to a 100 mL beaker  to which  broth (10 mL) was added.  The mixture 
was dissolved using moderate heat while mixing.  The contents from the 100 mL beaker were then 
transferred back into the 2 L flask. To ensure that all the contents were transferred to the 2 L flask, 
the beaker was rinsed several times with broth. Glycerol (2 mL) was then added to the 2 L flask.  
This was then mixed and 180 mL dispensed into each of five 500 mL screw cap bottles. The latter 
was then autoclaved for 10 min at 121o C, allowed to cool and then stored at 2-8o C. ADC (20 mL) 
was added to each 180 mL broth before use. 
 
 
 
Staphylococcus aureus - 32710 (MSSA)  
Same procedure but instead of 7H9 media, LB media was used. LB was bought from the 
chemical store in UMDNJ. 
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Escherichia coli - DH10B strain 
Same procedure but instead of 7H9, LB media was used. LB was bought from the chemical 
store in UMDNJ., Rifampicin was used Instead of Kanamycin. 
Bacillus subtilis - strain no 168 
A 96 wells Microtitre plates was used to determine the MICs for bacteria. A 10.00 mg/mL solution 
of each compound was prepared by dissolving the powder in a required volume of DMSO. For 
example 10.12 mg of the compound should be dissolved in 1.012 mL of DMSO. Keep stock 
solution in the refrigerator at +4 °C.  Rifampicin was used as a positive control. The negative 
control was wells with LB media and bacteria dilutions. The second negative control is wells with 
only the media in order to check for contamination. The solutions were diluted to 20 µg/ml. The 
bacteria suspension was prepared by scraping small amount of fresh bacteria from a plate with a 
wet cotton stick. LB media was used to make the cotton wet. The bacteria were dispensed by 
rubbing the wet cotton wool with bacteria against the walls of a tube with 2.5 mL of LB media. 
The tube was vortexed and then measured the OD at 600 nm. Standard for OD is 0.3 = 5 x 108 
CFU/mL. Make serial dilutions of the bacterial suspension to the required concentration. (for our 
experiment C1 = 1x102/well = 2 x103 CFU/mL and C2 = 1x103/well = 2 x106 CFU/mL ). We 
ispensed(a word?) 100 µL of the required concentrations of the bacteria into each well to have a 
total volume of 200 µL per well. The negative control was wells with media and bacteria dilutions. 
The positive control should was with media and kanamycin. We read the concentration of the 
bacteria in a microtitre plate reader. We put the 96 well plates in a plastic bag and incubate at 37°C. 
We ead the concentration of the bacteria every day. 
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Mycobacterium smegmatis - (MC2 155) 
A 96 well microtiter plates was used to determine the MICs for bacteria. A 10.00 mg/mL solution 
of each compound was prepared by dissolving the powder in a required volume of DMSO. For 
example 10.12 mg of the compound should be dissolved in 1.012 mL of DMSO. Keep stock 
solution in the refrigerator at +4⁰C.  Kanamycin was used as a positive control. The negative 
control was wells with 7H9 media and bacteria dilutions. The second negative control was wells 
with only the media in order to check for contamination. A 1:2 serial dilution of the tested 
compound was prepared. Initial concentration of 100 µg/ml in well 1 and final concentration of 
0.78 µg/ml. The bacteria suspension was prepared by scraping small amount of fresh bacteria from 
a plate with a wet cotton stick. 7H9 media was used to make the cotton wet. The bacteria were 
dispensed by rubbing the wet cotton wool with bacteria against the walls of a tube with 2.5 mL of 
7H9 media. The tube was vortexed and then the OD 600 nm measured . Standard for OD was 0.3 
= 5 x 108 CFU/mL.  Where necessary serial dilutions of the bacterial suspension where made to 
the required concentration For readings (for our experiment C1 = 1x102/well = 2 x103 CFU/mL and 
C2 = 1x103/well = 2 x106 CFU/mL ). Dispensed volumes (100 µL) of the required concentrations 
of the bacteria into each well had a total volume of 200 µL per well. The negative control 
comprised of wells with media and bacteria dilutions. The positive control comprised of wells with 
media and kanamycin.  The concentration of the bacteria was determined using a microtiter plate 
reader at time zero and then daily. The 96 well plates were incubated at 37°C in a plastic bag.  
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9.2 FULL EXPERIMENTAL 
 
9.2 General 
Proton nuclear magnetic resonance (1H NMR) spectra were recorded on a Varian Mercury 
400 MHz spectrometer. Carbon-13 nuclear magnetic resonance (13C NMR) spectra were recorded 
on the same instrument at 100 MHz. Chemical shifts are reported in parts per million (ppm) relative 
to the solvent peaks and coupling constants are given in Hertz (Hz).  
A Waters UPLC coupled in tandem to a Waters photodiode array (PDA) detector and a SYNAPT 
G1 HDMS mass spectrometer was used to generate accurate mass data. The PDA detector was 
used for all purity determinations (Maxplot 200–500 nm). All chemicals for UPLC-MS work were 
of ultra-pure LC-MS grade and purchased from Fluka (Steinheim, Germany) while ultra-pure 
solvents were purchased from Honeywell (Burdick & Jackson, Muskegon, USA). Ultra-pure water 
was generated using a Millipore Elix 5 RO system and Millipore Advantage Milli-Q system 
(Millipore SAS, Molsheim, France). Reactions were monitored by thin layer chromatography 
(TLC) on aluminium-backed Merck silica gel 60 F254 plates. Gravity column chromatography 
was performed using Merck Silica Gel 60 (70–230 mesh).Melting points were determined using a 
Glassco melting point apparatus and are uncorrected. All other chemicals were reagent grade 
materials. The 1,3-dicarbonyls were purchased from Sigma–Aldrich, South Africa. Suberase® 
(10757.8 PCU/mL) is a fungal laccase from M. thermophila produced by submerged fermentation 
of a genetically modified Aspergillus oryzaestrain. The enzymatic preparation is supplied as a 
brown liquid which is completely miscible with water. Suberase® was obtained from Novozymes 
in South Africa. 
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Methods for the synthesis of the 5,6-dihydroxylated benzo[b]furans  
Method A 
The laccase (Suberase®, 2.0 mL) was added to a mixture of the catechol (2.0 mmol), 1,3-
dicarbonyl (2.0 mmol) and phosphate buffer (20.0 mL, 0.10 M, pH 7.15) in a 250-mL round-
bottom flask stirred under air at rt. More laccase (2.0 mL) was added after 2, 18 and 20 h. The 
mixture was vigorously stirred under air until the substrates were consumed as judged by TLC. 
After stirring the reaction mixture was acidified with 32% HCl to pH 4.0. The mixture was 
extracted with EtOAc and washed with water (20.0 mL). The organic phases were then combined 
and the solvent evaporated. The residue, a powder, was purified by washing with EtOAc or 
recrystallizing from a combination of MeOH and EtOAc. 
Method B 
Same as Method B except that more laccase (2.0 mL) was added after 4, 24 and 28 h. 
Method C 
The laccase (Suberase®, 1.5 mL) was added to a mixture of the catechol (0.60 mmol), 1,3-
dicarbonyl (2.40 mmol), phosphate buffer (4.0 mL, 0.10 M, pH 7.15) and DMF (2.0 mL) in a test 
tube stirred under air at rt. More laccase (1.5 mL) was added after 2 h and then again after 4 h. The 
mixture was vigorously stirred under air until the substrates had been consumed as judged by TLC. 
After stirring the reaction mixture was transferred to a separating funnel and the mixture extracted 
with EtOAc and washed with water (20.0 mL). The organic phases were combined, the solvent 
evaporated and the residue (a powder) purified by flash chromatography. 
1-(5,6-Dihydroxy-2-methyl-1-benzofuran-3-yl)ethanone 1121, 122 
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O OH
OH
O
 
Method A 
Stirring time 24 h. The product was recrystallized from 5% MeOH in EtOAc solution at 35°C to 
afford a dark-brown powder (198 mg, 48%) (Found: M–H+, 205.0518. C11H9O4 requires M–H, 
205.0501). UPLC 95.5%. Rf 0.40 (EtOAc/hexane, 1:1). mp 200–203°C. 1H NMR (400 MHz, 
DMSO-d6): δ 2.51 (3H, s, CH3), 2.68 (3H, s, CH3), 6.91 (1H, s, ArH), 7.33 (1H, s, ArH), 8.94 (1H, 
br s, OH), 9.06 (2H, br s, OH); 13C NMR (100 MHz, DMSO-d6): δ 15.3, 30.8, 97.8, 106.4, 117.2, 
117.2, 143.6, 144.2, 147.0, 160.7, 193.9. 
Method B 
Stirring time 44 h. The product was washed with EtOAc to afford a black powder (202.0 mg, 49%). 
 
 
 
1-(5,6-Dihydroxy-2,7-dimethyl-1-benzofuran-3-yl)ethanone 2121,123 
O OH
OH
O
 
Method A 
Stirring time 24 h. The product was washed with EtOAc to afford a red-brown powder (220 mg, 
50%) (Found: M–H+, 219.0615. C12H11O4 requires M–H, 219.0657). UPLC 97.3%. Rf 0.46 
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(EtOAc/hexane, 1:1). mp 234°C. 1H NMR (400 MHz, DMSO-d6): δ 2.19 (3H, s, CH3), 2.45 (3H, 
s, CH3), 2.64 (3H, s, CH3), 7.17 (1H, s, ArH), 8.38 (1H, br s, OH), 9.25 (1H, br s, OH); 13C NMR 
(100 MHz, DMSO-d6): δ 8.9, 15.4, 30.7, 103.2, 107.1, 116.2, 117.4, 141.8, 143.1, 146.5, 160.5, 
193.9. 
7,8-Dihydroxy-3,4-dihydrodibenzo[b,d]furan-1(2H)-one 3124, 125 
O OH
OH
O
 
Method A 
Stirring time 24 h. The product was recrystallized from 5% MeOH in EtOAc solution at 35°C to 
afford a brown powder (284 mg, 65%) (Found: M–H+, 217.0458. C12H9O4 requires M–H, 
217.0501). UPLC 96.2%. Rf 0.48 (EtOAc/hexane, 1:1). 1H NMR (400 MHz, DMSO-d6): δ 2.21 
(2H, m, CH2), 2.47 (2H, t J 6.4 Hz, CH2) 2.96 (2H, t, J 6.4 Hz, CH2), 7.00 (1H, s, ArH), 7.22 (1H, 
s, ArH), 9.18 (2H, br s, OH); 13C NMR (100 MHz, DMSO-d6): δ 22.2, 23.2, 37.3, 98.4, 105.4, 
114.4, 115.6, 143.7, 144.4, 147.9, 169.7, 194.4. 
 
7,8-Dihydroxy-6-methyl-3,4-dihydrodibenzo[b,d]furan-1(2H)-one 4124 
O OH
OH
O
 
 
Method A 
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Stirring time 24 h. The product was recrystallized from 5% MeOH in EtOAc solution at 35°C to 
afford a brown powder (288 mg, 62%) (Found: M–H+, 231.0683. C13H11O4 requires M–H, 
231.0657). UPLC 99.7%. Rf 0.48 (EtOAc/hexane, 1:1). mp 250°C. 1H NMR (400 MHz, DMSO-
d6): δ 2.14 (2H, m, CH2), 2.26 (3H, s, CH3), 2.45 (2H, t, J 6.1 Hz, CH2), 2.98 (2H, t J 6.1 Hz, CH2), 
7.11 (s, 1H, ArH); 13C NMR (100 MHz, DMSO-d6): δ 9.0, 22.2, 23.3, 37.9, 102.4, 107.9, 113.5, 
115.9, 142.2, 143.4, 147.6, 169.6, 194.6. 
 
Method B 
Stirring time 44 h. The product was washed with EtOAc to afford a brown powder (311.0 mg, 
67%). 
 
7,8-Dihydroxy-6-methoxy-3,4-dihydrodibenzo[b,d]furan-1(2H)-one 5124, 126 
O OH
OH
O
O
 
Method A 
Stirring time 24 h. The product was recrystallized from 5% MeOH in EtOAc solution at 35°C to 
afford a brown powder (348 mg, 70%) (Found: M–H+, 247.0557. C13H11O5 requires M–H, 
247.0606). UPLC 97.0%. Rf 0.38 (EtOAc/hexane, 2:1). mp 232°C. 1H NMR (400 MHz, DMSO-
d6): δ 2.14 (2H, m, CH2), 2.46 (2H, t, J 6.4 Hz, CH2), 3.00 (2H, t, J 6.4 Hz, CH2), 3.94 (3H, s, 
CH3), 7.00 (1H, s, ArH), 8.71 (1H, br s, OH), 9.24 (1H, br s, OH); 13C NMR (100 MHz, DMSO-
d6): δ22.1, 23.2, 37.4, 60.4, 99.9, 114.8, 115.6, 133.3, 136.2, 140.3, 145.0, 169.9, 194.5. 
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7,8-Dihydroxy-3-methyl-3,4-dihydrodibenzo[b,d]furan-1(2H)-one 6124, 127-129,131 
O OH
OH
O
 
Method A 
Stirring time 24 h. The product was washed with EtOAc to afford a brown powder (274 mg, 59%) 
(Found: M–H+, 231.0610. C13H11O4 requires M–H, 231.0657). UPLC 95.3%. Rf 0.38 
(EtOAc/hexane, 1:1). mp 263°C. 1H NMR (400 MHz, DMSO-d6): δ 1.11 (3H, d, J 6.0 Hz, CH3), 
2.30 (1H, dd, J 4.6, 12.8 Hz, CH), 2.43 (2H, dd, J 3.6, 12.8 Hz, CH2), 2.68 (1H, m, CH), 3.01 (1H, 
dd, J 4.6, 12.8 Hz, CH), 6.98 (1H, s, ArH), 7.21 (1H, s, ArH) and 9.15 (2H, br s, OH); 13C NMR 
(100 MHz, DMSO-d6): δ 20.7, 30.3, 40.0, 45.6, 98.5, 105.3, 114.3, 115.3, 143.7, 144.4, 148.2, 
169.4 and 194.0. 
 
Method C 
Stirring time 42 h. The product was purified by flash chromatography (silica: EtOAc/hexane, 
0.5:9.5, 1:9, 2.5:7.5, 1:1) to afford a brown powder (84 mg, 30%). 
7,8-Dihydroxy-3,6-dimethyl-3,4-dihydrodibenzo[b,d]furan-1(2H)-one 7124, 129, 131 
O OH
OH
O
 
 
Method A 
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Stirring time 24 h. The product was washed with EtOAc to afford a light-brown powder (384 mg, 
78%) (Found: M–H+, 245.0817. C14H13O4 requires M–H, 245.0814). UPLC 96.0%. Rf 0.74 
(EtOAc/hexane, 1:1). mp 165–168°C. 1H NMR (400 MHz, DMSO-d6): δ 1.11 (3H, d J 6.0 Hz, 
CH3), 2.25 (3H, s, CH3), 2.29 (1H, dd, J 4.7, 12.4 Hz, CH2), 2.43 (2H, dd, J3.4, 12.8 Hz, CH2), 
2.68 (1H, m, CH), 3.03 (1H, dd, J 4.7, 12.4 Hz, CH), 7.11 (1H, s, ArH), 8.47 (1H, br s, OH), 9.38 
(1H, br s, OH); 13C NMR (100 MHz, DMSO-d6): δ 9.0, 20.7, 30.3, 31.0, 45.6, 102.3, 107.9, 113.4, 
115.5, 142.1, 143.3, 147.8, 169.2, 194.1. 
 
Method C 
Stirring time 42 h. The product was purified by flash chromatography (silica: EtOAc/hexane, 
0.5:9.5, 1:9, 1:1; EtOAc) to afford a light-brown powder (209.0 mg, 71%). 
7,8-Dihydroxy-6-methoxy-3-methyl-3,4-dihydrodibenzo[b,d]furan-1(2H)-one 8124,126 
O OH
OH
O
O
 
Method A 
Stirring time 24 h. The product was washed with EtOAc to afford a light-brown powder (194 mg, 
37%) (Found: M–H+, 261.0843. C14H13O4 requires M–H, 261.0763). UPLC 99.6%. Rf 0.50 
(EtOAc/hexane, 1:1). mp 179–182°C. 1H NMR (400 MHz, DMSO-d6): δ 1.12 (3H, d J 6.4 Hz, 
CH3), 2.32 (1H, dd, J 4.0, 12.4 Hz, CH) 2.44 (2H, dd, J 3.4, 13.2 Hz, CH2), 2.72 (1H, m, CH), 3.06 
(1H, dd, J 5.0, 12.4 Hz, CH), 3.94 (3H, s, CH3), 6.97 (1H, s, ArH). 13C NMR (100 MHz, DMSO-
d6): δ 20.7, 30.3, 31.0, 45.7, 60.4, 99.8, 114.8, 115.3, 133.4, 136.3, 140.6, 145.1, 169.6, 194.1. 
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7,8-Dihydroxy-3,3-dimethyl-3,4-dihydrodibenzo[b,d]furan-1(2H)-one 9126 
O OH
OH
O
 
Method A 
Stirring time 24 h. The product was washed with EtOAc to afford a yellow powder (286 mg, 58%). 
(Found: M–H+, 245.0867. C14H14O4 requires M–H, 245.0814). UPLC 99.8%. Rf 0.64 
(EtOAc/hexane, 1:1). mp 278–280°C [lit. 280°C]. 1H NMR (400 MHz, DMSO-d6): δ 1.09 (6H, s, 
2× CH3), 2.38 (2H, s, CH2), 2.88 (2H, s, CH2), 6.98 (1H, s, ArH), 7.20 (1H, s, ArH), 9.15 (2H, br 
s, OH); 13C NMR (100 MHz, DMSO-d6): δ 28.0 (2× CH3), 34.9, 36.7, 51.5, 98.5, 105.3, 114.2, 
114.4, 143.7, 144.3, 148.3, 168.6, 193.7. 
Method C 
Stirring time 42 h. The product was purified by flash chromatography (silica: EtOAc/hexane, 
0.5:9.5, 1:9, 2.5:7.5, 1:1) to afford a yellow powder (118 mg, 40%). 
7,8-Dihydroxy-3,3,6-trimethyl-3,4-dihydrodibenzo[b,d]furan-1(2H)-one 10124 
O OH
OH
O
 
 
Method A 
Stirring time 24 h. The product was recrystallized from a 5% MeOH in EtOAc solution at 35°C to 
afford a light-brown powder (510 mg, 98%). (Found: M–H+ 259.0931. C15H15O4 requires M–H, 
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259.0970). UPLC 96.6%. Rf 0.45 (EtOAc/hexane, 1:2). mp 255°C [lit. 260–262°C]. 1H NMR 
(400 MHz, DMSO-d6): δ 1.09 (6H, s, 2 × CH3), 2.26 (3H, s, CH3) 2.37 (2H, s, CH2), 2.90 (2H, s, 
CH2), 7.10 (1H, s, ArH), 8.41 (1H, br s, OH), 9.32 (1H, br s, OH); 13C NMR (100 MHz, DMSO-
d6): δ 9.0, 28.0, 34.9, 36.8, 51.5, 102.4, 107.9, 113.3, 114.7, 142.0, 143.3, 168.5, 193.8. 
 
Method C 
Stirring time 42 h. The product was purified by flash chromatography (silica: EtOAc/hexane, 5:95, 
1:9, 1:1) to afford a light-brown powder (184 mg, 59%). 
7,8-Dihydroxy-3,3,6-trimethyl-3,4-dihydrodibenzo[b,d]furan-1(2H)-one 11124 
O OH
OH
O
O
 
Method A 
Stirring time 24 h. The product was recrystallized from 5% MeOH in EtOAc solution at 35°C to 
afford a brown powder (403 mg, 73%). (Found: M–H+, 275.0922. C15H15O5 requires M–H, 
275.0919). UPLC 94.5%. Rf 0.44 (EtOAc/hexane, 1:1). mp 288–291°C [lit. 289–291°C]. 1H NMR 
(400 MHz, MeOH-d4): δ 1.16 (6H, s, 2 × CH3), 2.43 (2H, s, CH2) 2.90 (2H, s, CH2), 4.06 (3H, s, 
CH3), 7.01 (1H, s, ArH); 13C NMR (100 MHz, DMSO-d6): δ 28.1, 35.0, 36.8, 51.2, 60.4, 99.8, 
114.5, 114.7, 113.4, 136.2, 140.8, 145.1, 168.9, 193.9. 
 
Method B 
Stirring time 44 h. The product was washed with EtOAc to afford a brown powder (425 mg, 77%). 
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• 7,8-Dihydroxy-3-phenyl-3,4-dihydrodibenzo[b,d]furan-1(2H)-one 12 
O OH
OH
O
 
Method A 
Stirring time 24 h. The product was washed with EtOAc to afford a white solid (449 mg, 76%). 
(Found: M–H+, 293.0821. C18H13O4 requires M–H, 293.0814). UPLC 99.8%. Rf 0.50 
(EtOAc/hexane, 1:1). mp 240–243°C. 1H NMR (400 MHz, DMSO-d6): δ 2.58 (1H, dd J 3.2, 
16.0 Hz, CH), 2.93 (1H, dd, J 12.4, 16.0 Hz, CH), 3.24 (2H, m, H-11), 3.66 (1H, m, CH), 7.01 
(1H, s, ArH), 7.26 (1H, s, ArH), 7.35 (2H, t, J 7.2, 7.6 Hz, ArH), 7.42 (2H, d J 7.6 Hz, ArH), 9.09 
(1H, s, CH), 9.13 (1H, s, CH); 13C NMR (100 MHz, DMSO-d6): δ 30.7, 44.6, 62.5, 63.4, 68.8, 
71.5, 72.3, 73.8, 98.5, 105.4, 114.2, 115.5, 126.9, 128.6, 143.1, 143.9, 144.5, 148.3, 169.0, 193.1. 
 
Method C 
Stirring time 42 h. The product was purified by flash chromatography (silica: EtOAc/hexane, 5:95, 
1:9, 1:1; EtOAc) to afford a white solid (132 mg, 50%). 
7,8-Dihydroxy-6-methyl-3-phenyl-3,4-dihydrodibenzo[b,d]furan-1(2H)-one 13124 
O OH
OH
O
 
Method A 
Stirring time 24 h. The product was recrystallized from 5% MeOH in EtOAc solution at 35°C to 
afford a light-brown powder (279 mg, 80%) (Found: M–H+, 307.0977.1120. C19H15O4 requires 
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M–H+, 307.0970). UPLC 99.0%. Rf 0.45 (EtOAc/hexane, 1:1). mp 250–253°C. 1H NMR 
(400 MHz, DMSO-d6): δ 2.28 (3H, s, CH3), 2.59 (1H, dd J 4.0, 16.4 Hz, CH), 2.91 (1H, dd, J 12.2, 
16.2 Hz, CH), 3.28 (1H, m, CH2), 3.66 (1H, m, H-11 CH), 7.16 (1H, s, ArH), 7.26 (1H, t J 7.0 Hz, 
ArH), 7.35 (2H, t, J 7.6 Hz, ArH), 7.42 (2H, d, J 8.0 Hz, ArH), 8.45 (1H, br s, OH), 9.36 (1H, br 
s, OH); 13C NMR (100 MHz, DMSO-d6): δ 9.1, 30.7, 44.7, 102.4, 108.0, 113.4, 115.8, 126.9, 
127.0, 127.1, 128.6, 142.3, 143.2, 143.4, 148.0, 168.8, 193.2. 
 
7,8-Dihydroxy-6-methoxy-3-phenyl-3,4-dihydrodibenzo[b,d]furan-1(2H)-one 14 
O OH
OH
O
O
 
Method A 
Stirring time 24 h. The product was washed with EtOAc to afford a dull grey powder (279 mg, 
43%). (Found: M–H+, 323.0922. C19H15O5 requires M–H, 323.0919). UPLC 96.8%. Rf 0.38 
(EtOAc/hexane, 1:2). mp 165–168°C. 1H NMR (400 MHz, DMSO-d6): δ 2.57 (1H, dd J 4.0, 
16.0 Hz, CH), 2.93 (1H, dd, J 12.0 Hz, 12.4 Hz, CH), 3.26 (2H, m, CH2), 3.67 (1H, m, CH), 3.95 
(3H, s, CH3), 7.03 (1H, s, ArH), 7.26 (1H, t, J 7.2 Hz, ArH), 7.35 (2H, t, J 7.2, 8.0 Hz, ArH), 7.42 
(2H, d, J 8.0 Hz, ArH), 8.76 (1H, br s, OH) and 9.33 (1H, br s, OH); 13C NMR (100 MHz, DMSO-
d6): δ 30.6, 44.6, 60.4, 99.8, 114.6, 115.5, 126.8, 127.0, 128.5, 133.4, 136.2, 140.6, 143.0, 145.0, 
169.0, 193.0. 
Method C 
Stirring time 42 h. The product was purified by flash chromatography (silica: EtOAc/hexane, 5:95, 
1:9, 1:1; EtOAc) to afford a black powder (58.0 mg, 15%). 
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3-(3,4-Dihydroxy-5-methylphenyl)-3-methylpentane-2,4-dione 15 
OH
OH
O
O
 
Method A 
Stirring time 24 h. The product was washed with EtOAc to afford a dark-brown powder (1.60 g, 
80%) (Found: M–H+, 235.0926. C13H14O4 requires M–H, 235.0970. UPLC 98.0%. Rf 0.48 
(EtOAc/hexane, 1:1). mp 82–85°C. 1H NMR (400 MHz, DMSO-d6): δ 1.60 (3H, s, CH3), 2.03 
(6H, s, CH3), 2.08 (3H, s, CH3), 6.43 (1H, d, J 2.0 Hz, ArH), 6.46 (1H, d, J 2.4 Hz, ArH), 8.36 
(1H, br s, OH), 9.29 (1H, br s, OH); 13C NMR (100 MHz, DMSO-d6): δ 16.2, 19.0, 27.2, 30.7, 
68.8, 112.4, 120.1, 124.7, 127.7, 143.0, 144.8, 207.8. 
 
3-(3,4-Dihydroxy-5-methoxyphenyl)-3-methylpentane-2,4-dione 16 
OH
OH
O
O
O
 
Method A 
Stirring time 24 h. The product was washed with EtOAc to afford a dark-brown powder (1.10 g, 
55%) (Found: M–H+, 251.0933. C13H14O5 requires M–H, 251.0919. Rf  0.48 (EtOAc/hexane, 1:1). 
mp 108–110°C. 1H NMR (400 MHz, DMSO-d6): δ 1.62 (3H, s, CH3), 2.05 (6H, s, CH3), 3.74 (3H, 
s, OMe), 6.27 (1H, s, ArH), 6.28 (1H, s, ArH), 8.44 (1H, br s, OH), 9.03 (1H, br s, OH); 13C NMR 
(100 MHz, DMSO-d6): δ 19.1, 27.3, 56.0, 69.0, 103.1, 108.7, 127.7, 133.9, 145.8, 148.5, 207.7 
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METHOD A 
 
The laccase (Suberase®, 2.0 mL) was added to a mixture of the catechol (2.0 mmol), coumarin 
(2.0 mmol) and phosphate buffer (20.0 mL, 0.10 M, pH 7.15) in a 250 mL round bottom flask 
stirred under air at rt. More laccase (2.0 mL) was added after 2, 18 and 20 h. The mixture was 
vigorously stirred under air until the substrates were consumed as judged by TLC. The mixture 
was extracted with EtOAc and washed two times with water (20.0 mL). The organic phases were 
then combined and the solvent evaporated. The residue, a powder, was purified by washing with 
EtOAc, flash chromatography or recrystallization from a combination of MeOH and EtOAc. 
Products were characterized by 1H NMR, 13C NMR, and MS. 
 
 
 
• 8,9-Dihydroxy-6H-benzofuro[3,2-c]chromen-6-one 17154-158 
 
O
O
OH
OH
O
 
 
Method A. Stirring time = 24 h. Purification by a wash with EtOAc and the flash chromatography 
(silica: EtOAc/hexane, 1:5, 1:4, 1:3, 1:2 and EtOAc) to afford a light-brown solid (0.4600 g, 
86.0%). (M-H+ Found: 267.0216. C15H7O5 requires M-H+, 267.0293). UPLC 99.8 %.   Rf 0.54 
(EtOAc/Hex, 1:2).  mp 300oC. 1H NMR (400 MHz, DMSO-d6): δ = 7.24 (1H, s, ArH). 7.31 (1H, 
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s, ArH), 7.48 (1H, t, J 8.0  Hz, ArH), 7.58 (1H, d, J  8.0 Hz, ArH), 7.66 (1H, ddd, J 1.6, 8.0, 15.6  
Hz, ArH), 8.00 (1H, dd, J, 1.6, 8.0 Hz, ArH; 13C NMR (100 MHz, DMSO-d6): δ = 98.9, 104.9, 
105.5, 112.4, 113.8, 117.0, 121.1, 124.8, 131.2, 144.7, 146.6, 149.4, 152.3, 157.4, 157.7.    
        
 
• 8,9-Dihydroxy-10-methyl-6H-benzofuro[3,2-c]chromen-6-one 18156,157 
 
O
O
OH
OH
O
 
 
Method A. Stirring time = 24 h. Purification by washing with EtOAc and recrystallization from a 
mixture of  methanol and hexane at 42ºC to afford a grey crystalline product (0.429 g, 76.0%). 
M+H+ Found: 283.0638, C16H11O5 requires M+H+, 283.0606). UPLC 98.8%.   Rf 0.38 
(EtOAc/hexane, 1:2).  mp 298oC. 1H NMR (400 MHz, DMSO-d6): δ = 2.41 (3H, s, CH3), 7.21 
(1H, s, ArH), 7.46 (1H, t, J 7.6  Hz, ArH), 7.58 (1H, d, J 7.6 Hz, ArH), 7.66 (1H, t, J 8.0  Hz, 
ArH), 8.05 (1H, dd, J 1.6, 8.0 Hz, ArH); 13C NMR (100 MHz, DMSO-d6): δ =  9.51, 102.3, 106.2, 
108.9, 113.0, 117.5, 121.7, 125.4, 131.7, 144.8, 149.5, 152.8, 158.1.  
 
 
• 8,9-Dihydroxy-10-methoxy-6H-benzofuro[3,2-c]chromen-6-one 19156 
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O
O
OH
OH
O
O
 
 
Method A. Stirring time = 24 h. Purification by washing with EtOAc and recrystallization from a 
mixture of methanol and hexane at 42ºC to afford a light-brown crystalline product (0.441 g, 
74.0%). (M+H+ Found: 299.0519, C16H11O6 requires M+H+, 299.0556). UPLC 95.1%.  Rf 0.38 
(EtOAc/hexane, 1:2). mp 234oC. 1H NMR (400 MHz, DMSO-d6): δ = 4.10 (3H, s, OMe), 7.08 
(1H, s, ArH), 7.49 (1H, t, J  7.80 Hz, ArH), 7.58 (1H, d, J 8.40 Hz, ArH), 7.69 (1H, t, J 8.4 Hz, 
ArH), 8.07 (1H, dd, J 1.4, 7.8 Hz, ArH),  9.10 (1H, s, ArH), 9.61 (1H, s, ArH).13C NMR (100 
MHz, DMSO-d6): δ = 60.6, 99.3, 105.5, 112.3, 114.2, 117.0, 121.3, 124.9, 131.4, 133.6, 138.1, 
141.7, 145.8, 152.4, 157.4, 157.9.  
• 10-Fluoro-8,9-dihydroxy-6H-benzofuro[3,2-c]chromen-6-one 20 
 
O
O
OH
OH
O
F
 
 
Method A. Stirring time = 24 h. Purification by a wash with EtOAc to afford a light brown solid 
(0.412 g, 72.0%). (M+H+ Found: 287.0299, C15H8O5F requires M+H+, 287.0356). UPLC 94.0%.  
Rf = 0.41 (EtOAc/hexane, 1:1). mp 142oC. 1H NMR (400 MHz, DMSO-d6): δ = 5.58 (1H, s, ArH), 
7.34 (1H, m, ArH), 7.64 (1H, ddd, J 1.6, 7.6, 9.6 Hz, ArH), 7.83 (1H, dd J 1.6, 7.6 Hz, ArH); 13C 
NMR (100 MHz, DMSO-d6): δ = 13C NMR (100 MHz, DMSO-d6): δ =59.6, 62.5, 68.3, 71.4, 72.3, 
73.7, 85.1, 115.4, 121.2, 124.0, 124.2, 129.6, 154.5, 164.6, 174.4. 
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• 8,9-dihydroxy-6-oxo-6H-benzofuro[3,2-c]chromene-10-carboxylic acid 21 
O
O
OH
OH
O
OH
O
 
 
Method B. Stirring time = 24 h. The product precipitated, was filtered and washed by EtOAc to 
afford a light-brown solid (0.486 g, 78.0%). (M+H+ Found: 313.0306, C16H9O7 requires M+H+, 
313.0348). UPLC 96.9%.  Rf 0.38 (EtOAc/Hex, 2:1). mp 170oC. 1H NMR (400 MHz, DMSO-d6): 
δ = 7.13 (1H, s, ArH), 7.41 (1H, t, J 7.20 Hz, ArH), 7.50 (1H, d, J  8.4 Hz, ArH), 7.60 (1H, t, J 
8.40 Hz, ArH), 7.96 (1H, d, J  7.20 Hz, ArH); 13C NMR (100 MHz, DMSO-d6): 98.4, 106.6, 111.7, 
112.3, 116.4, 121.0, 124.3, 130.9, 147.3, 147.6, 152.1, 155.2, 127.2, 168.4.  
 
 
• 8,9-Dihydroxy-2-methyl-6H-benzofuro[3,2-c]chromen-6-one 22 
 
O
O
OH
OH
O
 
 
Method A. Stirring time = 24 h. Purification by washing with EtOAc to afford a brown solid 
(0.440 g, 78.0%). (M+H+ Found: 283.0512, C16H11O5 requires M+H+, 283.0606). UPLC 88.4%.  
Rf 0.47 (EtOAc/hexane, 1:1). mp 283oC; 1H NMR (400 MHz, DMSO-d6): δ = 2.41 (3H, s, CH3), 
7.21 (1H, s, ArH). 7.28 (1H, s, ArH), 7.42 (2H, d, J 1.2 Hz, ArH), 7.73 (1H, s, ArH), 9.61 (2H, s, 
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2 x OH); 13C NMR (100 MHz, DMSO-d6): δ = 20.4, 98.9, 104.9, 105.3, 112.0, 113.9, 116.8, 120.6, 
132.1, 134.3, 144.7, 146.5, 149.4, 150.5, 157.6, 157.7.  
 
 
 
• 8,9-Dihydroxy-2,10-dimethyl-6H-benzofuro[3,2-c]chromen-6-one 23154 
 
O
O
OH
OH
O
 
 
Method A. Stirring time = 24 h. Purification by washing with EtOAc to afford a brown solid 
(0.468 g, 79.0%). (M+H+ Found: 297.0708, C17H13O5 requires M+H+, 297.0763). UPLC 80.1%.  
Rf 0.38 (EtOAc/hexane, 1:2). mp 234oC; 1H NMR (400 MHz, DMSO-d6): δ = 2.41 (3H, s, CH3), 
2.46 (3H, s, CH3) 7.20 (1H, s,  ArH), 7.47 (1H, d, J 1.2 Hz, ArH), 7.85 (1H, d, J 0.8 Hz, ArH); 13C 
NMR (100 MHz, DMSO-d6): δ 8.9, 20.3, 101.9, 105.6, 108.5, 112.1, 113.0, 116.8, 120.6, 132.1, 
134.3, 144.1, 149.0, 150.5, 157.6.  
 
• 8,9-Dihydroxy-10-methoxy-2-methyl-6H-benzofuro[3,2-c]chromen-6-one 24155 
 
O
O
OH
OH
O
O
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Method A. Stirring time = 24 h. Purification by washing with EtOAc to afford a grey solid (0.488 
g, 78.0%). (M+H+ Found: 313.0609, C17H13O6 requires M+H+, 313.0712). UPLC 99.2%.  Rf 0.30 
(EtOAc/hexane, 1:1). mp 260oC; 1H NMR (400 MHz, DMSO-d6): δ = 2.45 (3H, s, CH3), 4.09 (3H, 
s, OMe), 7.07 (1H, s, ArH). 7.47 (1H, s, ArH), 7.87 (1H, s, ArH), 9.09 (1H, s, OH), 9.59 (1H, s, 
OH); 13C NMR (100 MHz, DMSO-d6): δ = 20.2, 20.3, 60.5, 60.7, 99.3, 105.4, 112.0, 114.3, 116.8, 
120.7, 120.9, 133.6, 134.4, 138.0, 141.7, 145.8, 150.6, 157.5, 158.0.  
 
• 10-Fluoro-8,9-dihydroxy-2-methyl-6H-benzofuro[3,2-c]chromen-6-one 25 
 
O
O
OH
OH
O
F
 
 
Method A. Stirring time = 24 h. Purification by washing with EtOAc to afford a light-brown solid 
(0.431 g, 72.0%). (M-H+ Found:, C16H8O5F requires M-H+, 299). UPLC 89 %.   Rf 0.38 
(MeOH/EtOAc, 1:10). mp 142oC; 1H NMR (400 MHz, DMSO-d6): δ = 2.30 (3H, s, CH3), 5.56 
(1H, s, ArH). 7.25 (1H, d, J 8.4 Hz, ArH), 7.44 (1H, dd, J 1.8, 8.4 Hz, ArH ), 7.61 (1H, d, J 1.2 
Hz, ArH); 13C NMR (100 MHz, DMSO-d6): δ = 20.8, 91.4, 115.9, 116.7, 123.2, 133.6, 133.9, 
152.1, 162.4, 166.1.  
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8,9-dihydroxy-2-methyl-6-oxo-6H-benzofuro[3,2-c]chromene-10-carboxylic acid 26 
O
O
OH
OH
O
OH
O
 
 
Method B. Stirring time = 24 h. Purification by a wash with EtOAc to afford a light yellow solid 
(0.493 g, 76.0%). (M-H+ Found: 325.0254 C17H9O7 requires M-H+, 325.0348). UPLC 95.0%.  Rf 
0.41 ( EtOAc:Hex, 2:1).  mp = 180 oC;  1H NMR (400 MHz, DMSO-d6): δ = 2.37 (3H, s, CH3), 
7.08 (1H, s, H-Ar), 7.45 (2H, m, H-Ar), 7.76 (1H, s, H-Ar); 13C NMR (100 MHz, DMSO-d6): δ = 
20.3, 97.6, 107.0, 112.1, 116.0, 120.5, 131.5, 133.5, 147.1, 147.4, 150.2, 153.0, 155.1, 156.9, 
168.0.  
 
8,9-Dihydroxy-2,3-dimethyl-6H-benzofuro[3,2-c]chromen-6-one 27 
  
O
O
OH
OH
O
 
 
Method A. Stirring time = 24 h. Purification by washing with EtOAc to afford a brown solid 
(0.461 g, 78.0%). (M+H+ Found: 297.0768 C17H13O5 requires M+H+, 297.0763). UPLC 99%.  Rf  
0.56 (EtOAc/hexane, 1:2). mp 272 oC;  1H NMR (400 MHz, DMSO-d6): δ = 2.32 (3H, s, CH3), 
2.33 (3H, s, CH3), 7.19 (1H, s, ArH), 7.27 (1H, s, ArH), 7.34 (1H, s, ArH), 7.71(1H, s, ArH), 9.49 
(2H, s, 2 x OH). 13C NMR (100 MHz, DMSO-d6): δ = 18.7, 19.7, 98.8, 104.5, 104.8, 109.8, 113.9, 
117.3, 120.8, 133.5, 141.1, 144.5, 146.2, 150.8, 157.6, 158.1.  
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8,9-Dihydroxy-2,3,10-trimethyl-6H-benzofuro[3,2-c]chromen-6-one 28 
 
O
O
OH
OH
O
 
Method A. Stirring time = 24 h. Purification by washing with EtOAc to afford a brown solid 
(0.459 g, 74.0%). (M+H+ Found: 311.0939 C18H15O5 requires M+H+, 311.0919). UPLC 92%.  Rf 
0.52 (EtOAc/hexane, 1:2). mp 280oC; 1H NMR (400 MHz, DMSO-d6): δ = 2.35 (6H, s, 2 × CH3), 
2.40 (3H, s, CH3), 7.18 (1H, s, ArH). 7.38 (1H, s, ArH), 7.79 (1H, s, ArH); 13C NMR (100 MHz, 
DMSO-d6): δ = 8.9, 18.6, 19.7, 101.8, 104.8, 108.5, 109.9, 113.1, 117.4, 120.8, 133.5, 141.0, 
143.9, 144.0, 148.7, 150.8, 157.7, 158.0. 
8,9-Dihydroxy-10-methoxy-2,3-dimethyl-6H-benzofuro[3,2-c]chromen-6-one 29 
 
O
O
OH
OH
O
O
 
Method A. Stirring time = 24 h. Purification by wash with EtOAc to afford a brown solid (0.500 
g, 76.0%). (M-H+ Found: 325.0667. C18H13O6 requires M-H+, 325.0712). UPLC 99.0%.  Rf 0.38 
(EtOAc/hexane, 1:2). mp = 274 oC; 1H NMR (400 MHz, DMSO-d6): δ = 2.37 (6H, s, CH3), 4.08 
(3H, s, OMe), 7.06 (1H, s, ArH). 7.41 (1H, s, ArH), 7.85 (1H, s, ArH); 13C NMR (100 MHz, 
DMSO-d6): 13C NMR (100 MHz, DMSO-d6): δ = 62.5, 63.0, 63.4, 68.8, 71.4, 72.3, 73.7, 93.0, 
127.3, 128.4, 128.7, 128.8, 132.6, 185.0.  
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10-Fluoro-8,9-dihydroxy-2,3-dimethyl-6H-benzofuro[3,2-c]chromen-6-one 30 
 
O
O
OH
OH
O
F
 
 
Method A. Stirring time = 24 h. Purification by washing with EtOAc to afford a brown solid 
(0.500 g, 76.0%). (M+H+ Found: 314.0588. C17H11O5F requires M+H+, 314.0591). UPLC 93%.  
Rf 0.58 (EtOAc/hexane, 1:1).  mp = 174 oC; 1H NMR (400 MHz, DMSO-d6): δ = 2.26 (3H, s, 
CH3), 2.30 (3H, s, CH3), 5.46 (1H, s, ArH), 7.15 (1H, s, ArH), 7.56 (1H, s, ArH); 13C NMR (100 
MHz, DMSO-d6): δ = 18.7, 19.6, 62.5, 63.4, 68.8, 71.4, 72.3, 73.7, 89.9, 113.6, 116.7, 123.0, 
132.1, 142.1, 152.0, 162.3, 166.2.  
• 8,9-dihydroxy-2,3-dimethyl-6-oxo-6H-benzofuro[3,2-c]chromene-10-carboxylic acid 
31 
O
O
OH
OH
O
OH
O
 
 
 
Method B. Stirring time = 24 h. Purification by a wash with EtOAc to afford a light-grey solid 
(0.483 g, 74.0%). (M+H+ Found: 341.0594. C18H12O7 requires M+H+, 341.0661). UPLC 82%. Rf 
0.45 ( EtOAc:Hex). Mp = 140 oC; 1H NMR (400 MHz, DMSO-d6): δ = 2.27 (3H, s, CH3), 2.30 
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(3H, s, CH3), 5.43 (1H, s, H-Ar), 7.13 (1H, s, H-Ar), 7.56 (1H, s, H-Ar); 13C NMR (100 MHz, 
DMSO-d6): δ = 18.7, 19.7, 90.1, 90.2, 113.3, 116.8, 122.9, 123.0, 132.4, 142.4, 152.0 162.3, 165.8.  
 
2-Chloro-8,9-dihydroxy-6H-benzofuro[3,2-c]chromen-6-one 32 
 
O
O
OH
OH
O
Cl
 
 
Method A. Stirring time = 24 h. Purification by washing with EtOAc to afford a dark brown solid 
(0.442 g, 73.0%). (M+H+ Found: 303.0002. C15H8O5Cl requires M+H+, 303.0060). UPLC 88%. 
Rf  0.32 (EtOAc/hexane, 1:2). mp = 273oC; 1H NMR (600 MHz, DMSO-d6): δ = 7.22 (H, s, ArH), 
7.29 (1H, s, ArH), 7.61 (1H, d, J 9.0 Hz, ArH), 7.68 (1H, d, J 8.4 Hz, ArH), 8.02 (1H, s, ArH), 
8.02 (2H, s, 2 × OH) ; 13C NMR (600 MHz, DMSO-d6): δ = 98.8, 98.9, 104.8, 106.3, 113.6, 113.8, 
120.2, 120.3, 128.9, 144.9, 147.0, 149.6, 149.6, 150.8, 156.4, 157.0.  
 
2-Chloro-8,9-dihydroxy-10-methyl-6H-benzofuro[3,2-c]chromen-6-one 33 
 
O
O
OH
OH
O
Cl
 
 
Method A. Stirring time = 24 h. Purification by washing with EtOAc to afford a brown solid 
(0.494 g, 78.0%). (M+H+ Found: 315.0018. C16H8O5Cl requires M+H+, 315.0060). UPLC 99%. 
Rf  0.46 (EtOAc/hexane, 1:2). mp = 210oC; 1H NMR (400 MHz, DMSO-d6): δ = 2.41 (3H, s, CH3) 
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7.20 (1H, s,  ArH), 7.61 (1H, d, J, 8.80 Hz,  ArH), 7.68 (1H, dd, J 2.20, 8.80 Hz, ArH), 8.08 (1H, 
dd, s, ArH), 9.00 (1H, s, OH), 9.83 (1H, s, OH);13C NMR (100 MHz, DMSO-d6): δ  = 62.5, 63.1, 
63.4, 68.8, 71.4, 72.3, 73.9, 90.2, 109.6, 118.4, 119.3, 122.7, 127.5, 131.7, 152.4, 162.2, 167.0.  
 
 
• 2-Chloro-8,9-dihydroxy-10-methoxy-6H-benzofuro[3,2-c]chromen-6-one 34 
O
O
OH
OH
O
Cl
O
 
 
Method A. Stirring time = 24 h. Purification by washing with EtOAc to afford a dark-brown solid 
(0.494 g, 78.0%). (M-H+ Found: 330.9915. C16H8O6Cl requires M-H+, 331.0009). UPLC 98.6%. 
Rf 0.36 (EtOAc:Hex, 1:2). mp = 193-195 oC;  1H NMR (600 MHz, DMSO-d6):  δ = 4.11 (3H, s, 
OMe) 7.01 (1H, s, ArH), 7.62 (1H, d, J, 9.00 Hz,  ArH), 7.69 (1H, d, J 9.0 Hz, ArH), 8.13 (1H, d, 
J, 1.80 Hz, ArH);13C NMR (600 MHz, DMSO-d6): δ  = 60.6, 60.7, 99.1, 106.3, 113.7, 114.0, 
120.5, 120.5, 128.9, 133.6, 138.4, 141.9, 146.0, 150.9, 156.6, 157.1.  
 
 
 
• 2-Chloro-10-fluoro-8,9-dihydroxy-6H-benzofuro[3,2-c]chromen-6-one 35 
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Method A. Stirring time = 24 h. Purification by a washing with EtOAc to afford a light-brown 
solid (0.448 g, 70.0%). (M-H+ Found: 313.0692 C15H5O4FCl requires M-H+ 313.0643). UPLC 
90.6%.  Rf 0.36 (EtOAc/hexane, 1:1). mp = 192oC; 1H NMR (400 MHz, DMSO-d6): δ = 5.57 (1H, 
s, ArH), 7.40 (1H, d, J 8.40 Hz, ArH), 7.66 (1H, dd, J 2.4, 8.4 Hz, ArH), 7.77 (1H, d, J 2.4 Hz, 
ArH); 13C NMR (100 MHz, DMSO-d6): δ = 62.5, 63.4, 68.8, 71.4, 72.3, 73.7, 85.2, 117.6, 123.5, 
125.2, 125.2, 125.7, 129.3, 153.0, 164.2, 173.0.  
 
• 2-chloro-8,9-dihydroxy-6-oxo-6H-benzofuro[3,2-c]chromene-10-carboxylic acid 36 
 
O
O
OH
OH
O
OH
O
Cl
 
 
Method B. Stirring time = 24 h. Purification by a wash with EtOAc to afford a yellow solid (0.527 
g, 76.0%). (M+H+ Found: 346.9887 C16H8O7Cl requires M+H+, 346.9959). UPLC 98.1%. Rf  0.31 
(EtOAc/Hex, 2:1). mp 152oC; 1H NMR (600 MHz, DMSO-d6): δ =  7.13 (1H, s, H-Ar), 7.52 (1H, 
d, J 8.80  Hz, H-Ar), 7.60 (1H, dd, J 2.4, 8.80 Hz, H-Ar), 7.96  (1H, d,  J 2.40 Hz, H-Ar), 13C 
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NMR (100 MHz, DMSO-d6): δ =  98.1, 107.6, 109.0, 111.9, 113.7, 118.3, 120.1, 128.1, 130.1, 
147.5, 147.9, 150.5, 154.6, 155.6, 168.4.  
 
 
 
2-((E)-2-hydroxy-4-oxopent-2-en-3-yl)-3-methylnaphthalene-1,4-dione 37 
O
O O
OH
 
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization into afford a light 
yellow solid  (M-H+ Found: 271.0872, C16H15O4 requires M-H+, 271.0970). UPLC 97.8%.   Rf = 
0.59 (EtOAc/Hex, 1:2). mp 170°C 1H NMR (400 MHz, DMSO-d6): δ = 2.14 (3H, s, CH3), 2.22 
(3H, s, CH3), 2.44 (3H, s, CH3), 7.47 (2H, m, ArH) 7.64 (1H, dd J 1.8, 7.8, ArH), 8.20 (1H, dd J 
1.8, 7.8, ArH), 9.06 (1H, s, OH). 13C NMR (100 MHz, DMSO-d6): δ = 12.9, 14.0, 20.3, 42.4, 118.8, 
121.0, 122.1, 124.9, 125.0, 125.1, 125.2, 125.8, 137.8, 147.5, 169.5, 205.0.   
2-methyl-3-(3-methyl-2,4-dioxopentan-3yl)naphthalene-1,4-dione 38 
O
O
OH
O  
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization into afford a light 
brown solid  (M-H+ Found: 283.2972, C17H15O4 requires M-H+, 283.2970). UPLC 90.1%.   %.   Rf 
= 0.55 (EtOAc/Hex, 1:2). mp 165°C δ = 2.10 (3H, s, CH3), 2.21 (3H, s, CH3), 2.91 (6H, s, 2 x 
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CH3), 7.60 (1H, dd J 1.7, 7.8, ArH), 8.30 (1H, dd J 1.7, 7.8, ArH), 9.03 (1H, s, OH). 13C NMR 
(100 MHz, DMSO-d6): δ = 13.9, 17.1, 25.7, 25.8, 43.0, 79.2, 130.4, 130.5, 132.0, 132.2, 135.1, 
135.3, 142.1, 147.2, 183.2, 183.3, 201.8 
2-(2-hydroxy-6-oxocyclohex-1-enyl)-3-methylnaphthalene-1,4-dione 39 
 
O
O
OH
O
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a brown 
solid. (M-H+ Found: 281.2299, C17H13O4 requires M-H+, 281.2289). UPLC 89.6%. Rf  0.52.  
(EtOAc/Hex, 1:2). mp 180ºC 1H NMR (400 MHz, DMSO-d6): δ = 1.42 (2H, m, CH2), 1.90 (3H, 
s, CH3),1.94 (3H, t, J CH2), 2.92 (2H, t, CH2), 7.72 (2H, dd, J 3.4, 5.4 Hz, ArH), 7.96 (1H, dd, J 
3.4, 5.4 Hz, ArH), 11.8 (1H, s, OH). 13C NMR (100 MHz, DMSO-d6): δ = 13.5, 20.1, 31.3, 36.5, 
107.1, 130.4, 130.6, 131.9, 134.9, 135.1, 140.0, 177.4, 183.1, 184.7, 194.5 
 
2-(2-hydroxy-4-methyl-6-oxocyclohex-1-enyl)-3-methylnaphthalene-1,4-dione 40 
O
O
OH
O
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a brown 
solid. (M-H+ Found: 295.3188, C18H15O4 requires M-H+, 295.3180). UPLC 85.7%. Rf  0.50.  
(EtOAc/Hex, 1:2). mp 185ºC δ 1.10 (3H, d J 6.0 Hz, CH3), 1.93 (3H, s, CH3), 2.10 (1H, dd, J 4.7, 
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12.4 Hz, CH2), 2.43 (1H, dd, J 3.4, 12.8 Hz, CH2), 2.70 (1H, m, CH), 2.79 (1H, dd, J 3.4, 12.8 Hz, 
CH2), 3.03 (1H, dd, J 4.7, 12.4 Hz, CH2), 7.73 (2H, dd, J 3.4, 5.4 Hz, ArH), 8.01 (1H, dd, J 3.4, 
5.4 Hz, ArH), 12.1 (1H, s, OH). 13C NMR (100 MHz, DMSO-d6): δ = 13.8, 20.9, 23.8, 41.3, 47.0, 
106.9, 130.2, 130.5, 136.1, 136.9, 132.9, 133.2, 140.2, 147.9, 177.6, 183.1, 184.7, 194.5. 
 
 
2-(2-hydroxy-4,4-dimethyl-6-oxocyclohex-1-enyl)-3-methylnaphthalene-1,4-dione 41 
O
O
OH
O
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a brown 
solid. (M-H+ Found: 309.1012, C22H13O2 requires M-H+, 309.0916). UPLC 99.6%. Rf  0.52.  
(EtOAc/Hex, 1:2). mp 230ºC 1H NMR (400 MHz, DMSO-d6): δ = 1.09 (3H, s, CH3), 1.16 (3H, s, 
CH3), 1.90 (3H, s, CH3),2.36 (4H, s, 2 x CH2), 7.85 (2H, dd, J 3.4, 5.4 Hz, ArH), 7.96 (1H, dd, J 
3.4, 5.4 Hz, ArH), 8.04 (1H, dd, J 3.4, 5.4 Hz, ArH), 10.8 (1H, s, OH). 13C NMR (100 MHz, 
DMSO-d6): δ = 13.9, 27.7, 28.0, 31.9, 108.9, 125.8, 125.8, 131.6, 132.0, 133.7, 133.9, 141.6, 
145.4, 182.5, 184.6. 
2-(2-hydroxy-6-oxo-4-phenylcyclohex-1-enyl)-3-methylnaphthalene-1,4-dione 42 
O
O
OH
O
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallisation to afford a yellow 
solid (M-H+ Found: 357.1061, C23H17O4 requires M-H+, 357.1127). UPLC 99.4%. Rf  0.34  
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(EtOAc/Hex, 1:2). mp 239ºC 1H NMR (400 MHz, DMSO-d6): δ = 1.90  (3H, s, CH3), 2.60 (2H, 
dd, CH2), 2.80 (2H, dd, CH2), 3.45 (1H, m, CH), 7.23 (1H, t,  J 7.2  Hz, ArH), 7.33 (2H, t J  7.2 
Hz, ArH), 7.40 (2H, dd, J 7.8, 21.6 Hz, ArH), 7.83 (2H, dd,  J 3.3, 5.7  Hz, ArH), 7.95 (1H, d J  
5.4  Hz, ArH), 8.01 (1H, dd, J 4.2, 9.0 Hz, ArH), 11.0 (1H, s, OH). 13C NMR (100 MHz, DMSO-
d6): δ = 13.9, 38.2, 38.3, 109.7, 125.7, 125.8, 126.6, 126.7, 126.9, 127.0, 128.4, 128.5, 131.6, 
131.9, 132.1, 133.6, 133.9, 143.4, 145.3, 182.3, 184.7. 
2-(4-hydroxy-2-oxo-2H-chromen-3-yl)-3-methylnaphthalene-1,4-dione 43 
O
O
O
O
O
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a brown 
solid. UPLC 89.3%. Rf  0.42  (EtOAc/Hex, 1:2). mp 230ºC (M+H+ Found: 333.0658, C20H13O5 
requires M+H+, 333.0552).   1H NMR (400 MHz, DMSO-d6): δ = 1.97 (3H, s, CH3), 2.34 (3H, s, 
CH3), 7.08 (1H,d, J 8.40 Hz, ArH), 7.27(1H, d, J 8.40 Hz, ArH), 7.61 (1H, s, ArH), 7.81 (2H, dd, 
J 3.20, 5.60 Hz, ArH), 7.95 (1H,dd, J 3.60, 5.60 Hz, ArH), 7.95 (1H, dd, J 3.6, 4.8 Hz, ArH), 8.02 
(1H, dd, J 3.20, 5.60 Hz, ArH). δ = 13.9, 18.3, 95.2, 114.4, 120.2, 127.0, 136.5, 158.3, 159.5, 
130.5, 130.9, 132.9, 133.0, 136.1, 136.4, 140.1, 160.2, 177.5, 183.1 
 
 
 
2-(4-hydroxy-6-methyl-2-oxo-2H-chromen-3-yl)-3-methylnaphthalene-1,4-dione 44 
 
211 | P a g e  
 
 
 
O
O
O
O
O
 
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallisation to afford a brown 
solid.  UPLC 90.1%. Rf  0.41  (EtOAc/Hex, 1:2). mp 234oC, (M-H+ Found: 345.1011, C21H13O5 
requires M-H+, 345.1076).  1H NMR (400 MHz, DMSO-d6): δ = 2.00 (3H, s, CH3), 7.15 (2H,t, J 
7.80 Hz, ArH), 7.44 (1H, t, J 7.20 Hz, ArH), 7.80 (2H, dd, J 3.6, 6.0 Hz, ArH), 7.84 (1H,d, J 7.80  
Hz, ArH), 7.95 (1H, dd, J 3.6, 4.8 Hz, ArH), 8.01 (1H, dd, J 3.6, 5.1 Hz, ArH). 13C NMR (100 
MHz, DMSO-d6): δ = 14.2, 92.9, 115.6, 115.7, 121.8, 122.9, 124.8, 125.4, 125.8, 130.2, 131.8, 
133.0, 133.1, 133.3, 143.2, 146.2, 154.0, 161.8, 171.5, 183.1, 185.2. 
 
2-(4-hydroxy-6,7-dimethyl-2-oxo-2H-chromen-3-yl)-3-methylnaphthalene-1,4-dione 45 
O
O
O
O
O
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallisation to afford a brown 
solid (M-H+ Found: 359.3620, C22H15O5 requires M-H+, 359.3619). UPLC 89.4%. Rf  0.34  
(EtOAc/Hex, 1:2). mp 239ºC 1H NMR (400 MHz, DMSO-d6): 1H NMR (400 MHz, DMSO-d6): δ 
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= 1.97 (3H, s, CH3), 2.34 (3H, s, CH3), 2.39 (3H, s, CH3), 6.70 (1H,d, s, ArH), 6.95(1H, s,  ArH), 
7.73 (1H, s, ArH),   8.01 (1H, dd, J 3.6, 4.8 Hz, ArH). 13C NMR (100 MHz, DMSO-d6): δ = 14.4, 
22.9, 93.9, 115.6, 115.7, 122.6, 122.9, 124.8, 125.4, 125.8, 130.2, 131.8, 133.0, 133.1, 133.3, 
143.2, 146.2, 154.0, 161.8, 171.5, 183.1, 185.3.  
13C NMR (100 MHz, DMSO-d6): δ = 13.9, 18.3, 95.2, 114.4, 120.2, 127.0, 136.5, 158.3, 159.5, 
130.5, 130.9, 132.9, 133.0, 136.1, 136.4, 140.1, 160.2, 177.5, 183.1 
2-(6-chloro-4-hydroxy-2-oxo-2H-chromen-3-yl)-3-methylnaphthalene-1,4-dione 46  
 
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a brown 
solid (M-H+ Found: 365.0299, C20H10ClO5 requires M-H+, 365.0300). UPLC 90.1%. Rf  0.40  
(EtOAc/Hex, 1:2). mp 260-261ºC 1H NMR (400 MHz, DMSO-d6): δ = 2.12 (3H, s, CH3), 3.90 
(1H, br s, OH),  6.98 (1H, s, ArH), 7.55 (1H, dd, J 7.50, 15.6 Hz, ArH), 7.64 (1H, m, ArH), 7.86 
(2H, dd, J 3.60, 4.80 Hz, ArH), 7.97 (1H, t, J 4.50 Hz, ArH), 8.02 (1H, t, J 4.50 Hz, ArH). 13C 
NMR (100 MHz, DMSO-d6): δ = 14.2, 95.9, 116.6, 116.7, 122.8, 122.9, 124.8, 125.4, 125.8, 130.2, 
131.8, 133.0, 133.1, 133.3, 143.2, 146.2, 154.0, 161.8, 171.5, 183.1, 189.2.  
 
2-((Z)-1,1,1-trifluoro-4-hydroxy-2-oxopent-3-en-3-yl)-3-methylnaphthalene-1,4-dione 47 
O
O
O
O
HO
Cl
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Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a brown 
solid (EtOAc/Hex, 1:2). mp 220ºC (M-H+ Found: 345.1083, C22H17O4 requires M-H+, 345.1127).   
1H NMR (400 MHz, DMSO-d6): δ = 1.24 (3H, s, CH3), 1.49 (3H, s, CH3),  3.93 (1H, br s, OH), 
7.54 (1H, dd, J 1.80, 7.20 Hz, ArH), 7.56 (1H, dd, J 1.80, 7.20 Hz, ArH), 7.64 (2H, m, ArH). 
2-((E)-4,4,4-trifluoro-1-(tetrahydrothiophen-3-yl)-1-hydroxy-3-oxobut-1-en-2-yl)-3-
methylnaphthalene-1,4-dione 48 
 
O
O O
OH
F FF
S
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a brown 
solid (EtOAc/Hex, 1:2). mp 210-212°C (M-H+ Found: 345.1071, C22H17O4 requires M-H+, 
345.1127).   1H NMR (400 MHz, DMSO-d6): δ = 1.49 (3H, s, CH3), 3.93 (1H, br s, OH), 7.55 (2H, 
dd, J 1.80, 7.20 Hz, ArH), 7.62 (2H, dd, J 1.80, 7.20 Hz, ArH). 
 
 
2,3-bis(4,4-dimethyl-2,6-dioxocyclohexyl) naphthalene-1,4-dione 49 
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Stirring time 24h. The product was washed with EtOAc to afford dark brown solid (0.293g, 55% 
yield), (M+H+ Found: 433.109 C18H15O4 requires M+H+, 433.126); Rf = 0.58 (1:10 MeOH:EtoAc). 
mp = 200 oC. 1H NMR (400 MHz, DMSO-d6) 0.99 (3H, s, CH3), 1.08 (3H, s, CH3), 2.11 (2H, s, 2 
x CH), 2.13 (2H, s, CH2), 2.24 (2H, s, CH2), 7.85 (1H, dd, J 3.20, 5.60 Hz, H-Ar), 7.98 (1H, dd, J 
3.20, 5.60 Hz, H-Ar). 13C NMR (100 MHz, DMSO-d6): δ  27.8, 28.3, 30.8, 31.6, 109.9, 125.8, 
128.6, 129.3, 132.3, 133.6, 134.3, 138.8, 144.6, 182.6 
 
5-hydroxy-2,3-bis (4,4-dimethyl-2,6-dioxocyclohexyl) naphthalene-1,4-dione 50 
O
O
O
O
O
O
OH
 
Stirring time = 48h.  The product was washed with EtOAc to afford light brown solid (0.292g 48% 
yield), (M_H+ Found: 449.1595 C26H25O7 requires M-H, 449.1600). UPLC 91.2%.  Rf = 0.51 
(EtoAc) Mp = 170 oC. 1H NMR (400 MHz, DMSO-d6) 0.99 (3H, s, CH3), 1.07 (3H, s, CH3), 2.13 
(2H, s, 2 X CH), 2.15 (2H, s, CH2), 2.26 (2H,s,CH2), 7.33 (1H, dd, J 1.0, 8.7 Hz, H-Ar), 7.50 (1H, 
dd, J 1.20, 7.60 Hz, H-Ar), 7.75 (1H, t, J 8.0 Hz, H-Ar), 12.0 (1H, s, OH); 13C NMR (100 MHz, 
DMSO-d6): δ  28.8, 29.3, 31.8, 31.6, 109.9, 125.8, 128.6, 129.3, 132.3, 134.6, 135.3, 139.8, 146.6, 
183.6 
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2,3-bis (5-acetyl-5,6-dihydro-2-methyl-6-oxo-4H-pyran-3-yl)-5-hydroxynaphthalene-1,4-
dione 51 
 
O
O
OOH
OO
O
O
O
O
O
 
Stirring time = 24h. The product was purified by flash chromatography loaded with Et2O and 
washed with hexane, (Silica: 1:10, 1:8, 1:4, 1:2, Et2O-hexane, Et2O) to afford an orange solid 
(0.084g, 30% yield), (M_H+ Found: 509.0500. C28H13O10 requires M_H, 509.0509); Rf = 0.56 (1:20 
MeOH: EtoAc). mp = 200 oC. 2.26 (6H, d, J 0.80 Hz, 2 x CH3), 2.55 (6H, s, 2 x CH3), 6.30 (1H, 
d, J 0.4 Hz, CH), 7.09 (1H, q, J 10.8 Hz, CH), 7.37 (1H, dd, J 1.2, 8.8 Hz, H-Ar), 7.52 (1H, dd, J 
1.2, 7.20 Hz, H-Ar),  7.77 (1H, dd, J 7.6, 8.4 Hz, H-Ar), 11.8 (1H, s, OH). 
 
2,3-bis(5-acetyl-5,6-dihydro-2-methyl-6-oxo-4H-pyran-3-yl)naphthalene-1,4-dione 52 
 
O
O
O
OO
O
O
O
O
O
 
Stirring time =24h. Purification by flash chromatography loaded with Et2O and washed with 
hexane, (Silica: 1:10, 1:8, 1:4, 1:2,  Et2O-hexane, Et2O, then 5:1 Et2O:Hex Preparative TLC 
plate) to afford an orange solid; Rf = 0.25 0.607 (1:1 EtoAc:MeOH). mp = 220 oC. 1H NMR (400 
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MHz, DMSO-d6) 2.39 (6H, s, CH3), 2.43 (3H, s, CH3), 6.91 (1H, dd, J 1.60, 8.00 Hz, H-Ar), 
7.32 (1H, dd, J 1.60, 8.00 Hz, H-Ar), 7.34 (1H, t, J 7.6 Hz, H-Ar), 13.7 (1H, s, OOH). 
 
5-hydroxy-2,3-bis(4-methyl-2,6-dioxocyclohexyl)naphthalene-1,4-dione 53 
O
O
O
O
O
O
OH
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a brown 
solid (MeOH/EtOAc 1:2). mp 220°C (M-H+ Found: 421.1071, C24H21O7 requires M-H+, 
345.10270).   Rf = 0.25  (1:1 EtoAc: MeOH) 1H NMR (400 MHz, DMSO-d6): δ 1.11 (3H, 
d, J 6.4 Hz, CH3), 2.03 (1H, dd, J 5.8, 17.6 Hz, CH), 2.33 (1H, m, CH),  2.67 (1H, dd, J 2.0, 2.4 Hz, 
CH2), 2.71 (1H, d, J 6.4 Hz, CH), 2.80 (1H, dd J 6.0 Hz, CH), 7.16 (1H, dd,  J 1.6, 8.4  Hz, ArH), 
7.47 (1H, dd J  1.2, 7.2  Hz, ArH), 7.57 (1H, t J 7.8 Hz, ArH), 13.8 (1H, s, OH). 
 
 
• Isoniazid derivative 54 
O OH
OH
N
HN O
N
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Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a brown 
solid (MeOH/EtOAc 1:2). mp 240°C.   Rf = 0.33 (2:1 EtoAc: MeOH) 1H NMR (400 MHz, DMSO-
d6): δ 2.20 (2H, s, CH2), 2.73 (2H, d J 6.4 Hz, CH2) 2.87 (2H, s J 6.4 Hz, CH2), 6.93 (1H, s, ArH), 
7.49 (1H, s, ArH), 7.80 (2H, s, ArH), 8.76 (2H, dd J 1.60, 4.40 Hz, ArH),8.98 (2H, br s, OH), 11.00 
(1H, br s, NH); ); 13C NMR (100 MHz, DMSO-d6): δ  36.2, 59.3, 98.8, 113.8, 115.5, 120.9, 133.3, 
136.1, 140.2, 144.9, 150.1, 162.8, 169.8, 194.2. 
 
• Isoniazid derivative 55 
O
O
OH
OH
N
HN O
N
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a light 
brown solid (MeOH/EtOAc 1:2). mp 240°C.   Rf = 0.30 (2:1 EtoAc: MeOH) . 1H NMR (400 MHz, 
DMSO-d6): δ 2.15 (2H, m, CH2), 2.46 (2H, t J 6.4 Hz, CH2), 2.99 (2H, t J 6.4 Hz, CH2), 3.94 (3H, 
s, CH3), 7.00 (1H, s, ArH), 7.72 (2H, dd J 1.60, 4.40 Hz, ArH), 8.62 (1H, br s, OH), 8.70 (2H, 
d J 6.0 Hz, ArH), 9.17 (1H, br s, OH) 10.10 (1H, br s, NH); 13C NMR (100 MHz, DMSO-
d6): δ 22.0, 23.1, 37.3, 60.3, 99.8, 114.8, 115.5, 120.9, 133.3, 136.1, 140.2, 144.9, 150.1, 163.8, 
169.8, 194.4. 
 
• Isoniazid derivstive 56 
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O OH
OH
N
HN O
N
 
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a brown 
solid (MeOH/EtOAc 1:2). mp 240°C. (M+H+ Found: 365.1511, C20H20N3O4 requires M+H+, 
365.1566)  Rf = 0.35 (2:1 EtoAc: MeOH). 1H NMR (400 MHz, DMSO-d6): δ 1.14 (3H, d, J 6.4 Hz, 
CH3), 2.26 (3H, s, CH3), 2.29 (1H, dd, J 4.7, 12.4 Hz, CH2), 2.43 (2H, dd J 3.4, 12.8 Hz, CH2), 
2.68 (1H, m, CH), 3.03 (1H, dd J 4.7, 12.4 Hz, CH), 7.11 (1H, s, ArH), 7.72 (2H, dd, J 1.6, 4.4 
 Hz, ArH), 8.40 (1H, br s, OH), 8.70 (2H, d, J 6.0 Hz, ArH),9.31 (1H, br s, OH), 10.01 (1H, br s, 
NH); 13C NMR (100 MHz, DMSO-d6): δ 2.0, 23.1, 37.3, 60.3, 99.8, 114.8, 115.5, 120.9, 133.3, 
136.1, 140.2, 144.9, 150.1, 163.8, 169.8, 194.4. 
 
• Isoniazid derivative 57 
 
219 | P a g e  
 
 
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a light 
brown solid (MeOH/EtOAc 1:2). mp 235°C.   Rf = 0.30 (2:1 EtoAc: MeOH).-1H NMR (400 MHz, 
DMSO-d6): δ 1.12 (3H, d J 6.8 Hz, CH3), 2.32 (1H, dd J 12.0, 16.8 Hz, CH) 2.44 (2H, dd J 3.20, 
16.8 Hz, CH2), 2.72 (1H, m, CH), 3.06 (1H, dd J 5.0, 17.4 Hz, CH), 3.95 (3H, s, OCH3), 6.99 (1H, 
s, ArH), 7.72 (2H, dd, J 1.80, 4.20  Hz, ArH), 8.8.62 (1H, br s, OH), 8.70 (2H, d J 61.60, 4.80 Hz, 
ArH),9.18 (1H, br s, OH), 10.10 (1H, br s, NH);  13C NMR (100 MHz, DMSO-d6): δ 20.6, 30.1, 
30.9, 45.6, 60.3, 99.8, 114.7, 115.2, 120.9, 133.3, 136.1, 140.2, 140.5, 144.9, 150.2, 163.8, 169.4, 
193.9. 
 
• Isoniazid derivative 58 
O OH
OH
N
HN O
N
 
 
O
O
OH
OH
N
HN O
N
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Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a light 
brown solid (MeOH/EtOAc 1:2). mp 240°C.   Rf = 0.30 (2:1 EtoAc: MeOH). 1H NMR 
(400 MHz, DMSO-d6): δ 1.10 (6H, s, 2 × CH3), 2.38 (2H, s, CH2), 2.88 (2H, s, CH2), 6.98 (1H, s, 
ArH), 7.21 (1H, s, ArH), 7.72 (2H, dd J 2.0, 4.4  Hz, ArH), 8.70 (2H, dd J 1.20, 4.4  Hz, ArH), 
9.12 (2H, br s, OH), 10.1(1H, br s, NH). 13C? 
 
 
• Isoniazid derivative 59 
O OH
OH
N
HN O
N
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a brown 
solid (MeOH/EtOAc 1:2). mp 240°C. (M+H+ Found: 378.1493, C21H20N3O4 requires M+H+, 
379.1551)  Rf = 0.30 (2:1 EtoAc: MeOH).  1H NMR (400 MHz, DMSO-d6): δ 1.09 (6H, s, 2× 
CH3), 2.27 (3H, s, CH3) 2.61 (2H, s, CH2), 2.77 (2H, s, CH2), 7.38 (1H, s, ArH), 7.80 (2H, 
d J 5.60 Hz, ArH),8.27 (1H, br s, OH),  8.76 (2H, dd, J 1.20, 4.40 Hz, ArH), 9.26 (1H, br s, OH), 
11.00 (1H, br s, NH);  
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• Isoniazid derivative 60 
O OH
OH
N
HN O
N
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a light 
brown solid (MeOH/EtOAc 1:2). mp 240°C.   Rf = 0.30 (2:1 EtoAc: MeOH). 1H NMR (400 MHz, 
DMSO-d6): δ 2.58 (1H, dd, J 3.2, 16.0 Hz, CH), 2.93 (1H, dd J 12.4, 16.0 Hz, CH), 3.24 (2H, m, 
CH2), 3.66 (1H, m, CH), 7.01 (1H, s, ArH), 7.26 (1H, s, ArH), 7.35 (2H, t J 7.2, 7.6 Hz, ArH), 7.42 
(2H, d J 7.6 Hz, ArH), 7.72 (2H, d J 6.0 Hz, ArH), 7.72 (2H, d J 6.40 Hz, ArH), 9.11 (1H, s, 2 x 
OH), 10.10 (1H, br s, NH); 13C NMR 30.5, 44.5, 96.4, 105.3, 114.2, 115.4, 120.9, 126.9, 127.0, 
140.2, 143.0, 143.7, 144.4, 148.2, 150.1, 163.8, 166.8, 192.9. 
• Isoniazid derivative 61 
 
O OH
OH
N
HN O
N
 
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a light 
brown solid (MeOH/EtOAc 1:2). (M+H+ Found: 428.1546, C25H22N3O4 requires M+H+, 428.1610) 
mp 236°C.   Rf = 0.31 1H NMR (400 MHz, DMSO-d6): δ 2.28 (3H, s, CH3), 2.60 (1H, dd J 4.0, 
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16.4 Hz, CH), 2.91 (1H, dd, J 12.2, 16.2 Hz, CH), 3.29 (1H, m, CH2), 3.68 (1H, m, H-11 CH), 7.16 
(1H, s, ArH), 7.26 (1H, t J 7.0 Hz, ArH), 7.35 (2H, t, J 7.6 Hz, ArH), 7.39 (2H, d J 7.6 Hz, ArH), 
7.42 (2H, d, J 8.0 Hz, ArH), 7.86 (2H, d J 6.0 Hz, ArH), 8.68 (2H, d J 6.40 Hz, ArH). 
 
 
• Isoniazid derivative 62 
 
O OH
OH
N
HN O
N
O
 
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a brown 
solid (MeOH/EtOAc 1:2).  UPLC 99.5%. (M-H+ Found: 442.1313, C25H20N3O5 requires M-H+, 
442.1403). mp 240°C.   Rf = 0.30 (2:1 EtoAc: MeOH). 1H NMR (400 MHz, DMSO-d6): δ 2.68 
(1H, dd, J 4.0, 16.0 Hz, CH), 2.93 (1H, dd J 12.0 Hz, 12.4 Hz, CH), 3.26 (2H, m, CH2), 3.67 (1H, 
m, CH), 3.95 (3H, s, CH3), 7.03 (1H, s, ArH), 7.26 (1H, t J 7.2 Hz, ArH), 7.35 (2H, t J 7.2, 8.0 Hz, 
ArH), 7.75 (2H, d J 3.60  Hz, ArH), 8.56 (1H, br s, OH), 8.72 (2H, d J 6.00 Hz, ArH), 9.10 (1H, 
br s, OH) 11.00 (1H, br s, NH); 13C NMR 31.5, 44.5, 60.3, 96.5, 106.3, 114.2, 115.4, 121.9, 126.9, 
127.0, 140.2, 143.0, 143.7, 144.4, 148.2, 150.1, 163.8, 166.8, 194.9. 
 
Isoniazid derivative 63 
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O OH
OH
N
H
N NH2
S
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a brown 
solid (MeOH/EtOAc 1:2). mp 240°C.   Rf = 0.30 (2:1 EtoAc: MeOH). 1H NMR (400 MHz, DMSO-
d6) δ = 2.14 (2H, m, CH2), 2.46 (2H, t, J 6.60 Hz, CH2), 2.96 (2H, t, J 6.3 Hz, CH2), 4.48 (1H, s, 
NH), 6.97 (1H, s, Ar-H), 7.22 (1H, s, Ar-H), 9.09 (2H, s, NH2). 13C NMR (100 MHz, DMSO-d6): δ 
28.2, 29.2, 30.8, 97.4, 105.3, 113.3, 114.9, 143.6, 144.3, 148.1, 168.2, 191.9. 
• Thiosemicarbizide derivative 64 
O OH
OH
N
H
N NH2
S
O
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a light 
brown solid (MeOH/EtOAc 1:2). (M-H+ Found: 320.0668, C14H14O4N3,S requires M-H+, 
320.0705). mp 240°C.   Rf = 0.30 (2:1 EtoAc: MeOH).   1H NMR (400 MHz, DMSO-d6): δ 2.13 
(2H, m, CH2), 2.46 (2H, t, J 6.8 Hz, CH2), 3.01 (2H, t J 6.4 Hz, CH2), 3.94 (3H, s, OCH3), 4.48 
(1H, s, NH); 7.00 (1H, s, ArH), 7.16 (1H, br s, OH), 7.51 (1H, br s, OH)  8.60 (1H, s, NH); 13C 
NMR (100 MHz, DMSO-d6): δ 29.2, 30.6, 30.8, 43.6, 97.4, 105.3, 114.3, 115.2, 143.6, 144.3, 
148.1, 168.2, 192.8. 
 
• Thiosemicarbizide derivative 65 
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O OH
OH
N
H
N NH2
S
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a light 
brown solid (MeOH/EtOAc 1:2). (M+H+ Found: 306.0904, C14H16N3O3S requires M-H+, 
306.0912).  mp 240°C. Rf = 0.30 (2:1 EtoAc: MeOH).  1H NMR (400 MHz, DMSO-d6): δ 1.12 
(3H, d, J 6.40 Hz, CH3), 2.31 (1H, dd, J 4.6, 12.8 Hz, CH), 2.44 (2H, dd, J 3.6, 12.8 Hz, CH2), 2.70 
(1H, m, CH), 3.03 (1H, dd J 4.6, 12.8 Hz, CH), 4.49 (1H, s, NH), 6.97 (1H, s, ArH), 7.21 (1H, s, 
ArH) and 8.60 (2H, br s, OH), 9.05 (2H, s, NH2), 13C NMR (100 MHz, DMSO-d6): δ 20.6, 30.2, 
30.6, 30.9, 45.6, 98.4, 105.3, 114.3, 115.2, 143.6, 144.3, 148.1, 169.2, 193.8. 
 
• Thiosemicarbizide derivative 66 
O OH
OH
N
H
N NH2
S
O
8
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a white 
solid (MeOH/EtOAc 1:2). (M-H+ Found: 334.0829, C15H16O4N3S requires M-H+, 334.0862).  mp 
240°C.   Rf = 0.30 (2:1 EtoAc: MeOH).  1H NMR (400 MHz, DMSO-d6) δ = 1.13 (3H, d, J 6.40 
Hz, CH3), 2.32 (1H, dd, J 11.6, 16.8 Hz, CH), 2.46 (2H, dd, J 3.80, 16.8 Hz, CH2),  3.07 (1H, dd, 
J 5.0, 17.4 Hz, CH), 3.29 (1H, s, NH), 3.95 (3H, s, OCH3), 6.99 (1H, s, ArH), 8.61 (2H, s, NH2), 
9.18 (1H, s, ArH). 13C NMR (100 MHz, DMSO-d6): δ 21.3, 31.2, 33.1, 35.9, 46.6, 62.2, 98.4, 
105.3, 114.6, 115.4, 143.6, 145.3, 148.1, 170.2, 193.8. 
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• Thiosemicarbizide derivative 67 
O OH
OH
N
H
N NH2
S
O
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a white 
solid (MeOH/EtOAc 1:2).  mp 240°C.   Rf = 0.30 (2:1 EtoAc: MeOH). 1H NMR (400 MHz, 
DMSO-d6): δ 1.13 (3H, d J 6.4 Hz, CH3), 2.32 (1H, dd J 12.4, 16.8 Hz, CH) 2.45 (2H, dd J 3.6, 
16.8 Hz, CH2), 2.73 (1H, dd, J 9.4, 17.0 Hz, CH), 3.07 (1H, m, CH), 3.94 (3H, s, CH3), 4.48 (2H, 
s, NH2), 6.99 (1H, s, OH), 7.17 (1H, s, OH), 8.60 (1H, s, NH); 13C NMR (100 MHz, DMSO-d6): 
19.0, 32.4, 32.6,36.3, 47.1, 56.5, 99.8, 102.0, 120.8, 126.0, 131.8, 137.8, 146.8, 147.0, 160.0, 
181.4. 
• Thiosemicarbizide derivative 68 
O OH
OH
N
H
N NH2
S
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a dark 
brown solid (MeOH/EtOAc 1:2). mp 240°C.   Rf = 0.30 (2:1 EtoAc: MeOH).   1H NMR (400 
MHz, DMSO-d6) δ =1.04 (3H, s, CH3), 2.33 (2H, s, CH2), 2.83 (2H, s, CH2), 4.42 (2H, s, NH2), 
6.92 (1H, s, H-Ar), 7.15 (1H, s, H-Ar), 8.54 (1H, s, NH), 9.00 (1H, s, NH). 13C NMR (100 MHz, 
DMSO-d6): 13C NMR (100 MHz, DMSO-d6): 25.7, 26.1, 36.4, 39.7, 46.9, 99.5, 103.1, 108.6, 
119.9, 145.9, 146.7, 148.5, 148.8, 163.1, 181.4 
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• Thiosermicarbizide derivative 69 
O OH
OH
N
H
N NH2
S
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a brown 
solid (MeOH/EtOAc 1:2). mp 240°C.   Rf = 0.30 (2:1 EtoAc: MeOH). 1H NMR (400 MHz, DMSO-
d6): δ 2.58 (1H, dd J 4.0, 16.0 Hz, CH), 2.93 (1H, dd J 12.2, 16.4 Hz, CH), 3.24 (2H, m, H-11), 
3.70 (1H, m, CH), 7.01 (1H, s, ArH), 7.26 (1H, s, ArH), 7.35 (2H, t J 7.2, 7.6 Hz, ArH), 7.42 (2H, 
d J 7.6 Hz, ArH), 9.09 (1H, s, CH), 9.13 (1H, s, CH); 13C NMR (100 MHz, DMSO-d6): 34.4, 35.3, 
45.6, 99.4, 102.0, 107.5, 119.8, 126.3, 126.4, 126.7, 128.9, 129.3, 141.4, 145.9, 146.7, 147.4, 
148.0.   
 
• Thiosemicaribizide derivative 70 
O OH
OH
N
H
N NH2
S
O
 
 
Stirring time = 24 h. Purification by a wash with EtOAc and recrystallization to afford a brown 
solid (MeOH/EtOAc 1:2). (M+H+ Found: 398.1158, C20H20N3O4S requires M+H+, 398.1175).  
mp 240°C.   Rf = 0.30 (2:1 EtoAc: MeOH). 1H NMR (400 MHz, DMSO-d6): δ 2.16 (1H, 
t J 13.2 Hz, CH), 2.93 (1H, dd J 12.0 Hz, 12.4 Hz, CH), 3.26 (2H, m, CH2), 3.67 (1H, m, CH), 
3.95 (3H, s, CH3), 7.03 (1H, s, ArH), 7.26 (1H, t J 7.2 Hz, ArH), 7.35 (2H, t J 7.2, 8.0 Hz, 
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ArH), 7.42 (2H, d J 8.0 Hz, ArH), 8.76 (1H, br s, OH) and 9.33 (1H, br s, OH). 13C NMR 
(100 MHz, DMSO-d6): 34.2, 34.4, 43.6, 56.5, 102.0, 120.8, 126.0, 126.3, 126.5, 126.7, 128.5, 
128.6, 131.8, 137.7, 146.6, 148.6, 147.0, 160.0, 186.1. 
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One-Pot Laccase-Catalysed Synthesis of 5,6-Dihydroxylated
Benzo[b]furans and Catechol Derivatives, and Their
Anticancer Activity
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A commercial laccase, Suberase1 from Novozymes, was used to catalyse the synthesis of 5,6-
dihydroxylated benzo[b]furans and catechol derivatives. The yields were, in some cases, similar to
or better than that obtained by other enzymatic, chemical or electrochemical syntheses. The
synthesised derivatives were screened against renal (TK10), melanoma (UACC62), breast (MCF7)
and cervical (HeLa) cancer cell lines. GI50, TGI and LC50 are reported for the first time. Anticancer
screening showed that the cytostatic effects of the 5,6-dihydroxylated benzo[b]furans were most
effective against the melanoma (UACC62) cancer cell line with several compounds exhibiting
potent growth inhibitory activities (GI50 ¼ 0.77–9.76 mM), of which two compounds had better
activity than the anticancer agent etoposide (GI50 ¼ 0.89 mM). One compound exhibited potent
activity (GI50 ¼ 9.73 mM) against the renal (TK10) cancer cell line and two exhibited potent
activity (GI50 ¼ 8.79 and 9.30 mM) against the breast (MCF7) cancer cell line. These results
encourage further studies of the 5,6-dihydroxylated benzo[b]furans for their potential application
in anticancer therapy.
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Introduction
Cancer is a leading cause of death worldwide and accounted
for 7.6 million deaths (13% of all deaths) in 2008 (http://
www.who.int/mediacentre/factsheets/fs297/en/). Amongst the
most deadly cancers are lung, stomach, liver, colon and breast
cancer. It is projected that worldwide deaths from cancer will
continue to rise to an estimated 13.1 million in 2030 (http://
www.who.int/mediacentre/factsheets/fs297/en/).
The primary treatment for many cancers is chemotherapy.
The development of multidrug resistance to chemotherapeu-
tic drugs is a main obstacle for the successful treatment
of malignant tumours. Overexpression of the ATP-binding
cassette (ABC) transporters that actively pump drugs out of
tumour cells is one of the best known mechanisms of multi-
drug resistance [1, 2].
The number of effective drugs available for treating malig-
nant tumours has been reduced by the development of
chemoresistance and this has led to a search for therapeutic
alternatives through the discovery of new classes of anti-
cancer compounds.
The hydroxylated benzo[b]furan moiety has attracted much
attention due to its wide range of biological activities [3–7]. This
group of compounds act as antifungal agents, antioxidant
agents, 5-lipoxygenase inhibitors, cyclooxygenase-2 inhibitors,
Naþ and Kþ-ATPase inhibitors and modulators of the estrogen
receptor [8–12]. Examples of benzofuran scaffolds that exhibit
anticancer activity are shown in Fig. 1.
Usnic acid 1, a common and abundant lichen metabolite,
showed activity against the wild-type p53 breast cancer cell
line MCF7, the breast cancer cell line MDA-MB-231 and the
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lung cancer cell line H1299 [13]. Benzofuran derivatives 2 and
3 (Fig. 1) were identified as anticancer agents of which
derivatives displayed selective cytotoxicity against a tumouri-
genic cell line [14]. Laccases (EC 1.10.3.1) are enzymes that
are widely distributed in plants and fungi. They are
characterised by a multinuclear copper-containing active
site and have been classified as oxidoreductases. Laccases
catalyse the oxidation of a broad range of substrates
such as phenols, o- and p-diphenols, aminophenols, methoxy-
phenols, aryl thiols, anilines, polyphenols, polyamines and
lignin-derivatives [15–17]. In the monoelectronic oxidation of
substrates molecular oxygen is used and water is produced
as the only by-product (http://www.who.int/mediacentre/
factsheets/fs297/en/) [1, 2, 15–17]. Laccases have been success-
fully applied in organic synthesis which has culminated in
several reports in the field of green chemistry [18].
In our laboratories, we have been interested in the use of
enzymes for the development of green methods of synthesis,
and for accessing compounds that have pharmaceutical
value. We have previously reported on the synthesis of di-
aminobenzoquinones [19a] and aminonaphthoquinones
[19b] via C–N bond formation as well as 1,4-naphthoqui-
none-2,3-bis-sulfides [19c] via C–S bond formation using com-
mercial laccases (Denilite II Base on an inert support, and
Novozyme 51003) from Novozymes [19]. In this article, we
report on the synthesis of 5,6-dihydroxylated benzo[b]furan
derivatives using another commercial laccase (Suberase1
from Novozymes) and on the anticancer activity of the
synthesised compounds. We anticipated that the 5,6-di-
hydroxylated benzo[b]furans 4 possessing ortho phenolic sub-
stituents could be metabolised to the o-quinonoid structure 5
in cancer cells (Fig. 1). Since quinonoid compounds display
potent biological properties such as antibacterial, anticancer,
antifungal and antimalarial activity [20], we postulated that
the benzo[b]furan 5 could have similar biological activities.
This study is, to the best of our knowledge, the first on the
synthesis of a variety of 5,6-dihydroxylated benzo[b]furans 4
and catechol derivatives using the commercial laccase,
Suberase1, as well as the first report on the anticancer
activity of the synthesised compounds.
Results and discussion
Synthesis
The catechols (6a–c) and the 1,3-dicarbonyls (7a–f) used in
this study are depicted in Fig. 2.
The method used for the synthesis entailed reacting
one equivalent of the catechol with one equivalent of the
1,3-dicarbonyl at room temperature using Suberase1 in a
vessel open to air at pH 7.15 (Scheme 1). A pH of 7.15
was chosen because it would make the reaction medium
sufficiently basic to deprotonate the alpha-proton from the
1,3-dicarbonyls and thus facilitate the Michael addition
reaction with the in situ-generated o-quinone.
The first approach, Method A, entailed reacting the cate-
chols 6a–cwith the 1,3-dicarbonyls 7a–f at room temperature
(rt) at pH 7.15 for 24 h. The second approach, Method B,
entailed conducting the reaction under the same conditions
but for a longer time (44 h) to determine whether a longer
reaction time would improve the yield of the product. In the
third approach, Method C, a co-solvent, DMF, was added to
the reaction mixture to improve the solubility of the organic
substrates. The number of equivalents of the 1,3-dicarbonylwas
also increased so that a ratio of 1,3-dicarbonyl to catechol was
4:1. These reactions were conducted for 42 h. The results of the
investigations with Methods A to C are depicted in Table 1.
From these results it can be seen that 5,6-dihydroxylated
benzo[b]furans can be accessed using all three synthesis
methods. For Method A the highest yield that was obtained
is 98% for 17 (Entry 15, Table 1) and the lowest is 37% for 15
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(Entry 12, Table 1). ForMethod B the highest yield was 77% for
18 (Entry 18, Table 1) and the lowest 49% for 8 (Entry 2,
Table 1). In the case of Method C, the highest yield was
71% for 14 (Entry 11, Table 1) and the lowest 15% for 21
(Entry 23, Table 1).
When comparing the yield of product using Method A to
that obtained using Method B, it can be seen that there is not
a significant increase in yield even though the reaction time
has almost doubled (Entries 1 and 2, 5 and 6, 17 and 18,
Table 1). It is therefore concluded that there is a limit to the
quantity of product that can be formed in the reaction.
The presence of DMF (Method C) may have deactivated the
laccase, Suberase1, resulting in a lower yield of the product.
A higher volume of organic solvent increases the solubility of
a substrate but significantly decreases the overall reaction
rate by deactivating the enzyme [21].
The optimum conditions for synthesising these 5,6-dihy-
droxylated benzo[b]furans 4 using Suberase1 is thus that
used under Method A.
The enzymatic synthesis of 5,6-dihydroxylated benzo[b]fur-
ans has been reported previously. The first enzymatic syn-
thesis of compound 9 was reported in 2007 by Witayakran
et al. [22] using Trametes villosa laccase in phosphate buffer
(pH 7.0) with a Lewis acid, scandiumtris(trifluoromethane-
sulfonate), and sodium lauryl sulfate at 208C and afforded it
in 76% yield. In 2009, Witayakran et al. also reported on a
laccase–lipase co-catalytic system for the synthesis of com-
pounds 8 and 9 using phosphate buffer (pH 7.0) with lipase
[23]. In this reaction, the Michael addition step was enhanced
by lipase addition providing improved yields. Compound 8
was obtained in 60% yield using Candida rugosa lipase and
laccase from T. villosa at 238C. Compound 9 was obtained in
62% yield using Candida antarctica (CALB) lipase and laccase
from T. villosa at 238C [23]. We have synthesised compounds 8
and 9 without the use of scandiumtris(trifluoromethane-
sulfonate) or lipase and achieved a 49% yield of compound
8 (Entry 2, Table 1) and a 50% yield of compound 9 (Entry 3,
Table 1).
Hajdok et al. [24] was the first to report on the synthesis of
compounds 10–21 using laccase initiated oxidative domino
reactions. One method entailed using a commercial laccase
from Trametes versicolor in an acetate buffer (pH 4.38) at room
temperature while the other method used laccase from
Agaricus bisporus in phosphate buffer (pH 5.96) also at rt.
The latter method was found to be better since it gave the
product in higher yield and purity with yields ranging from
71 to 97%. The yields of compounds 10–21 using ourmethods
are 37–98%. The commercial fungal laccase, Suberase1 from
Myceliophthora thermophila, was overall less effective than the
laccase from A. bisporus which was used by Hajdok et al. [24].
Compounds 13 and 19 have also been synthesised by
employing tyrosinase and laccase from A. bisporus and were
obtained in 39 and 44% yields, respectively [25]. Our method
was higher yielding since compound 13 was obtained in 59%
yield and compound 19 in 76% yield (Entries 8 and 19,
respectively, Table 1; Fig. 3).
There have also been literature reports on the chemical
syntheses of 5,6-dihydroxylated benzo[b]furans. The first
report of compound 8 was a chemical synthesis which
afforded 8 in 47% yield using pyridine and sodium metaio-
date in ethanol at 208C [26]. Our methods afforded similar
yields for compound 8 (48 and 49%, Entries 1 and 2, respect-
ively, Table 1). Duthaler and Scherrer [27] reported on the
chemical synthesis of compound 10 which was obtained in
22% yield using sodium acetate in water. We were able to
obtain compound 10 in 65% yield (Entry 4, Table 1).
Electrochemical syntheses have also been reported for
the synthesis of 5,6-dihydroxylated benzo[b]furans. The first
report on the synthesis of 16 was by Grujic´ et al. [28] in 1976
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and afforded it in 90% yield. Later Tabakovic´ et al. [29] also
reported on the electrochemical synthesis of 16 in 90% yield
in water. Another electrochemical synthesis of 16 using
sodium acetate in water by Nematollahi et al. [30] afforded
it in 82% yield. The electrochemical synthesis of 16 by
Davarani et al. [31] only afforded a 66% yield. We could only
obtain a 58% yield for 16 (Entry 13, Table 1). Nematollahi et al.
[30] also reported on the electrochemical synthesis of 17 and
18 which were obtained in 87 and 93% yields, respectively,
also using sodium acetate in water as a reaction medium.
The electrochemical synthesis of 17 and 18 in a sodium
acetate solution by Davarani et al. [31] afforded these com-
pounds in slightly lower yields, 81 and 80%, respectively.
Compound 17 was obtained in 98% yield (Entry 15,
Table 1) which is higher than the yields obtained by electro-
chemical synthesis, while compound 18 was obtained in 77%
yield (Entry 18, Table 1) which was lower than that obtained
by electrochemical syntheses.
The synthesis of two novel catechol derivatives 22 and 23
was also investigated (Scheme 2).
These reactions were conducted using Method A which
was used for the synthesis of the 5,6-dihydroxylated benzo[b]-
furans 8–21. In this case, the aim was to achieve only C–C
bond formation using the 1,3-dicarbonyl 7f. The purpose was
to determine whether anticancer activity would still be
observed without the formation of the furan ring. The results
of the investigation are shown in Table 2.
Both reactions proceeded in mediocre yield to afford 22
and 23 (Entries 1 and 2, respectively). A proposed mechanism
involving an o-quinone intermediate of 22 and 23 is shown
in Fig. 4 below.
Anticancer evaluation
Screening was conducted against renal (TK10), melanoma
(UACC62), breast (MCF7) and cervical (HeLa) cancer cell lines
using the Sulforhodamine B (SRB) assay to determine the
growth inhibitory effects of the compounds [32]. These cell
lines have been used routinely at the U.S. National Cancer
Institute for screening for new anticancer agents and were
derived from tumours that have different sensitivities to
chemotherapeutic drugs [33]. Etoposide, an anticancer agent,
was used as a positive control. It is known to be an inhibitor of
topoisomerase, particularly topoisomerase II, and aids in
DNA unwinding which causes the DNA strands to break
Table 1. Synthesised benzo[b]furans 8–21 (yield in parentheses) at rt in phosphate buffer at pH 7.15.
Entry Catechol Dicarbonyl Reaction
time (h)
Method Product
(%Yield)
Yields of other
enzymatic
syntheses
Yields of
other syntheses
1 6a 7a 24 A 8 (48) 60 [23] 47 [26]
2 6a 7a 44 B 8 (49)
3 6b 7a 24 A 9 (50) 76 [22], 62 [23]
4 6a 7b 24 A 10 (65) 87 [24] 22 [27]
5 6b 7b 24 A 11 (62) 70 [24]
6 6b 7b 44 B 11 (67)
7 6c 7b 24 A 12 (70) 89 [24]
8 6a 7c 24 A 13 (59) 85 [24], 39 [25]
9 6a 7c 42 C 13 (30)
10 6b 7c 24 A 14 (78) 71 [24]
11 6b 7c 42 C 14 (71)
12 6c 7c 24 A 15 (37) 97 [24]
13 6a 7d 24 A 16 (58) 91 [24] 90 [28], 90 [29], 82 [30], 66 [31]
14 6a 7d 42 C 16 (40)
15 6b 7d 24 A 17 (98) 92 [24] 87 [30], 81 [31]
16 6b 7d 42 C 17 (59)
17 6c 7d 24 A 18 (73) 95 [24] 93 [30], 80 [31]
18 6c 7d 44 B 18 (77)
19 6a 7e 24 A 19 (76) 96 [24], 44 [25]
20 6a 7e 42 C 19 (50)
21 6b 7e 24 A 20 (80) 91 [24]
22 6c 7e 24 A 21 (43) 97 [24]
23 6c 7e 42 C 21 (15)
Method A – Suberase1 (8.0 mL), catechol (2.0 mmol), 1,3-dicarbonyl (2.0 mmol, 1 eq), phosphate buffer (20.0 mL, 0.10 M, pH 7.15),
stirring time at rt ¼ 24 h.
Method B – Suberase1 (8.0 mL), catechol (2.0 mmol), 1,3-dicarbonyl (2.0 mmol, 1 eq), phosphate buffer (20 mL, 0.10 M, pH 7.15),
stirring time at rt ¼ 44 h.
Method C – Suberase1 (4.5 mL), catechol (0.60 mmol), 1,3-dicarbonyl (2.4 mmol, 4 eq), phosphate buffer (4.0 mL, 0.10 M, pH 7.15) and
DMF (2.0 mL), stirring time at rt ¼ 42 h.
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[34]. Three parameters were determined during the screening
process: 50% cell growth inhibition (GI50), total cell growth
inhibition (TGI) and the lethal concentration that kills 50% of
cells (LC50). The results of this investigation are shown in
Table 3 from which it can be seen that several compounds
exhibited potent cytostatic effects.
The GI50 values of the catechols 6a–c, the catechol deriva-
tive 22 and selected benzo[b]furans were compared to that of
etoposide. No selection criteria were used for the compounds
that were screened. Screening against the TK10 cell line
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Figure 3. Structures of the 5,6-dihydroxylated benzo[b]furans 8–21 synthesised at rt.
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Table 2. Synthesised catechol derivatives 23 and 24 (yield in
parentheses) at rt in phosphate buffer at pH 7.15.
Entry Catechol Dicarbonyl Reaction
time (h)
Product
(Yield)
1 6b 7f 24 22 (80)
2 6c 7f 24 23 (55)
Method A – Suberase1 (8.0 mL), catechol (2.0 mmol), 1,3-
dicarbonyl (2.0 mmol, 1 eq), phosphate buffer (20.0 mL,
0.10 M, pH 7.15), stirring time at rt ¼ 24 h.
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showed that only 21 had potent activity (GI50 ¼ 9.73 mM,
Entry 12) which was not as good as that of etoposide
(GI50 ¼ 7.19 mM, Entry 14).
Most of the compounds exhibited potent growth inhibi-
tory activity against the UACC62 cell line. The potent
activity exhibited by 15 (GI50 ¼ 0.78 mM, Entry 9) and 21
(GI50 ¼ 0.77 mM, Entry 12) was slightly better activity than
that of etoposide (GI50 ¼ 0.89 mM, Entry 14).
Moreover, the same two compounds, 15 (GI50 ¼ 8.79 mM,
Entry 9) and 21 (GI50 ¼ 9.30 mM, Entry 12), also exhibited potent
growth inhibitory activity against theMCF7 cell line but thiswas
not as good as that of etoposide (GI50 ¼ 0.56 mM, Entry 14).
Most compounds exhibited weak TGI activity and three
were inactive against the TK10 cell line. The activities of 18,
20 and 21 (Entries 10–12, respectively) were slightly
better (TGI ¼ 46.14–48.25 mM) than that of etoposide
(TGI ¼ 49.74 mM, Entry 14).
The compounds also exhibited moderate to weak activity
against the UACC62 cell line with most compounds, 11, 12,
14, 15, 18 and 21, exhibiting better activity (TGI ¼ 18.32–
51.06 mM) than that of etoposide (TGI ¼ 52.71 mM, Entry 14).
The best activity was observed for 15 (TGI ¼ 18.32 mM, Entry 9)
which was almost threefold better than that of etoposide.
The test compounds exhibited weak activity against the
MCF7 cell line, but the cytostatic effects of these compounds
were better than that of etoposide which was inactive
(TGI > 100 mM, Entry 14).
The LC50 values of the compounds were also compared to
that of etoposide to get an idea of the cytotoxic effects of
these compounds against the different cell lines. Screening
against the TK10 cell line showed that most of the com-
pounds were more lethal than etoposide (LC50 > 100 mM)
with 18 (LC50 ¼ 73.59 mM, Entry 10) being the most lethal.
Again, most of the compounds weremore lethal than etopo-
side (LC50 > 100 mM) against the UACC62 cell line and 15
(LC50 ¼ 60.32 mM, Entry 9) was the most lethal. Apart from
18, none of the test compounds were lethal for HeLa cells,
indicating a degree of selectivity between cell lines.
The compounds also exhibited more lethal cytotoxic
effects against the MCF7 cell line than that of etoposide
(LC50 > 100 mM, Entry 14) and 21 (LC50 ¼ 86.93 mM, Entry
12) was the most lethal. Apart from 18, none of the test
compounds were lethal for HeLa cells indicating a degree
of selectivity between cell lines.
The catechols 6a–c and the catechol derivative 22 (Entry 13)
did not exhibit any significant anticancer activity. From the
results it can be seen that the GI50 concentrations of benzo[b]-
furan 9 (Entry 4) are almost half of those of 22 (Entry 13)
against the renal (TK10), melanoma (UACC62) and breast
(MCF7) cancer cell lines. It may thus be concluded that the
presence of the furan ring enhances anticancer activity. The
benzo[b]furans were most effective against the melanoma
(UACC62) cell line. Only one benzo[b]furan, 21, exhibited
growth inhibitory activity against all three cancer cell lines
which may be attributed to the presence of the methoxy
group on the benzene ring. When the methoxy group was
replaced with a methyl group, as in 20, growth activity
against the renal (TK10) and breast (MCF7) cell lines was
diminished. The benzo[b]furan 15 exhibited activity against
melanoma (UACC62) and breast (MCF7) cell lines. The replace-
Table 3. In vitro anticancer screening of the compounds against renal (TK10), melanoma (UACC62), breast (MCF7) and HeLa cancer cells
expressed as GI50, TGI and LC50 values (mM).
Entry Compound Renal (TK10) Melanoma (UACC62) Breast (MCF7) Cervical (HeLa)
GI50 TGI LC50 GI50 TGI LC50 GI50 TGI LC50 GI50 TGI LC50
1 6a 68.02 >100 >100 45.00 >100 >100 52.41 >100 >100 –a –a –a
2 6b 38.14 75.72 >100 15.18 46.22 77.26 27.34 64.31 >100 –a –a –a
3 6c 51.63 96.98 >100 23.64 50.26 76.87 27.55 60.68 93.81 –a –a –a
4 9 41.05 69.94 98.82 32.74 60.84 88.94 35.10 66.12 97.14 60.70 >100 >100
5 10 65.00 >100 >100 37.73 68.65 99.57 35.53 64.19 92.85 49.09 >100 >100
6 11 24.25 54.74 85.23 23.63 51.06 78.49 25.97 61.87 97.78 44.55 >100 >100
7 12 52.47 >100 >100 6.04 33.15 >100 15.85 54.74 93.63 56.46 >100 >100
8 14 16.56 55.32 94.09 6.50 33.85 74.35 25.55 68.82 >100 25.93 >100 >100
9 15 26.54 51.65 76.75 0.78 18.32 60.32 8.79 48.79 95.11 26.68 69.67 >100
10 18 18.69 46.14 73.59 6.79 28.93 66.27 28.44 60.90 93.35 34.37 62.15 89.93
11 20 18.60 48.25 77.90 9.76 >100 >100 17.96 60.79 >100 47.28 >100 >100
12 21 9.73 47.15 85.35 0.77 23.60 64.58 9.30 46.93 86.93 22.32 73.19 >100
13 22 86.99 >100 >100 51.29 >100 >100 68.03 >100 >100 –a –a –a
14 Etoposide 7.19 49.74 >100 0.89 52.71 >100 0.56 >100 >100 3.56 40.18 87.54
Inactive, i: GI50 or TGI > 100 mM; weak activity, w: > 30 mM GI50 or TGI < 100 mM; moderate activity, m: < 30 mM GI50 or
TGI > 10 mM; potent activity, p: GI50 or TGI < 10 mM.
a Not screened.
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ment of the methoxy group with that of a methyl, as in 14,
also resulted in diminished activity and in this case against
the breast (MCF7) cancer cell line. When comparing the
structure of 21 to that of 15 it appears that the replacement
of the methyl group with that of a phenyl specifically affords
growth inhibitory activity against the renal (TK10) cancer cell
line. It was concluded that the phenyl and methoxy groups
are essential for activity against all three cancer cell lines.
Conclusions
The fungal laccase from M. thermophila, commercially avail-
able as an inexpensive preparation known as Suberase1,
can be used in the catalytic synthesis of 5,6-dihydroxylated
benzo[b]furan and catechol derivatives under mild and
environmentally friendly reaction conditions. The yields
are, in some cases, similar to or better than that obtained
by other enzymatic, chemical, or electrochemical synthesis.
This method has eliminated the use of the Lewis acid, scan-
diumtris(trifluoromethanesulfonate), and lipase which was
used in previous laccase methods.
The 5,6-dihydroxylated benzo[b]furans exhibit potent cyto-
static effects against the three cancer cell lines but are most
effective against UACC62 (melanoma) with two compounds
exhibiting better activity than etoposide based on the
GI50 concentrations. The 5,6-dihydroxylated benzo[b]furans
generally have better TGI activity than that of etoposide.
These results warrant further studies of the 5,6-dihydroxy-
lated benzo[b]furans for their application in anticancer
therapy. These studies will entail further synthesis of 5,6-dihy-
droxylated benzo[b]furans and evaluation of their anticancer
activity in addition to structural modification of hits to deter-
mine whether the anticancer activity can be optimised.
Experimental
General
Proton nuclear magnetic resonance (1H NMR) spectra were
recorded on a Varian Mercury 400 MHz spectrometer. Carbon-
13 nuclear magnetic resonance (13C NMR) spectra were recorded
on the same instruments at 100 MHz. Chemical shifts are
reported in parts per million (ppm) relative to the solvent peaks
and coupling constants are given in Hertz (Hz). A Waters UPLC
coupled in tandem to a Waters photodiode array (PDA) detector
and a SYNAPT G1 HDMSmass spectrometer was used to generate
accurate mass data. The PDA detector was used for all purity
determinations (Maxplot 200–500 nm). All chemicals for UPLC-MS
work were of ultra-pure LC-MS grade and purchased from Fluka
(Steinheim, Germany) while ultra-pure solvents were purchased
from Honeywell (Burdick & Jackson, Muskegon, USA). Ultra-pure
water was generated using a Millipore Elix 5 RO system and
Millipore Advantage Milli-Q system (Millipore SAS, Molsheim,
France). Reactions were monitored by thin layer chromatography
(TLC) on aluminium-backedMerck silica gel 60 F254 plates. Gravity
column chromatography was performed usingMerck Silica Gel 60
(70–230 mesh). Melting points were determined using a Glassco
melting point apparatus and are uncorrected.
All chemicals were reagent grade materials. The 1,3-dicarbonyls
were purchased from Sigma–Aldrich, South Africa. Suberase1
(10757.8 PCU/mL) is a fungal laccase fromM. thermophila produced
by submerged fermentation of a genetically modified Aspergillus
oryzae strain. The enzymatic preparation is supplied as a brown
liquid which is completely miscible with water. Suberase1 was
obtained from Novozymes in South Africa.
General methods for the synthesis of the
benzo[b]furan derivatives
Method A
The laccase (Suberase1, 2.0 mL) was added to a mixture of the
catechol (2.0 mmol), 1,3-dicarbonyl (2.0 mmol) and phosphate
buffer (20.0 mL, 0.10 M, pH 7.15) in a 250-mL round-bottom flask
stirred under air at rt. More laccase (2.0 mL) was added after 2, 18
and 20 h. The mixture was vigorously stirred under air until
the substrates were consumed as judged by TLC. After stirring
the reaction mixture was acidified with 32% HCl to pH 4.0. The
mixture was extracted with EtOAc and washed with water
(20.0 mL). The organic phases were then combined and the solvent
evaporated. The residue, a powder, was purified by washing with
EtOAc or recrystallising from a combination of MeOH and EtOAc.
Method B
Same as Method B except that more laccase (2.0 mL) was added
after 4, 24 and 28 h.
Method C
The laccase (Suberase1, 1.5 mL) was added to a mixture of
the catechol (0.60 mmol), 1,3-dicarbonyl (2.40 mmol), phosphate
buffer (4.0 mL, 0.10 M, pH 7.15) and DMF (2.0 mL) in a test tube
stirred under air at rt. More laccase (1.5 mL) was added after 2 h
and then again after 4 h. Themixture was vigorously stirred under
air until the substrates had been consumed as judged by TLC. After
stirring the reactionmixturewas transferred to a separating funnel
and the mixture extracted with EtOAc and washed with water
(20.0 mL). The organic phases were combined, the solvent evapor-
ated and the residue (a powder) purified by flash chromatography.
1-(5,6-Dihydroxy-2-methyl-1-benzofuran-3-yl)ethanone 8
O OH
OH
CH3
CH3
O
Method A
Stirring time 24 h. The product was recrystallised from 5%MeOH
in EtOAc solution at 358C to afford a dark-brown powder
(198 mg, 48%) (Found: M–Hþ, 205.0518. C11H9O4 requires M–H,
205.0501). UPLC 95.5%. Rf 0.40 (EtOAc/hexane, 1:1). mp 200–
2038C. 1H NMR (400 MHz, DMSO-d6): d 2.51 (3H, s, CH3), 2.68
(3H, s, CH3), 6.91 (1H, s, ArH), 7.33 (1H, s, ArH), 8.94 (1H, br s,
OH), 9.06 (2H, br s, OH); 13C NMR (100 MHz, DMSO-d6): d 15.3,
30.8, 97.8, 106.4, 117.2, 117.2, 143.6, 144.2, 147.0, 160.7, 193.9.
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Method B
Stirring time 44 h. The product was washed with EtOAc to afford
a black powder (202.0 mg, 49%).
1-(5,6-Dihydroxy-2,7-dimethyl-1-benzofuran-3-yl)-
ethanone 9
O OH
OH
CH3
CH3
O
CH3
Method A
Stirring time 24 h. The product was washed with EtOAc to afford a
red-brownpowder (220 mg, 50%) (Found:M–Hþ, 219.0615. C12H11O4
requires M–H, 219.0657). UPLC 97.3%. Rf 0.46 (EtOAc/hexane, 1:1).
mp 2348C. 1H NMR (400 MHz, DMSO-d6): d 2.19 (3H, s, CH3), 2.45
(3H, s, CH3), 2.64 (3H, s, CH3), 7.17 (1H, s, ArH), 8.38 (1H, br s, OH),
9.25 (1H, br s, OH); 13C NMR (100 MHz, DMSO-d6): d 8.9,
15.4, 30.7, 103.2, 107.1, 116.2, 117.4, 141.8, 143.1, 146.5,
160.5, 193.9.
7,8-Dihydroxy-3,4-dihydrodibenzo[b,d]furan-1(2H)-one 10
O OH
OH
O
Method A
Stirring time 24 h. The product was recrystallised from 5%MeOH
in EtOAc solution at 358C to afford a brown powder (284 mg,
65%) (Found: M–Hþ, 217.0458. C12H9O4 requires M–H, 217.0501).
UPLC 96.2%. Rf 0.48 (EtOAc/hexane, 1:1).
1H NMR (400 MHz,
DMSO-d6): d 2.21 (2H, m, CH2), 2.47 (2H, t J 6.4 Hz, CH2)
2.96 (2H, t J 6.4 Hz, CH2), 7.00 (1H, s, ArH), 7.22 (1H, s, ArH),
9.18 (2H, br s, OH); 13C NMR (100 MHz, DMSO-d6): d 22.2,
23.2, 37.3, 98.4, 105.4, 114.4, 115.6, 143.7, 144.4, 147.9, 169.7,
194.4.
7,8-Dihydroxy-6-methyl-3,4-dihydrodibenzo[b,d]furan-
1(2H)-one 11
O OH
OH
CH3
O
Method A
Stirring time 24 h. The product was recrystallised from 5%MeOH
in EtOAc solution at 358C to afford a brown powder (288 mg,
62%) (Found: M–Hþ, 231.0683. C13H11O4 requires M–H, 231.0657).
UPLC 99.7%. Rf 0.48 (EtOAc/hexane, 1:1). mp 2508C.
1H NMR
(400 MHz, DMSO-d6): d 2.14 (2H, m, CH2), 2.26 (3H, s, CH3),
2.45 (2H, t J 6.1 Hz, CH2), 2.98 (2H, t J 6.1 Hz, CH2), 7.11 (s, 1H,
ArH); 13C NMR (100 MHz, DMSO-d6): d 9.0, 22.2, 23.3, 37.9, 102.4,
107.9, 113.5, 115.9, 142.2, 143.4, 147.6, 169.6, 194.6.
Method B
Stirring time 44 h. The product was washed with EtOAc to afford
a brown powder (311.0 mg, 67%).
7,8-Dihydroxy-6-methoxy-3,4-dihydrodibenzo[b,d]furan-
1(2H)-one 12
O OH
OH
O
CH3
O
Method A
Stirring time 24 h. The product was recrystallised from 5%MeoH
in EtOAc solution at 358C to afford a brown powder (348 mg,
70%) (Found: M–Hþ, 247.0557. C13H11O5 requires M–H, 247.0606).
UPLC 97.0%. Rf 0.38 (EtOAc/hexane, 2:1). mp 2328C.
1H NMR
(400 MHz, DMSO-d6): d 2.14 (2H, m, CH2), 2.46 (2H, t J 6.4 Hz,
CH2), 3.00 (2H, t J 6.4 Hz, CH2), 3.94 (3H, s, CH3), 7.00 (1H, s, ArH),
8.71 (1H, br s, OH), 9.24 (1H, br s, OH); 13C NMR (100 MHz, DMSO-
d6): d 22.1, 23.2, 37.4, 60.4, 99.9, 114.8, 115.6, 133.3, 136.2, 140.3,
145.0, 169.9, 194.5.
7,8-Dihydroxy-3-methyl-3,4-dihydrodibenzo[b,d]furan-
1(2H)-one 13
O OH
OH
O
CH3
Method A
Stirring time 24 h. The product was washed with EtOAc to
afford a brown powder (274 mg, 59%) (Found: M–Hþ,
231.0610. C13H11O4 requires M–H, 231.0657). UPLC 95.3%.
Rf 0.38 (EtOAc/hexane, 1:1). mp 2638C.
1H NMR (400 MHz,
DMSO-d6): d 1.11 (3H, d, J 6.0 Hz, CH3), 2.30 (1H, dd, J 4.6,
12.8 Hz, CH), 2.43 (2H, dd J 3.6, 12.8 Hz, CH2), 2.68 (1H,
m, CH), 3.01 (1H, dd J 4.6, 12.8 Hz, CH), 6.98 (1H, s, ArH), 7.21
(1H, s, ArH) and 9.15 (2H, br s, OH); 13C NMR (100 MHz, DMSO-d6):
d 20.7, 30.3, 40.0, 45.6, 98.5, 105.3, 114.3, 115.3, 143.7, 144.4,
148.2, 169.4 and 194.0.
Method C
Stirring time 42 h. The product was purified by flash chroma-
tography (silica: EtOAc/hexane, 0.5:9.5, 1:9, 2.5:7.5, 1:1) to afford
a brown powder (84 mg, 30%).
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7,8-Dihydroxy-3,6-dimethyl-3,4-dihydrodibenzo[b,d]furan-
1(2H)-one 14
O OH
OH
CH3
O
CH3
Method A
Stirring time 24 h. The product was washed with EtOAc to afford a
light-brown powder (384 mg, 78%) (Found: M–Hþ, 245.0817.
C14H13O4 requires M–H, 245.0814). UPLC 96.0%. Rf 0.74
(EtOAc/hexane, 1:1). mp 165–1688C. 1H NMR (400 MHz, DMSO-d6):
d 1.11 (3H, d J 6.0 Hz, CH3), 2.25 (3H, s, CH3), 2.29 (1H, dd J 4.7,
12.4 Hz, CH2), 2.43 (2H, dd J 3.4, 12.8 Hz, CH2), 2.68 (1H,m, CH), 3.03
(1H, dd J 4.7, 12.4 Hz, CH), 7.11 (1H, s, ArH), 8.47 (1H, br s, OH), 9.38
(1H, br s, OH); 13C NMR (100 MHz, DMSO-d6): d 9.0, 20.7, 30.3, 31.0,
45.6, 102.3, 107.9, 113.4, 115.5, 142.1, 143.3, 147.8, 169.2, 194.1.
Method C
Stirring time 42 h. The product was purified by flash chroma-
tography (silica: EtOAc/hexane, 0.5:9.5, 1:9, 1:1; EtOAc) to afford a
light-brown powder (209.0 mg, 71%).
7,8-Dihydroxy-6-methoxy-3-methyl-3,4-dihydrodibenzo-
[b,d]furan-1(2H)-one 15
O OH
OH
O
CH3
O
CH3
Method A
Stirring time 24 h. The product was washed with EtOAc to afford a
light-brownpowder (194 mg, 37%) (Found:M–Hþ, 261.0843. C14H13O4
requires M–H, 261.0763). UPLC 99.6%. Rf 0.50 (EtOAc/hexane, 1:1).
mp 179–1828C. 1H NMR (400 MHz, DMSO-d6): d 1.12 (3H, d J 6.4 Hz,
CH3), 2.32 (1H, dd J 4.0, 12.4 Hz, CH) 2.44 (2H, dd J 3.4, 13.2 Hz, CH2),
2.72 (1H,m, CH), 3.06 (1H, dd J 5.0, 12.4 Hz, CH), 3.94 (3H, s, CH3), 6.97
(1H, s, ArH). 13CNMR (100 MHz, DMSO-d6): d 20.7, 30.3, 31.0, 45.7, 60.4,
99.8, 114.8, 115.3, 133.4, 136.3, 140.6, 145.1, 169.6, 194.1.
7,8-Dihydroxy-3,3-dimethyl-3,4-dihydrodibenzo[b,d]furan-
1(2H)-one 16
O OH
OH
O
CH3
CH3
Method A
Stirring time 24 h. The product was washed with EtOAc
to afford a yellow powder (286 mg, 58%). (Found: M–Hþ,
245.0867. C14H14O4 requires M–H, 245.0814). UPLC 99.8%.
Rf 0.64 (EtOAc/hexane, 1:1). mp 278–2808C [lit. [28] 2808C].
1H NMR (400 MHz, DMSO-d6): d 1.09 (6H, s, 2 CH3),
2.38 (2H, s, CH2), 2.88 (2H, s, CH2), 6.98 (1H, s, ArH), 7.20
(1H, s, ArH), 9.15 (2H, br s, OH); 13C NMR (100 MHz, DMSO-d6):
d 28.0 (2 CH3), 34.9, 36.7, 51.5, 98.5, 105.3, 114.2, 114.4, 143.7,
144.3, 148.3, 168.6, 193.7.
Method C
Stirring time 42 h. The product was purified by flash chroma-
tography (silica: EtOAc/hexane, 0.5:9.5, 1:9, 2.5:7.5, 1:1) to afford
a yellow powder (118 mg, 40%).
7,8-Dihydroxy-3,3,6-trimethyl-3,4-dihydrodibenzo-
[b,d]furan-1(2H)-one 17
O OH
OH
CH3
O
CH3
CH3
Method A
Stirring time 24 h. The product was recrystallised from a
5% MeOH in EtOAc solution at 358C to afford a light-brown
powder (510 mg, 98%). (Found: M–Hþ 259.0931. C15H15O4
requires M–H, 259.0970). UPLC 96.6%. Rf 0.45 (EtOAc/hexane,
1:2). mp 2558C [lit. [33] 260–2628C]. 1H NMR (400 MHz, DMSO-
d6): d 1.09 (6H, s, 2 CH3), 2.26 (3H, s, CH3) 2.37 (2H, s, CH2),
2.90 (2H, s, CH2), 7.10 (1H, s, ArH), 8.41 (1H, br s, OH), 9.32
(1H, br s, OH); 13C NMR (100 MHz, DMSO-d6): d 9.0, 28.0,
34.9, 36.8, 51.5, 102.4, 107.9, 113.3, 114.7, 142.0, 143.3,
168.5, 193.8.
Method C
Stirring time 42 h. The product was purified by flash chroma-
tography (silica: EtOAc/hexane, 5:95, 1:9, 1:1) to afford a light-
brown powder (184 mg, 59%).
7,8-Dihydroxy-3,3,6-trimethyl-3,4-dihydrodibenzo-
[b,d]furan-1(2H)-one 18
O OH
OH
O
CH3
O
CH3
CH3
Method A
Stirring time 24 h. The product was recrystallised from 5%MeOH
in EtOAc solution at 358C to afford a brown powder (403 mg,
73%). (Found: M–Hþ, 275.0922. C15H15O5 requires M–H,
275.0919). UPLC 94.5%. Rf 0.44 (EtOAc/hexane, 1:1). mp 288–
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2918C [lit. [31] 289–2918C]. 1H NMR (400 MHz, MeOH-d4): d 1.16
(6H, s, 2 CH3), 2.43 (2H, s, CH2) 2.90 (2H, s, CH2), 4.06 (3H, s, CH3),
7.01 (1H, s, ArH); 13C NMR (100 MHz, DMSO-d6): d 28.1, 35.0, 36.8,
51.2, 60.4, 99.8, 114.5, 114.7, 113.4, 136.2, 140.8, 145.1, 168.9,
193.9.
Method B
Stirring time 44 h. The product was washed with EtOAc to afford
a brown powder (425 mg, 77%).
7,8-Dihydroxy-3-phenyl-3,4-dihydrodibenzo[b,d]furan-
1(2H)-one 19
O OH
OH
O
Ph
Method A
Stirring time 24 h. The product was washed with EtOAc to
afford a white solid (449 mg, 76%). (Found: M–Hþ,
293.0821. C18H13O4 requires M–H, 293.0814). UPLC 99.8%.
Rf 0.50 (EtOAc/hexane, 1:1). mp 240–2438C.
1H NMR
(400 MHz, DMSO-d6): d 2.58 (1H, dd J 3.2, 16.0 Hz, CH), 2.93
(1H, dd J 12.4, 16.0 Hz, CH), 3.24 (2H, m, H-11), 3.66 (1H, m, CH),
7.01 (1H, s, ArH), 7.26 (1H, s, ArH), 7.35 (2H, t J 7.2, 7.6 Hz, ArH),
7.42 (2H, d J 7.6 Hz, ArH), 9.09 (1H, s, CH), 9.13 (1H, s, CH);
13C NMR (100 MHz, DMSO-d6): d 30.7, 44.6, 62.5, 63.4, 68.8, 71.5,
72.3, 73.8, 98.5, 105.4, 114.2, 115.5, 126.9, 128.6, 143.1, 143.9,
144.5, 148.3, 169.0, 193.1.
Method C
Stirring time 42 h. The product was purified by flash chroma-
tography (silica: EtOAc/hexane, 5:95, 1:9, 1:1; EtOAc) to afford a
white solid (132 mg, 50%).
7,8-Dihydroxy-6-methyl-3-phenyl-3,4-dihydrodibenzo-
[b,d]furan-1(2H)-one 20
O OH
OH
CH3
O
Ph
Method A
Stirring time 24 h. The product was recrystallised from
5% MeOH in EtOAc solution at 358C to afford a light-brown
powder (279 mg, 80%) (Found: M–Hþ, 307.0977.1120. C19H15O4
requires M–Hþ, 307.0970). UPLC 99.0%. Rf 0.45 (EtOAc/hexane,
1:1). mp 250–2538C. 1H NMR (400 MHz, DMSO-d6): d 2.28 (3H, s,
CH3), 2.59 (1H, dd J 4.0, 16.4 Hz, CH), 2.91 (1H, dd J 12.2, 16.2 Hz,
CH), 3.28 (1H, m, CH2), 3.66 (1H, m, H-11 CH), 7.16 (1H, s, ArH),
7.26 (1H, t J 7.0 Hz, ArH), 7.35 (2H, t J 7.6 Hz, ArH), 7.42 (2H, d J
8.0 Hz, ArH), 8.45 (1H, br s, OH), 9.36 (1H, br s, OH); 13C NMR
(100 MHz, DMSO-d6): d 9.1, 30.7, 44.7, 102.4, 108.0, 113.4, 115.8,
126.9, 127.0, 127.1, 128.6, 142.3, 143.2, 143.4, 148.0, 168.8,
193.2.
7,8-Dihydroxy-6-methoxy-3-phenyl-3,4-dihydrodibenzo-
[b,d]furan-1(2H)-one 21
O OH
OH
O
Ph
O
CH3
Method A
Stirring time 24 h. The product was washed with EtOAc to
afford a dull grey powder (279 mg, 43%). (Found: M–Hþ,
323.0922. C19H15O5 requires M–H, 323.0919). UPLC 96.8%.
Rf 0.38 (EtOAc/hexane, 1:2). mp 165–1688C.
1H NMR
(400 MHz, DMSO-d6): d 2.57 (1H, dd J 4.0, 16.0 Hz, CH),
2.93 (1H, dd J 12.0 Hz, 12.4 Hz, CH), 3.26 (2H, m, CH2), 3.67
(1H, m, CH), 3.95 (3H, s, CH3), 7.03 (1H, s, ArH), 7.26 (1H, t J
7.2 Hz, ArH), 7.35 (2H, t J 7.2, 8.0 Hz, ArH), 7.42 (2H, d J 8.0 Hz,
ArH), 8.76 (1H, br s, OH) and 9.33 (1H, br s, OH); 13C NMR
(100 MHz, DMSO-d6): d 30.6, 44.6, 60.4, 99.8, 114.6, 115.5,
126.8, 127.0, 128.5, 133.4, 136.2, 140.6, 143.0, 145.0, 169.0,
193.0.
Method C
Stirring time 42 h. The product was purified by flash chroma-
tography (silica: EtOAc/hexane, 5:95, 1:9, 1:1; EtOAc) to afford a
black powder (58.0 mg, 15%).
3-(3,4-Dihydroxy-5-methylphenyl)-3-methylpentane-2,4-
dione 22
OH
OH
Me
CH3
O
CH3
O
CH3
Method A
Stirring time 24 h. The product was washed with EtOAc to
afford a dark-brown powder (1.60 g, 80%) (Found: M–Hþ,
235.0926. C13H14O4 requires M–H, 235.0970. UPLC 98.0%.
Rf 0.48 (EtOAc/hexane, 1:1). mp 82–858C.
1H NMR (400 MHz,
DMSO-d6): d 1.60 (3H, s, CH3), 2.03 (6H, s, CH3), 2.08 (3H, s, CH3),
6.43 (1H, d J 2.0 Hz, ArH), 6.46 (1H, d J 2.4 Hz, ArH), 8.36
(1H, br s, OH), 9.29 (1H, br s, OH); 13C NMR (100 MHz,
DMSO-d6): d 16.2, 19.0, 27.2, 30.7, 68.8, 112.4, 120.1, 124.7,
127.7, 143.0, 144.8, 207.8.
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3-(3,4-Dihydroxy-5-methoxyphenyl)-3-methylpentane-2,4-
dione 23
OH
OH
OMe
CH3
O
CH3
O
CH3
Method A
Stirring time 24 h. The product was washed with EtOAc to afford
a dark-brown powder (1.10 g, 55%) (Found: M–Hþ, 251.0933.
C13H14O5 requires M–H, 251.0919. Rf 0.48 (EtOAc/hexane, 1:1).
mp 108–1108C. 1H NMR (400 MHz, DMSO-d6): d 1.62 (3H, s, CH3),
2.05 (6H, s, CH3), 3.74 (3H, s, OMe), 6.27 (1H, s, ArH), 6.28 (1H, s,
ArH), 8.44 (1H, br s, OH), 9.03 (1H, br s, OH); 13C NMR (100 MHz,
DMSO-d6): d 19.1, 27.3, 56.0, 69.0, 103.1, 108.7, 127.7, 133.9, 145.8,
148.5, 207.7.
In vitro anticancer activity evaluation
Assay background
The growth inhibitory effects of the compounds were tested in a
3-cell line panel consisting of TK10 (renal), UACC62 (melanoma)
and MCF7 (breast) cancer cells using the Sulforhodamine B (SRB)
assay [32]. The SRB assay was developed by Skehan and colleagues
to measure drug-induced cytotoxicity and cell proliferation. Its
principle is based on the ability of the protein dye, sulforhod-
amine B (Acid Red 52), to bind electrostatically in a pH-dependent
manner to protein basic amino acid residues of trichloroacetic
acid-fixed cells. Under mild acidic conditions it binds to the fixed
cellular protein, while under mild basic conditions it can be
extracted from cells and solubilised for measurement. The SRB
assay is performed at CSIR in accordance with the protocol of the
Drug Evaluation Branch, NCI, and the assay has been adopted for
this screen.
Materials and method
The human cell lines TK10, UACC62 and MCF7 were obtained
from the NCI in a collaborative research program between the
CSIR and the NCI. cell lines were routinely maintained as a
monolayer cell culture at 378C, 5% CO2, 95% air and 100%
relative humidity in RPMI containing 5% fetal bovine serum,
2 mM L-glutamine and 50 mg/mL gentamicin.
For the screening experiment the cells (3–19 passages) were
inoculated in a 96-well microtitre plate at plating densities of 7–
10 000 cells/well and were incubated for 24 h. After 24 h one
plate was fixed with TCA to represent a measurement of the cell
population for each cell line at the time of drug addition (T0). The
other plates with cells were treated with the experimental drugs
which were previously dissolved in DMSO and diluted in
medium to produce five concentrations (0.01–100 mM). Cells
without drug addition served as control. The blank contains
complete medium without cells. Etoposide was used as a refer-
ence standard.
The plates were incubated for 48 h after addition of the com-
pounds. Viable cells were fixed to the bottom of each well with
cold 50% trichloroacetic acid, washed, dried and dyed by SRB.
Unbound dye was removed and protein-bound dye was extracted
with 10 mM Tris base for optical density determination at a
wavelength of 540 nm using a multiwell spectrophotometer.
Optical density measurements were used to calculate the net
percentage cell growth.
The optical density of the test well after a 48 h period of
exposure to test drug is Ti, the optical density at time zero is
T0, and the control optical density is C. Percentage cell growth is
calculated as:
ðTi  T0Þ
ðC T0Þ
 
 100 for concentrations at which Ti  T0
ðTi  T0Þ
T0
 
 100 for concentrations at which Ti < T0:
The results of a five dose screening were reported as TGI (total
growth inhibition). The TGI is the concentration of test drug
where 100  (T  T0)/(C  T0) ¼ 0. The TGI signifies a cytostatic
effect.
The biological activities were separated into four categories:
inactive (GI50 or TGI > 100 mM), weak activity (30 mM < GI50 or
TGI < 100 mM), moderate activity (10 mM < GI50 or
TGI < 30 mM) and potent activity (GI50 or TGI < 10 mM).
For each tested compound, three response parameters, GI50
(50% growth inhibition and signifies the growth inhibitory
power of the test agent), TGI (which is the drug concentration
resulting in total growth inhibition and signifies the cytostatic
effect of the test agent) and LC50 (50% lethal concentration and
signifies the cytotoxic effect of the test agent), were calculated for
each cell line.
We thank Dr Paul Steenkamp for HRMS analysis, the CSIR (Thematic A
grant) for financial support and Novozymes SA (Pty) Ltd for a kind
donation of the enzyme.
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